Crispr-based AAV gene therapy against SARS-COV-2

Engineered AAV vectors, like AAV.CPP.16, efficiently deliver CRISPR-Cas systems to respiratory cells via intranasal routes, addressing inefficiencies in gene therapy delivery and showing promise in treating respiratory diseases and SARS-CoV-2 infections.

WO2026236183A1PCT designated stage Publication Date: 2026-11-12THE BRIGHAM & WOMEN S HOSPITAL INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026654
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current gene therapy methods face inefficiencies in delivering genetic material to respiratory tissues, particularly for treating respiratory diseases and infections, due to a lack of effective delivery vectors.

Method used

Development of engineered AAV vectors, such as AAV.CPP.16, that efficiently transduce airway and lung cells through intranasal administration, incorporating Cas endonucleases and CRISPR-associated guide RNAs targeting SARS-CoV-2 genes, and optionally including soluble VEGF receptors and antibody reagents.

Benefits of technology

These vectors effectively target key respiratory cell types, supporting gene supplementation and editing therapies in respiratory diseases and infections, including SARS-CoV-2, outperforming wild-type AAVs and demonstrating therapeutic potential in preclinical models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026654_12112026_PF_FP_ABST
    Figure US2026026654_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The technology described herein relates to engineered AAVs and compositions comprising engineered AAVs for use in gene therapies. In some embodiments, described herein are engineered AAVs that can be efficiently delivered to airway and lung cells via intranasal administration.
Need to check novelty before this filing date? Find Prior Art

Description

Atty. Dkt. No. 043214-000114WOPTCRISPR-BASED AAV GENE THERAPY AGAINST SARS-COV-2 CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims benefit under 35 U. S. C. § 119 of U. S. Provisional Application 63 / 801,028 filed on May 6, 2025, the content of which is incorporated herein by reference in its entirety.SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on May 4, 2026, is named 043214-000114WOPT_SL.xml and is 430,080 bytes in size.TECHNICAL FIELD

[0003] The technology described herein relates to engineered AAVs and compositions comprising engineered AAVs for use in gene therapies.BACKGROUND

[0004] Gene therapy is a method of treating or preventing diseases through the modification of gene expression in a subject. This can be accomplished by replacing, inactivating, or introducing genes to cells to correct dysfunction. Adeno-associated viruses (AAVs) present an attractive strategy for gene therapies. These small, non-pathogenic viruses can be engineered to deliver genetic material to cells. Engineered AAVs, also known as recombinant AAVs (rAAVs), can be used to deliver transgenes, such as those encoding CRISPR-Cas systems, to permit genomic editing. Progress in gene therapy and gene editing is hampered by a lack of efficient delivery vectors.SUMMARY

[0005] The inventors have developed engineered AAVs that allow for efficient delivery of gene therapies, e.g., to the respiratory system and lungs. These findings permit and improve the therapeutic development of AAVs as tools for the delivery of gene therapy vectors, particularly for treatment of respiratory diseases and infections.

[0006] One aspect of any of the embodiments is an adeno-associated virus (AAV) vector comprising:a) one or more nucleic acids encoding:i) a Cas endonuclease; andii) at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene selected from the group consisting of: 3C-like protease (3CL), Programmed ribosomal frameshifting (PRF), RNA-Atty. Dkt. No. 043214-000114WOPTdependent RNA polymerase (Rdrp), Spike (S), Envelope (E), Membrane (M), and Nucleocapsid (N).

[0007] One aspect of any of the embodiments is an adeno-associated virus (AAV) vector comprising:b) one or more nucleic acids encoding:i) A polypeptide having at least 80% sequence identity to SEQ ID NO: 206; and ii) at least one CRISPR-associated guide RNA sequence.

[0008] In some embodiments of any of the aspects, the nucleic acid encodes a CasRx endonuclease. In some embodiments of any of the aspects, the CasRx endonuclease comprises two SV40 nuclear localization sequences. In some embodiments of any of the aspects, the CasRx endonuclease comprises one HA tag. In some embodiments of any of the aspects, the one or more nucleic acids encode four CRISPR-associated guide RNA sequences in series. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence targets the Rdrp gene in SARS-CoV-2.

[0009] In some embodiments of any of the aspects, the nucleic acid encoding a Cas endonuclease is operably linked to a promoter. In some embodiments of any of the aspects, the nucleic acid encoding at least one CRISPR-associated guide RNA sequence is operably connected to a promoter. In some embodiments of any of the aspects, the nucleic acid encoding a Cas endonuclease and the nucleic acid encoding at least one CRISPR-associated guide RNA sequence are operably linked to the same promoter. In some embodiments of any of the aspects, the nucleic acid encoding a Cas endonuclease is operably linked to a first promoter and the nucleic acid encoding at least one CRISPR-associated guide RNA sequence is operably linked to a second promoter. In some embodiments of any of the aspects, the promoter is an EFS promoter. In some embodiments of any of the aspects, the promoter is a U6 promoter.

[0010] One aspect of any of the embodiments is an adeno-associated virus (AAV) vector comprising a nucleic acid encoding:a) a soluble receptor; andb) an antibody reagent.

[0011] In some embodiments of any of the aspects, the soluble receptor is a soluble VEGF receptor. In some embodiments of any of the aspects, the soluble VEGF receptor comprises extracellular domains of human VEGF receptors 1 and 2. In some embodiments of any of the aspects, the antibody reagent is a scFv. In some embodiments of any of the aspects, the antibody reagent binds specifically to TGF01.

[0012] One aspect of any of the embodiments is an AAV comprising:a) the vector of any one of the embodiments described herein; andb) at least one capsid polypeptide.Atty. Dkt. No. 043214-000114WOPT

[0013] In some embodiments of any of the aspects, the at least one capsid polypeptide comprises at least four contiguous amino acids from the sequence TVSALFK (SEQ ID NO: 301); TVSALK (SEQ ID NO: 302); KLASVT (SEQ ID NO: 303); or KFLASVT (SEQ ID NO: 304).

[0014] One aspect of any of the embodiments is a composition for intranasal delivery, the composition comprising the AAV of any one of the embodiments described herein. In some embodiments of any of the aspects, the composition further comprises a pharmaceutically acceptable excipient. In some embodiments of any of the aspects, the composition further comprises a mucoadhesive agent, a thermosensitive agent, a viscosity enhancing agent, or a combination thereof. In some embodiments of any of the aspects, the composition further comprises a sweetener, a polyol, a fragrance, or a combination thereof.

[0015] In some embodiments of any of the aspects, the composition is a solution. In some embodiments of any of the aspects, the composition is a suspension. In some embodiments of any of the aspects, the composition is an aerosol. In some embodiments of any of the aspects, the composition is a liquid. In some embodiments of any of the aspects, the composition is a powder. In some embodiments of any of the aspects, the composition is a gel.

[0016] One aspect of any of the embodiments is a method comprising contacting a cell with an adeno-associated virus (AAV) or composition of any one of the embodiments described herein.

[0017] In some embodiments of any of the aspects, the cell is a respiratory cell. In some embodiments of any of the aspects, the cell is a ciliated cell, a brush cell, an airway basal cell, a small granule cell, goblet cell, an a-tubulin-positive ciliated cell, a club cell, a trachea cell, or a ATI cell.

[0018] In some embodiments of any of the aspects, the cell is in a subject. In some embodiments of any of the aspects, the cell is in a mammalian subject. In some embodiments of any of the aspects, the cell is in a human subject. In some embodiments of any of the aspects, the subject has a respiratory disease or infection. In some embodiments of any of the aspects, the disease is idiopathic pulmonary fibrosis (IPF). In some embodiments of any of the aspects, the infection is a viral infection. In some embodiments of any of the aspects, the viral infection is caused by SARS-CoV-2.

[0019] One aspect of any of the embodiments is a method of treating respiratory disease or infection in a subject in need thereof, the method comprising: administering an AAV or compositions of any one of the embodiments described herein to the subject. In some embodiments of any of the aspects, the disease is idiopathic pulmonary fibrosis (IPF). In some embodiments of any of the aspects, the infection is a viral infection. In some embodiments of any of the aspects, the viral infection is caused by SARS-CoV-2.

[0020] In some embodiments of any of the aspects, the AAV is administered by intranasal delivery. In some embodiments of any of the aspects, the AAV is administered by a dropper. In someAtty. Dkt. No. 043214-000114WOPTembodiments of any of the aspects, the AAV is administered as a spray. In some embodiments of any of the aspects, the AAV is administered by a nebulizer.

[0021] One aspect of any of the embodiments is a device for intranasal administration of a composition comprising an AAV or composition of any one of the embodiments described herein to a subject. In some embodiments of any of the aspects, the device is a dropper. In some embodiments of any of the aspects, the device is a spray. In some embodiments of any of the aspects, the device is a nebulizer.

[0022] One aspect of any of the embodiments is a kit comprising the device of any one of the embodiments described herein and instructions for use.BRIEF DESCRIPTION OF THE DRAWINGS

[0023] FIGs. 1 A-1I: AAV transduction of airway cells in cell culture and mouse models. FIG. 1A: Schematic diagram showing experimental design. FIGs. 1B-1C: Images showing transduction of cultured human nasal epithelial cells RPMI 2650 in vitro (Multiplicity of Infection, MOI, 1 x 105) by AAV6-CAG-GFP, AAV9-CAG-GFP, and AAV. CPP.16-CAG-GFP (CPP.16) FIG. IB: and quantification of GFP fluorescence intensity normalized as fold-change relative to AAV6 (FIG. 1C) Mean ± s.e.m., n = 3. Scale bar: 100 pm. D-I, Representative fluorescence images and quantitative analysis showing AAV-mediated GFP expression in the nasal cavity (FIGs. 1D-1E), trachea (FIGs. 1F-1G), lung (FIGs. 1H-1I) in C57BL / 6J mice 21 days after intranasal delivery of 1 x 1011 vg of AAV6, AAV9 or CPP.16. Mean ± s.e.m., n = 6-7 each treatment. Scale bar in D: 500 pm. Scale bar in F, H: 100 pm. Statistical analyses were performed using one-way ANOVA with Tukey’s multiple comparison test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

[0024] FIGs.2A-2G: Characterization of AAV-transduced cell types in the mouse respiratory tract and lungs. FIG. 2A: Schematic diagram illustrating major airway cell types, their anatomical locations, and antibody markers. Mouse tissues were collected 21 days after intranasal administration of 1 x 1011vg of AAV-CAG-GFP. FIG. 2B: Representative images showing transduced goblet cells (MUC5A+) in the nasal cavity. Scale bar: 25 pm for low-magnification images and 5 pm for enlarged images. FIG. 2C: AAV-mediated transduction of club cells (CC10+) in the trachea. Arrows point to cells co-labeled with GFP and CC10 antibodies. Scale bar: 25 pm. FIG. 2D:AAV-mediated transduction of alveolar type I (ATI) (RAGE+) in lung parenchyma tissues. Scale bar: 25 pm. E-G, Quantifications on the percentage of GFP+goblet cells in the nasal cavity (FIG. 2E), club cells in the trachea (FIG. 2F) and ATI cells in the lung (FIG. 2G). Mean ± s.e.m., n = 3-4 for each group. Statistical analyses were performed using one-way ANOVA with Tukey’s multiple comparison test (**p < 0.01, ***p < 0.001).

[0025] FIGs.3A-3F: Intranasal AAV. CPP.16-mediated gene delivery in non-human primates. FIGs. 3A, 3C, 3E: Representative images showing AAV-mediated GFP and RFP coexpression in the nasal cavity (FIG.3A), trachea (FIG.3C) and lung (FIG.3E) in three adult non-Atty. Dkt. No. 043214-000114WOPThuman primates (NHPs). DAPI nuclear staining was shown. In NHP #1, AAV9-GFP and AAV9-RFP were pre-mixed and co-administered intranasally. In NHPs #2 and 3, CPP.16-GFP and AAV9-RFP were co-administered. AAV9-RFP serves as an internal control. 4 x 1012vg of AAVs per AAV per animal were applied. Tissues were collected 28 days after AAV administration. Scale bar: 20 pm. FIGs.3B, 3D, 3F: Quantification of GFP fluorescence intensity measured as the ratio of GFP / RFP in the nasal cavity (FIG.3B), trachea (FIG.3D) and lung (FIG. 3F). Values were normalized to those in NHP#1 to show the fold changes of CPP.16-mediated GFP expression relative to AAV9.

[0026] FIGs.4A-4F: An AAV. CPP.16-mediated gene therapy for idiopathic pulmonary fibrosis. FIG. 4A: Schematic diagram illustrating design of a biftmctional fusion protein that inhibits VEGF and TGF 1, and construction of an AAV vector expressing such a protein. Figure discloses “(Gly4Ser)3” as SEQ ID NO: 609. FIG. 4B: Experimental design for testing the AAV. CPP.16 gene therapy (CPP.16-IPF trap) in a bleomycin-induced IPF mouse model, i.t.: intratracheal; inhal.:Inhaled; i.g.: intragastric. FIG. 4C: Representative HE staining on lung sections in mice with different treatments. Scale bar: 200 pm for low-magnification images and 50 pm for enlarged images.FIG. 4D: Quantification of lung cell areas in HE-stained lung sections, n = 3-6 per group, mean ± s.e.m., one-way ANOVA with Tukey’s post-test. FIG. 4E: Representative Masson, picrosirius red and aSMA immunohistochemical staining of lung sections in mice with different treatments. Masson and picrosirius red stainings label collagen expression. Scale bar: 200 pm. FIG. 4F: Quantification of fibrotic areas on lung sections, n = 3-6 per group, mean ± s.e.m., one-way ANOVA with Tukey’s posttest. *p < 0.05, **p < 0.01, ***p < 0.001. PBS: phosphate-buffered saline. BLM: bleomycin. IPF: idiopathic pulmonary fibrosis. PFD: pirfenidone. HE: hematoxylin and eosin.

[0027] FIGs.5A-5H: Inhibition of VEGF and TGF (i 1 pathways in the mouse lung treated with AAV. CPP.16-IPF trap gene therapy. FIG.5A: Transgene expression in the mouse lung treated with AAV. CPP.16-IPF trap. RT-PCR was performed using primers that targeted the two fragments of the fusion protein, n = 4 per group, mean ± s.e.m., one-way ANOVA with Tukey’s post-test. FIG. 5B:Concentration of VEGFa in the mouse serum measured by ELISA, n = 3-8 per group, mean ± s.e.m., one-way ANOVA with Tukey’s post-test. FIG. 5c: Concentration of TGF 0 1 in the mouse serum measured by ELISA, n = 3-8 per group, mean ± s.e.m., one-way ANOVA with Tukey’s post-test. FIG.5D: mRNA expression levels of firbrogenic genes Acta2, Postn, anAFn in the lung tissues, n = 4 per group, mean ± s.e.m., one-way ANOVA with Tukey’s post-test. FIG. 5E: mRNA expression levels of inflammation genes Tnfa, 116 and. Il lb in the lung tissues, n = 4 per group, mean ± s.e.m., one-way ANOVA with Tukey’s post-test. FIGs. 5F-5H: Immunoblot quantification of key fibrogenic and inflammation proteins, n = 3 per group, mean ± s.e.m., one-way ANOVA with Tukey’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001. PBS: phosphate-buffered saline. BLM: bleomycin. IPF: idiopathic pulmonary fibrosis. PFD: pirfenidone.Atty. Dkt. No. 043214-000114WOPT

[0028] FIGs.6A-6G: An AAV. CPP.16-mediated gene therapy against SARS-CoV2 using an all-in-one CRISPR-CasRx RNA editing system. FIG. 6A: Schematic diagram showing an all-in-one AAV vector expressing both CasRx and four gRNAs that target the SARS-CoV-2-derived RNA-dependent RNA polymerase (Rdrp) gene. FIG. 6B: Workflow for testing Rdrp RNA knock-down in 293T cells by co-transfection with CasRx-gRNA and Rdrp plasmids. FIG. 6C: Quantification of Rdrp knock-down after co-transfection in 293T. Abbott et al: gRNA from a published study40, n = 6-9 per group, mean ± s.e.m., one-way ANOVA with Tukey’s post-test. FIG. 6D: Workflow for testing Rdrp RNA knock-down inRPMI 1650 cells by co-transduction with AAV. CPP.16-CasRx-gRNA and Ad5-Rdrp. FIG. 6E: Quantification for knock-down of Ad5-expressed Rdrp transcript by AAV. CPP.16-CasRx-gRNA in RPMI 1650 cells, n = 3 per group, mean ± s.e.m., one-way ANOVA with Tukey’s post-test. FIG. 6F: Timeline for studying intranasal AAV. CPP.16-CasRx-gRNA. Interface in Ad5-Rdrp-challenged mice. FIG. 6G: Quantification of Rdrp knock down in the nostril, trachea and lung of Ad5-Rdrp-challenged mice treated with AAV. CPP.16-CasRx-gRNA. Interface or AAV. CPP.16-CasRx-scramble control, n = 6 each group, mean ± s.e.m., two-way ANOVA with Sidak’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

[0029] FIG. 7: AAV transduction in brain, retina and multiple peripheral organs after intranasal administration. Related to FIGs. 1A-1I. C57BL / 6J mice received intranasal administration of 1 x 1011vg of AAV6-CAG-GFP, AAV9-CAG-GFP, or AAV. CPP.16-CAG-GFP and were sacrificed 21 days later for harvesting tissues. Immunostaining with antibody against GFP was used to visualize transduced cells. No GFP-labeled cells were observed in the brain, retina, tongue, spleen, intestine, stomach, kidney or muscle. Some GFP-labeled cells were detected in the liver of AAV. CPP.16-treated mice. Scale bar: 200 pm forbrain, 100 pm for other organs.

[0030] FIGs.8A-8C: AAV-mediated transduction of mouse epithelial ciliated cells after intranasal administration. Related to FIGs. 2A-2G. Representative images showing GFP-labeled ciliated cells in the nasal cavity (FIG. 8A), trachea (FIG.8B), and lung (FIG. 8C) 21 days after intranasal administration of 1 x 1011vg of AAV6-CAG-GFP, AAV9-CAG-GFP, or AAV. CPP.16-CAG-GFP. Ciliated cells were stained using an antibody against a-Tubulin. Scale bar in FIG. 8A: 10 pm for low-magnification images and 5 pm for enlarged images. Scale bar in FIG. 8B: 25 pm. Scale bar in FIG. 8C: 50 pm for low-magnification images and 10 pm for enlarged images.

[0031] FIG. 9A-9F: AAV vector characterization, serum screening and transduction of cell type in NHP experiments. Related to FIGs 3A-3F. FIG. 9A: Diagram showing AAV vectors. FIG.9B: In vitro transduction of AAV9-GFP, AAV9-RFP and AAV. CPP 16-GFP in HEK293T cells. Scale bar 100 pm. FIG. 9C: Pre-screening of NHPs. NHPs were pre-screened against the pre-existing neutralizing antibodies of AAV9 (titer < 1:10). FIGs. 9D-9F: Percentage of AAV-GFP-transduced airway cells in NHP out of DAPT-labeled total cells. ATI, alveolar type 1.Atty. Dkt. No. 043214-000114WOPT

[0032] FIG. 10: AAV transduction in the heart, kidney, spleen and liver of the NHPs. Related to FIGs. 3A-3F. Representative fluorescence images of GFP or RFP signals in the heart, kidney, spleen and liver of NHPs, 4 weeks after intranasal co-injection of total 4xl012vg AAV9-GFP / AAV9-RFP or AAV. CPP.16-GFP / AAV9-RFP per animal. Scale bars: 50 pm.

[0033] FIG. 11: No AAV. CPP.16 transduction in the NHP brain after intranasal injection. Related to FIGs.3A-3F. Representative fluorescence images in the NHP brain, 4 weeks after intranasal co-injection of total 4x1012vg AAV9-GFP / AAV9-RFP or AAV. CPP.16-GFP / AAV9-RFP per animal. Scale bars: 500 pm for cerebellum and 50 pm for others.

[0034] FIGs. 12A-12D: Body weight change of BLM-induced mice. Related to FIGs. 4A-4F.

[0035] FIG. 12A: Mouse body weight monitoring after intratracheal PBS or bleomycin (BLM) treatment. FIG. 12B: No difference of body weight on Day 0 before PBS or BLM treatment.FIG. 12C: Body weight comparison between PBS and BLM treatment on Day 4. FIG. 12D: Body weight change ratio between PBS and BLM treatment on Day 4. n = 5 (PBS group), n=30 (BLM Model group), mean ± s.e.m., Two-sided Student's t-test. ***p < 0.001.

[0036] FIG. 13: Uncropped blotting images. Related to FIGs. 5A-5H.

[0037] FIGs. 14A-14E: Identification of CasRx target sites in RNA virus genomes. Related to FIGs. 6A-6G. FIG. 14A: Alignment of 2815 patient-derived SARS-CoV-2 sequences downloaded from public database NCBT SARS-CoV2 Resources. 7 regions are highlighted including 3C-like protease (3 CL), Programmed ribosomal frameshifting (PRF), RNA-dependent RNA polymerase (Rdrp), Spike (S), Envelop (E), Membrane (M) and Nucleocapsid (N). FIG. 14B: Conservation of selected genes across virus genomes. See also Table 4. FIG. 14C: Workflow for selecting CasRx gRNAs that target the Rdrp gene. FIG. 14D: schematic diagram showing targeting sites in the Rdrp gene for all selected gRNAs. The Rdrp gene encodes for the 932-aa Rdrp protein that contains four conserved regions including Niran, Tnterface, Finger, Finger / Pahn and Thumb. See also Table 5. FIG. 14E: Quantification of Rdrp RNA expression in the nostril, trachea and lung 4 weeks after intranasal injection of Ad5-Rdrp in mice, n = 3 each group, mean ± s.e.m., two-way ANOVA with Sidak's post-test (*p < 0.05, ****p < 0.0001).

[0038] FIG. 15: Schematic overview.DETAILED DESCRIPTION

[0039] It should be understood that this invention is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such can vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is defined solely by the claims.

[0040] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited inAtty. Dkt. No. 043214-000114WOPTthis application, including, but not limited to, patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference in their entirety for any purpose.

[0041] Described herein are compositions and methods that are useful in the development and delivery of AAVs for gene therapies.

[0042] Efficient gene delivery vectors are crucial for respiratory and lung disease therapies. In some embodiments, the technology disclosed herein relates to improved AAC vectors, e.g., AAV. CPP.16, an engineered adeno-associated virus (AAV) variant derived from AAV9. The inventors have found that these vectors efficiently transduce airway and lung cells in mice and non-human primates via intranasal administration. The inventors have further found that these vectors outperform AAV 6 and AAV9, two wild-type AAV s with demonstrated tropism for respiratory tissues, efficiently targets key respiratory cell types, and supports gene supplementation and editing therapies in two clinically relevant models of respiratory and lung diseases. Accordingly, provided herein are intranasal gene therapies for respiratory diseases and infections.

[0043] In some aspects of any of the embodiments, disclosed herein is an adeno-associated virus (AAV) vector comprising one or more nucleic acids encoding i) a Cas endonuclease and ii) at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene selected from the group consisting of: 3C-like protease (3CL), Programmed ribosomal frameshifting (PRF), RNA-dependent RNA polymerase (Rdrp), Spike (S), Envelope (E), Membrane (M), and Nucleocapsid (N).

[0044] As described herein, the term “SARS-CoV-2” refers to the severe acute respiratory syndrome coronavirus 2 (SEQ ID NO: 100). SARS-CoV-2 has four structural proteins (spike (S) (SEQ ID NO: 101), envelope (E) (SEQ ID NO: 102), membrane (M) (SEQ ID NO: 103), and nucleocapsid (N) (SEQ ID NO: 104) which are wrapped with an RNA genome to form viral particles. The genome of SARS-CoV-2 is approximately 30 kb in size and can be transcribed in 14 open reading frames (ORFs). The 5' ORFla / lb (SEQ ID NOs: 107 and 108) represents approximately 67% of the entire genome and encodes ppla (SEQ ID NO: 109) andpplab (SEQ ID NO: 11) precursor polyproteins (by a -1 ribosomal frameshift) that are hydrolyzed to 16 nonstructural proteins (nspl to nspl6, SEQ ID NOs: 111-126)) through proteolytic processing. These 16 nsps form the replicase-transcriptase complex (RTC) that consists of multiple enzymes, including papain-like protease (nsp3) (SEQ ID NO: 113), chymotrypsin-like main protease (3CL protease, nsp5) (SEQ ID NOs: 115, 127), primase complex (nsp7-nsp8) (SEQ ID NOs: 117-118), rdrp (nspl2) (SEQ ID NOs: 112, 106), helicase (nspl3) (SEQ ID NOs: 113), and exoribonuclease (nspl4) (SEQ ID NOs: 114). As many as 13 of the remaining ORFs at the 3' end encode the four structural proteins and nine putative accessory factors. The sequences of the SARS-CoV-2 genome and proteins, for numerous variants, are known in the art, see, e.g., SEQ ID NOs: 110-127. More information about SARS-CoV-2 and its genome canAtty. Dkt. No. 043214-000114WOPTbe found, for example, in Zhu, W. et al., SLAS Discov.2022 Mar 29;25(10): 1141— 1151, the contents of which are hereby incorporated in its entirety.

[0045] A viral vector system useful for delivery of nucleic acids in the present methods is the adeno-associated virus (AAV). “AAV” as used herein refers to a viral particle composed of at least one AAV capsid protein and an encapsidated polynucleotide. In some embodiments of any of the embodiments, the AAV comprises a 25 nm capsid and a single-stranded DNA (ssDNA) genome. If the particle comprises a heterologous polynucleotide (i.e., a polynucleotide other than a wild-type AAV genome such as a transgene to be delivered to a mammalian cell), it can be referred to as a recombinant adeno-associated virus (rAAV). Sequences of a variety of AAV genomes and AAV vectors are known in the art.

[0046] AAV as used herein may be used to refer to the wild-type virus itself or derivatives thereof. The term covers all subtypes, serotypes and pseudotypes, and both naturally occurring and recombinant forms, except where required otherwise. As used herein, the term “serotype” refers to an AAV which is identified by and distinguished from other AAVs based on its binding properties.

[0047] The term “vector” encompasses any genetic element that is capable of replication when associated with the proper control elements and that can transfer gene sequences to cells. As used herein, a vector can be viral or non-viral. A vector can include, but is not limited to, a cloning vector, an expression vector, a plasmid, phage, transposon, cosmid, chromosome, virus, virion, etc.

[0048] In some embodiments of any of the aspects, the vector is recombinant, e.g., it comprises sequences originating from at least two different sources. In some embodiments of any of the aspects, the vector comprises sequences originating from at least two different species. In some embodiments of any of the aspects, the vector comprises sequences originating from at least two different genes, e.g., it comprises a fusion protein or a nucleic acid encoding an expression product which is operably linked to at least one non-native (e.g., heterologous) genetic control element (e.g., a promoter, suppressor, activator, enhancer, response element, or the like).

[0049] As used herein, the term “viral vector" refers to a nucleic acid vector construct that includes at least one element of viral origin and has the capacity to be packaged into a viral vector particle. The viral vector can contain the nucleic acid encoding a polypeptide as described herein in place of non-essential viral genes. The vector and / or particle may be utilized for the purpose of transferring any nucleic acids into cells either in vitro or in vivo. Introduction of AAV vector into cells has been described in the art in, for example, Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985). Numerous forms of viral vectors are known in the art. It should be understood that the vectors described herein can, in some embodiments, be combined with other suitable compositions and therapies.

[0050] In some embodiments of any of the aspects, the vector comprises at least one nucleic acid molecule. In some embodiments of any of the aspects, the vector comprises a nucleic acidAtty. Dkt. No. 043214-000114WOPTmolecule. In some embodiments of any of the aspects, the vector comprises more than one nucleic acid molecule. In some embodiments of any of the aspects, the vector comprises at least one nucleic acid encoding a Cas endonuclease and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene. In some embodiments of any of the aspects, the vector comprises a nucleic acid encoding a Cas endonuclease and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene. In some embodiments of any of the aspects, the vector comprises more than one nucleic acid encoding a Cas endonuclease and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene.

[0051] In some embodiments of any of the aspects, the vector comprises at least one nucleic acid molecule encoding a Cas endonuclease and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene. In some embodiments of any of the aspects, the vector comprises a nucleic acid molecule encoding a Cas endonuclease and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene. In some embodiments of any of the aspects, the vector comprises more than one nucleic acid molecule encoding a Cas endonuclease and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene.

[0052] In some embodiments of any of the aspects, the vector comprises at least one nucleic acid encoding a Cas endonuclease and one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene. In some embodiments of any of the aspects, the vector comprises a nucleic acid encoding a Cas endonuclease and one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene. In some embodiments of any of the aspects, the vector comprises more than one nucleic acid encoding a Cas endonuclease and one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene.

[0053] In some embodiments of any of the aspects, the vector comprises at least one nucleic acid encoding a Cas endonuclease and more than one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene. In some embodiments of any of the aspects, the vector comprises a nucleic acid encoding a Cas endonuclease and more than one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene. In some embodiments of any of the aspects, the vector comprises more than one nucleic acid encoding a Cas endonuclease and more than one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene.

[0054] In some embodiments of any of the aspects, the SARS-Cov-2 gene is 3C-like protease (3CL) (e.g., SEQ ID NO: 1150). In some embodiments of any of the aspects, the SARS-Cov-2 gene is Programmed ribosomal frameshifting (PRF) (e.g., SEQ ID NO: 1050). In some embodiments of any of the aspects, the SARS-Cov-2 gene is RNA-dependent RNA polymeraseAtty. Dkt. No. 043214-000114WOPT(Rdrp) (e.g., SEQ ID NO: 1060). In some embodiments of any of the aspects, the SARS-Cov-2 gene is Spike (S) (e.g., SEQ ID NO: 1010). In some embodiments of any of the aspects, the SARS-Cov-2 gene is Envelope (E) (e.g., SEQ ID NO: 1020). In some embodiments of any of the aspects, the SARS-Cov-2 gene is Membrane (M) (e.g., SEQ ID NO: 1030). In some embodiments of any of the aspects, the SARS-Cov-2 gene is Nucleocapsid (N) (e.g., SEQ ID NO: 1040).

[0055] The vector can also include one or more sequences that promote expression of a transgene, e.g., one or more promoter sequences; enhancer sequences, e.g., 5' untranslated region (UTR) or a 3' UTR; a polyadenylation sequence; and / or insulator sequences. In some embodiments of any of the aspects, the polyadenylation sequence is the soluble neuropilin-1 (sNRPl) polyadenylation sequence (SEQ ID NO: 205).

[0056] In some aspects of any of the embodiments, disclosed herein is AAV comprising the vector of any one of the embodiments described herein and at least one capsid polypeptide.

[0057] As used herein, a capsid polypeptide refers to a protein subunit of the outer shell (capsid) of a virus, e.g., an AAV. AAV capsid sequences are known in the art, see, e.g., Bennet et al., Future Virol. 2017 Jun 8;12(6):283-297, the contents of which are hereby incorporated in its entirety.

[0058] In some embodiments of any of the aspects, the at least one capsid polypeptide comprises at least four contiguous amino acids from the sequence TVSALFK (SEQ ID NO: 301); TVSALK (SEQ ID NO: 302); KLASVT (SEQ ID NO: 303); or KFLASVT (SEQ ID NO: 304). Further examples of capsid polypeptides applicable to the technology disclosed herein are described in US20230048492A1 and US11518787B2, the contents of each of which are incorporated herein by reference in their entireties.

[0059] In some embodiments, the at least one capsid polypeptide comprises a sequence of Xi X2X3X4 X5, wherein (i) Xi, X2, X3, X4 are any four non-identical amino acids of V, A, L, I, G, P, S, T, or M; and (ii) X5is K, R, H, D, or E.

[0060] In some embodiments, the at least one capsid polypeptide comprises a sequence of at least 6 amino acids. In some embodiments, the at least one capsid polypeptide comprises at least 4, e.g., 5 or 6 contiguous amino acids of the sequences TVPALR (SEQ ID NO: 306), TVSALK (SEQ ID NO: 302), TVPMLK (SEQ ID NO: 307), and TVPTLK (SEQ ID NO: 308).

[0061] In some embodiments, the at least one capsid polypeptide comprises a sequence of Xi X2X3X4 X5X6, wherein (i) Xi is T; (ii) X2, X3, X4, X5are any four non-identical amino acids of V, A, L, I, G, P, S, T, or M; and (iii) X6is K, R, H, D, or E.

[0062] In some embodiments, the at least one capsid polypeptide comprises a sequence of Xi X2X3X4 X5 Xe, wherein (i) Xi, X2, X3, X4 are any four non-identical amino acids from V, A, L, I, G, P, S, T, or M; (ii) X5 is K, R, H, D, or E; and (iii) Xg is E or D.

[0063] In some embodiments, the at least one capsid polypeptide comprises a sequence of at least 7 amino acids. In some embodiments, the at least one capsid polypeptide comprises a sequenceAtty. Dkt. No. 043214-000114WOPTof at least 4, e.g., 5, 6, or 7 contiguous amino acids of the sequences FTVSALK (SEQ ID NO: 311), LTVSALK (SEQ ID NO:312), TVSALFK (SEQ ID NO: 313), TVPALFR (SEQ ID NO: 314), TVPMLFK (SEQ ID NO: 315) and TVPTLFK (SEQ ID NO: 316).

[0064] In some embodiments, the at least one capsid polypeptide comprises a sequence of Xi X2X3X4 X5X6X7, wherein (i) Xi is F, L, W, or Y; (ii) X2is T; (iii) X3, X4, X5, X6are any four nonidentical amino acids of V, A, L, I, G, P, S, T, or M; and (iv) X7is K, R, H, D, or E.

[0065] In some embodiments, the at least one capsid polypeptide comprises a sequence of Xi X2X3X4 X5 Xe X7, wherein (i) Xi is T; (ii) X2, X3, X4, X5 are any four non-identical amino acids of V, A, L, I, G, P, S, T, or M; (iii) X6is K, R, H, D, or E; and (iv) X7is E or D.

[0066] In some embodiments, the at least one capsid polypeptide comprises a sequence of Xi X2X3X4 X5X6X7, wherein: (i) Xi, X2, X3, X4 are any four non-identical amino acids of V, A, L, I, G, P, S, T, or M; (ii) X5 is K, R, H, D, or E; (iii) Xs is E or D; and (iv) X7is A or I.

[0067] The technology disclosed herein relates to the CRISPR / Cas system. The native prokaryotic CRISPR-associated nuclease system comprises an array of short repeats with intervening variable sequences of constant length (i.e., clusters of regularly interspaced short palindromic repeats), and CRISPR-associated (" Cas") nuclease proteins. The RNA of the transcribed CRISPR array is processed by a subset of the Cas proteins into small guide RNAs, which generally have two components as discussed below. In the native prokaryotic system, the guide RNA ("gRNA") comprises two short, non-coding RNA species referred to as CRISPR RNA ("crRNA") and trans-acting RNA ("tracrRNA"). In an exemplary system, the gRNA forms a complex with a nuclease, for example, a Cas nuclease. The gRNA: nuclease complex binds a target polynucleotide sequence having a protospacer adjacent motif (" PAM") and a protospacer, which is a sequence complementary to a portion of the gRNA. The recognition and binding of the target polynucleotide by the gRNA: nuclease complex induces cleavage of the target.

[0068] As used herein, the terms “CRISPR-associated guide RNA”, “guide nucleic acid,” “guide sequence,” “crRNA,” “guide RNA,” “single guide RNA,” “gRNA”, “gNA” or “CRISPR guide sequence” refer to a nucleic acid molecule or complex comprising at least i) a sequence with at least partial complementarity to a target nucleic acid sequence (e.g., one of the SARS-CoV-2 genes described herein) and ii) a sequence comprising a plurality of stem-loops..

[0069] In some embodiments of any of the aspects, the gRNA is a single guide RNA molecule (sgRNA) comprising both i) a sequence with at least partial complementarity to a target nucleic acid sequence (e.g., one of the SARS-CoV-2 genes described herein) and ii) a sequence comprising a plurality of stem-loops. A sgRNA is typically an artificial fusion of a crRNA and a tracrRNA. The i) a sequence with at least partial complementarity to a target nucleic acid sequence (e.g., one of the SARS-Atty. Dkt. No. 043214-000114WOPTCoV-2 genes described herein), referred to in the art as the “spacer”, and ii) a sequence comprising a plurality of stem-loops are linked by a tetraloop and each have a short sequence for hybridization with each other (e.g., a repeat and an anti-repeat) thus generating a chimeric sgRNA.

[0070] One can change the genomic target of the Cas nuclease by simply changing the complementary region sequence present in the gRNA. The complementary region will direct the Cas nuclease to the target DNA site through standard RNA-DNA complementary base pairing rules.

[0071] In some embodiments of any of the aspects, the sequence with at least partial complementarity to a target nucleic acid sequence is fully complementary. Full complementarity between the target sequence and the guide sequence is not necessarily required, provided there is sufficient complementarity to permit hybridization and promote formation of an active CRISPR complex. In some embodiments of any of the aspects, the sequence with at least partial complementarity to a target nucleic acid sequence can hybridize with the target nucleic acid sequence. In some embodiments of any of the aspects, the sequence with at least partial complementarity to a target nucleic acid sequence can hybridize specifically with the target nucleic acid sequence.

[0072] As used herein, the term “hybridization” refers to the formation of one or more complementary base pairs between two nucleic acids, e.g., two complementary nucleic acids strands or two complementary regions annealing by base pair interactions. In some embodiments, conditions for hybridization may vary based on the length and sequence of the complementary sequences. In some embodiments, conditions for hybridization are based upon a Tm(e.g., a calculated Tm) of the complementary sequences. In some embodiments, the methods described herein can be conducted at a temperature which is lower than the Tm(e.g., a calculated Tm) for the complementary sequences. In some embodiments, a Tmcan be determined using any of a number of algorithms (e.g., OLIGO™ (Molecular Biology Insights Inc. Colorado) primer design software and VENTRO NTI™ (Invitrogen, Inc. California) design software and programs available on the internet, including Primer3, Oligo Calculator, and NetPrimer (Premier Biosoft; Palo Alto, CA; and freely available on the world wide web (e.g., at premierbiosoft.com / netprimer / netprlaunch / Help / xnetprlaunch.html). In some embodiments, the Tmof the complementary sequences can be calculated using following formula, which is used by NetPrimer software and is described in more detail in Frieir et al. PNAS 1986 83:9373-9377 which is incorporated by reference herein in its entirety.Tm= AH / (AS + R * ln(C / 4)) + 16.6 log ([K+] / (l + 0.7 [K+])) - 273.15wherein, AH is enthalpy for helix formation; AS is entropy for helix formation; R is molar gas constant (1.987 cal / °C * mol); C is the nucleic acid concentration; and [K+] is salt concentration. In some embodiments, the closer a hybridization temperature is to the Tm, the more specific is the hybridization.

[0073] As used herein, “specific” when used in the context of the hybridization of two complementary nucleic acids refers to a level of complementarity between the two nucleic acids (orAtty. Dkt. No. 043214-000114WOPTregions thereof) such that there exists an annealing temperature at which the first nucleic acid will anneal to the second nucleic acid and will not anneal to non-target sequences present in a sample or cell.

[0074] In some embodiments, the target polynucleotide sequence comprises a protospacer adjacent motif (" PAM") and a protospacer. As used herein, a PAM is a sequence comprising 2-6 nucleic acids immediately adjacent to the sequence complementary to a portion of the gRNA. The protospacer is the sequence complementary to a portion of the gRNA. In some embodiments, the protospacer is 5-30 nucleotides in length. In some embodiments, the protospacer is 17-23 nucleotides in length. A target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides. In some embodiments, the SARS-CoV-2 gene is Rdrp (e.g., SEQ ID NO: 606). In some embodiments, the SARS-CoV-2 gene is 3CL (e.g., SEQ ID NO: 607). In some embodiments, the SARS-CoV-2 gene is PRF (e.g., SEQ ID NO: 605). In some embodiments, the SARS-CoV-2 gene is S (e,g., SEQ ID NO: 601). In some embodiments, the SARS-CoV-2 gene is E (e.g., SEQ ID NO: 602). In some embodiments, the SARS-CoV-2 gene is N (e.g., SEQ ID NO: 604). In some embodiments, the SARS-CoV-2 gene is M (e.g., SEQ ID NO: 603). In some embodiments, a target sequence is located in the nucleus or cytoplasm of a cell.

[0075] In some embodiments of any of the aspects, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 80% identical to a sequence of a naturally occurring SARS-CoV-2 gene, e.g., a portion or window of a naturally-occurring SARS-CoV-2 gene. For example, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 80% identical to the naturally occurring Rdrp gene, e.g., a portion or window of a naturally-occurring Rdrp gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 80% identical to the naturally occurring 3CL gene, e.g., a portion or window of a naturally-occurring 3CL gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 80% identical to the naturally occurring PRF gene, e.g., a portion or window of a naturally-occurring PRF gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 80% identical to the naturally occurring S gene, e.g., a portion or window of a naturally-occurring S gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 80% identical to the naturally occurring M gene, e.g., a portion or window of a naturally-occurring M gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 80% identical to the naturally occurring E gene, e.g., a portion or window of a naturally-occurring E gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 80% identical to the naturally occurring N gene, e.g., a portion or window of a naturally-occurring N gene.Atty. Dkt. No. 043214-000114WOPT

[0076] In some embodiments of any of the aspects, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 85% identical to a naturally occurring SARS-CoV-2 gene, e.g., a portion or window of a naturally-occurring SARS-CoV-2 gene. For example, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 85% identical to the naturally occurring Rdrp gene, e.g., a portion or window of a naturally-occurring Rdrp gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 85% identical to the naturally occurring 3CL gene, e.g., a portion or window of a naturally-occurring 3CL gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 85% identical to the naturally occurring PRF gene, e.g., a portion or window of a naturally-occurring PRF gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 85% identical to the naturally occurring S gene, e.g., a portion or window of a naturally-occurring S gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 85% identical to the naturally occurring M gene, e.g., a portion or window of a naturally-occurring M gene. In some embodiments, the protospacer comprises a sequence from 15-30, or 17-23 nucleotides in length which is at least 85% identical to the naturally occurring E gene, e.g., a portion or window of a naturally-occurring E gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 85% identical to the naturally occurring N gene, e.g., a portion or window of a naturally-occurring N gene.

[0077] In some embodiments of any of the aspects, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% identical to a naturally occurring SARS-CoV-2 gene, e.g., a portion or window of a naturally-occurring SARS-CoV-2 gene. For example, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% identical to the naturally occurring Rdrp gene, e.g., a portion or window of a naturally-occurring Rdrp gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% identical to the naturally occurring 3CL gene, e.g., a portion or window of a naturally-occurring 3CL gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% identical to the naturally occurring PRF gene, e.g., a portion or window of a naturally-occurring PRF gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% identical to the naturally occurring S gene, e.g., a portion or window of a naturally-occurring S gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% identical to the naturally occurring M gene, e.g., a portion or window of a naturally-occurring M gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% identical to the naturally occurring E gene, e.g., a portion or window of a naturally-occurring E gene. In some embodiments,Atty. Dkt. No. 043214-000114WOPTthe protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% identical to the naturally occurring N gene, e.g., a portion or window of a naturally-occurring N gene.

[0078] In some embodiments of any of the aspects, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% identical to a naturally occurring SARS-CoV-2 gene, e.g., a portion or window of a naturally-occurring SARS-CoV-2 gene. For example, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% identical to the naturally occurring Rdrp gene, e.g., a portion or window of a naturally-occurring Rdrp gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% identical to the naturally occurring 3CL gene, e.g., a portion or window of a naturally-occurring 3CL gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% identical to the naturally occurring PRF gene, e.g., a portion or window of a naturally-occurring PRF gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% identical to the naturally occurring S gene, e.g., a portion or window of a naturally-occurring S gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% identical to the naturally occurring M gene, e.g., a portion or window of a naturally-occurring M gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% identical to the naturally occurring E gene, e.g., a portion or window of a naturally-occurring E gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% identical to the naturally occurring N gene, e.g., a portion or window of a naturally-occurring N gene.

[0079] In some embodiments of any of the aspects, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 98% identical to a naturally occurring SARS-CoV-2 gene, e.g., a portion or window of a naturally-occurring SARS-CoV-2 gene. For example, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 98% identical to the naturally occurring Rdrp gene, e.g., a portion or window of a naturally-occurring Rdrp gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 98% identical to the naturally occurring 3CL gene, e.g., a portion or window of a naturally-occurring 3CL gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 98% identical to the naturally occurring PRF gene, e.g., a portion or window of a naturally-occurring PRF gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 98% identical to the naturally occurring S gene, e.g., a portion or window of a naturally-occurring S gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 98% identical to the naturally occurring M gene, e.g., a portion or window of a naturally-occurring M gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% identical to the naturallyAtty. Dkt. No. 043214-000114WOPToccurring E gene, e.g., a portion or window of a naturally-occurring E gene. In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 98% identical to the naturally occurring N gene, e.g., a portion or window of a naturally-occurring N gene.

[0080] The sequence comprising a plurality of stem-loops can vary in sequence depending on the Cas endonuclease being used. Sequences for the sequence comprising a plurality of stem-loops are known in the art, see, e.g., Briner et al. Molecular Cell 56(2):333-339 (2014); Weirdt et al. Nature Communications 013:5255 (2022); and Saeger SynBio 3(4): 19 (2025) each of which is incorporated by reference herein in its entirety.

[0081] In some embodiments of any of the aspects, the protospacer comprises a sequence 5-30, or 17-23 nucleotides in length which is at least 80% identical to a naturally occurring SARS-CoV-2 gene, e.g., a portion or window of a naturally-occurring SARS-CoV-2 gene. For example, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 80% identical to the naturally occurring Rdrp gene, e.g., a portion or window of a naturally-occurring Rdrp gene (e.g., SEQ ID NO: 606). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 80% identical to the naturally occurring 3CL gene, e.g., a portion or window of a naturally-occurring 3CL gene (e.g., SEQ ID NO: 607). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 80% identical to the naturally occurring PRF gene, e.g., a portion or window of a naturally-occurring PRF gene (e.g., SEQ ID NO: 605). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 80% identical to the naturally occurring S gene, e.g., a portion or window of a naturally-occurring S gene (e.g., SEQ ID NO: 601). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 80% identical to the naturally occurring M gene, e.g., a portion or window of a naturally-occurring M gene (e.g., SEQ ID NO: 603). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 80% identical to the naturally occurring E gene, e.g., a portion or window of a naturally-occurring E gene (e.g., SEQ ID NO: 602). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 80% identical to the naturally occurring N gene, e.g., a portion or window of a naturally-occurring N gene (e.g., SEQ ID NO: 604).

[0082] In some embodiments of any of the aspects, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 85% identical to a naturally occurring SARS-CoV-2 gene, e.g., a portion or window of a naturally-occurring SARS-CoV-2 gene. For example, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 85% complementary to the naturally occurring Rdrp gene, e.g., a portion or window of a naturally-occurring Rdrp gene (e.g., SEQ ID NO: 606). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 85% identical to the naturally occurring 3CL gene,Atty. Dkt. No. 043214-000114WOPTe.g., a portion or window of a naturally-occurring 3CL gene (e.g., SEQ ID NO: 607). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 85% identical to the naturally occurring PRF gene, e.g., a portion or window of a naturally-occurring PRF gene (e.g., SEQ ID NO: 605). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 85% identical to the naturally occurring S gene, e.g., a portion or window of a naturally-occurring S gene (e.g., SEQ ID NO: 601). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 85% identical to the naturally occurring M gene, e.g., a portion or window of a naturally-occurring M gene (e.g., SEQ ID NO: 603). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 85% identical to the naturally occurring E gene, e.g., a portion or window of a naturally-occurring E gene (e.g., SEQ ID NO: 602). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 85% identical to the naturally occurring N gene, e.g., a portion or window of a naturally-occurring N gene (e.g., SEQ ID NO: 604).

[0083] In some embodiments of any of the aspects, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% identical to a naturally occurring SARS-CoV-2 gene, e.g., a portion or window of a naturally-occurring SARS-CoV-2 gene. For example, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% complementary to the naturally occurring Rdrp gene, e.g., a portion or window of a naturally-occurring Rdrp gene (e.g., SEQ ID NO: 606). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% identical to the naturally occurring 3CL gene, e.g., a portion or window of a naturally-occurring 3CL gene (e.g., SEQ ID NO: 607). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% identical to the naturally occurring PRF gene, e.g., a portion or window of a naturally-occurring PRF gene (e.g., SEQ ID NO: 605). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% identical to the naturally occurring S gene, e.g., a portion or window of a naturally-occurring S gene (e.g., SEQ ID NO: 601). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% identical to the naturally occurring M gene, e.g., a portion or window of a naturally-occurring M gene (e.g., SEQ ID NO: 603). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% identical to the naturally occurring E gene, e.g., a portion or window of a naturally-occurring E gene (e.g., SEQ ID NO: 602). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 90% identical to the naturally occurring N gene, e.g., a portion or window of a naturally-occurring N gene (e.g., SEQ ID NO: 604).

[0084] In some embodiments of any of the aspects, the protospacer comprises a sequence 5-30, or 17-23 nucleotides in length which is at least 95% identical to a naturally occurring SARS-CoV-2Aty. Dkt. No. 043214-000114WOPTgene, e.g., a portion or window of a naturally-occurring SARS-CoV-2 gene. For example, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% complementary to the naturally occurring Rdrp gene, e.g., a portion or window of a naturally-occurring Rdrp gene (e.g., SEQ ID NO: 606). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% identical to the naturally occurring 3CL gene, e.g., a portion or window of a naturally-occurring 3CL gene (e.g., SEQ ID NO: 607). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% identical to the naturally occurring PRF gene, e.g., a portion or window of a naturally-occurring PRF gene (e.g., SEQ ID NO: 605). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% identical to the naturally occurring S gene, e.g., a portion or window of a naturally-occurring S gene (e.g., SEQ ID NO: 601). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% identical to the naturally occurring M gene, e.g., a portion or window of a naturally-occurring M gene (e.g., SEQ ID NO: 603). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% identical to the naturally occurring E gene, e.g., a portion or window of a naturally-occurring E gene (e.g., SEQ ID NO: 602). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 95% identical to the naturally occurring N gene, e.g., a portion or window of a naturally-occurring N gene (e.g., SEQ ID NO: 604).

[0085] In some embodiments of any of the aspects, the protospacer comprises a sequence 5-30, or 17-23 nucleotides in length which is at least 98% identical to a naturally occurring SARS-CoV-2 gene, e.g., a portion or window of a naturally-occurring SARS-CoV-2 gene. For example, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 98% complementary to the naturally occurring Rdrp gene, e.g., a portion or window of a naturally-occurring Rdrp gene (e.g., SEQ ID NO: 606). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 98% identical to the naturally occurring 3CL gene, e.g., a portion or window of a naturally-occurring 3CL gene (e.g., SEQ ID NO: 607). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 98% identical to the naturally occurring PRF gene, e.g., a portion or window of a naturally-occurring PRF gene (e.g., SEQ ID NO: 605). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 98% identical to the naturally occurring S gene, e.g., a portion or window of a naturally-occurring S gene (e.g., SEQ ID NO: 601). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 98% identical to the naturally occurring M gene, e.g., a portion or window of a naturally-occurring M gene (e.g., SEQ ID NO: 603). In some embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 98% identical to the naturally occurring E gene, e.g., a portion or window of a naturally-occurring E gene (e.g., SEQ ID NO: 602). InAtty. Dkt. No. 043214-000114WOPTsome embodiments, the protospacer comprises a sequence from 5-30, or 17-23 nucleotides in length which is at least 98% identical to the naturally occurring N gene, e.g., a portion or window of a naturally-occurring N gene (e.g, SEQ ID NO: 604).

[0086] In some embodiments of any of the aspects, the CRISPR-associated guide RNA sequence further comprises a leader sequence. In some embodiments of any of the aspects, the leader sequence is rich in adenine and thymine.

[0087] The full-length guide nucleic acid strand can be any length. For example, the guide nucleic acid strand can be about or more than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments of the various aspects described herein, a nucleic acid strand is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length. For example, the guide nucleic acid sequence is 10-30 nucleotides long.

[0088] In some embodiments of any of the aspects, the CRISPR-associated guide RNA determines the specificity of an enzyme, e.g., the Cas endonuclease of a CRISPR / Cas system, to a polynucleotide target.

[0089] As used herein, “Cas endonuclease” refers to a modular protein comprising at least one Recognition (REC) lobe and at least one NUC (Nuclease) lobe. In some embodiments of any of the aspects, a Cas endonuclease forms a complex with a CRISPR-associated guide RNA. In some embodiments of any of the aspects, the Cas endonuclease can be native or engineered.

[0090] In some embodiments of any of the aspects, the CRISPR-associated guide RNA can hybridize with a taiget nucleic acid sequence and direct sequence-specific binding of an enzyme, e.g, a Cas endonuclease, to the target polynucleotide sequence. In some embodiments of any of the aspects, the gRNA forms a complex with a nuclease, e.g., a Cas endonuclease, which binds a target polynucleotide sequence.

[0091] In some aspects of any of the embodiments, disclosed herein is an adeno-associated virus (AAV) vector comprising one or more nucleic acids encoding a Cas endonuclease and at least one CRISPR-associated guide RNA sequence.

[0092] In some embodiments of any of the aspects, the least one CRISPR-associated guide RNA sequence hybridizes specifically with a SARS-CoV-2 gene selected from the group consisting of: 3C-like protease (3CL), Programmed ribosomal frameshifting (PRF), RNA-dependent RNA polymerase (Rdrp), Spike (S), Envelope (E), Membrane (M), and Nucleocapsid (N).

[0093] In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with at least one of SEQ ID NOs: 601-607. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 80% identical to at least one of SEQ ID NOs: 601-607. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNAAtty. Dkt. No. 043214-000114WOPTsequence hybridizes specifically with a sequence that is at least 85% identical to at least one of SEQ ID NOs: 601-607. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 90% identical to at least one of SEQ ID NOs: 601-607. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 95% identical to at least one of SEQ ID NOs: 601-607. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 98% identical to at least one of SEQ ID NOs: 601-607.

[0094] In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with SEQ ID NO: 601. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 80% identical to SEQ ID NO: 601. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 85% identical to SEQ ID NO: 601. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 90% identical to SEQ ID NO: 601. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 95% identical to SEQ ID NO: 601. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 98% identical to SEQ ID NO: 601.

[0095] In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with SEQ ID NO: 602. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 80% identical to SEQ ID NO: 602. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 85% identical to SEQ ID NO: 602. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 90% identical to SEQ ID NO: 602. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 95% identical to SEQ ID NO: 602. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 98% identical to SEQ ID NO: 602.

[0096] In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with SEQ ID NO: 603. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 80% identical to SEQ ID NO: 603. In some embodiments of any of theAtty. Dkt. No. 043214-000114WOPTaspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 85% identical to SEQ ID NO: 603. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 90% identical to SEQ ID NO: 603. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 95% identical to SEQ ID NO: 603. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 98% identical to SEQ ID NO: 603.

[0097] In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with SEQ ID NO: 604. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 80% identical to SEQ ID NO: 604. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 85% identical to SEQ ID NO: 604. In some aspects of any of the embodiments, disclosed herein is an adeno-associated virus (AAV) vector comprising one or more nucleic acids encoding Cas endonuclease and at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 90% identical to SEQ ID NO: 604. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 95% identical to SEQ ID NO: 604. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 98% identical to SEQ ID NO: 604.

[0098] In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with SEQ ID NO: 605. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 80% identical to SEQ ID NO: 605. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 85% identical to SEQ ID NO: 605. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 90% identical to SEQ ID NO: 605. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 95% identical to SEQ ID NO: 605. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 98% identical to SEQ ID NO: 605.

[0099] In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with SEQ ID NO: 606. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with aAtty. Dkt. No. 043214-000114WOPTsequence that is at least 80% identical to SEQ ID NO: 606. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 85% identical to SEQ ID NO: 606. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 90% identical to SEQ ID NO: 606. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 95% identical to SEQ ID NO: 606. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 98% identical to SEQ ID NO: 606.

[0100] In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with SEQ ID NO: 607. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 80% identical to SEQ ID NO: 607. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 85% identical to SEQ ID NO: 607. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 90% identical to SEQ ID NO: 607. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 95% identical to SEQ ID NO: 607. In some embodiments of any of the aspects, the at least one CRISPR-associated guide RNA sequence hybridizes specifically with a sequence that is at least 98% identical to SEQ ID NO: 607.

[0101] In some embodiments of any of the aspects, the AAV vector comprises at least one nucleic acid encoding a Cas endonuclease. Exemplary Cas endonucleases include, but are not limited to, CasRX, Casl, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csxl2), CaslO, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, Csf4, and homologues or orthologues thereof, or modified versions thereof.

[0102] Any Cas endonuclease can be used in the system and methods of the invention. Cas endonuclease systems are known to those of skill in the art, e.g. Cas9, Cas 12, Cas 12a, or the like, see Patents / applications 8,993,233, US 2015 / 0291965, US 2016 / 0175462, US 2015 / 0020223, US 2014 / 0179770, 8,697,359; 8,771,945; 8, 795,965; WO 2015 / 191693; US 8,889,418; WO 2015 / 089351; WO 2015 / 089486; WO 2016 / 028682; WO 2016 / 049258; WO 2016 / 094867; WO 2016 / 094872; WO 2016 / 094874; WO 2016 / 112242; US 2016 / 0153004; US 2015 / 0056705; US 2016 / 0090607; US 2016 / 0029604; 8,865,406; 8,871,445; each of which are incorporated by referenceAtty. Dkt. No. 043214-000114WOPTin their entirety. The nuclease can also be a phage Cas nuclease, e.g., CasO (e.g., Pausch et al. Science 369:333-7 (2020); which is incorporated by reference herein in its entirety).

[0103] In some embodiments of any of the aspects, the nucleic acid encodes a CasRx endonuclease. As used herein, CasRx, also referred to as RfxCasl3d, is an engineered variant of Ruminococcus flavefaciens Casl3d endonuclease. CasRx comprises an N-terminal domain, two Higher eukaryotes and prokaryotes nucleotide-binding (HEPN) domains, and two linker domains. In some embodiments, CasRx possesses enhanced RNA cleavage activity and specificity in human cells compared to other Cas nucleases. In some embodiments, CasRx comprises around 900 to around 100 amino acids. CasRx is described in further detail in Chuang, Y. et al., Front Cell Dev Biol. 2021 Jun 11;9:667879, the contents of which are hereby incorporated in its entirety.

[0104] In some aspects of any of the embodiments, disclosed herein is an adeno-associated virus (AAV) vector comprising one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206); and at least one CRISPR-associated guide RNA sequence.

[0105] In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene selected from the group consisting of: 3C-like protease (3CL), Programmed ribosomal frameshifting (PRF), RNA-dependent RNA polymerase (Rdrp), Spike (S), Envelope (E), Membrane (M), and Nucleocapsid (N).

[0106] In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with at least one of SEQ ID NOs: 601-607. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 80% identical to at least one of SEQ ID NOs: 601-607. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 85% identical to at least one of SEQ ID NOs: 601-607. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 90% identical to at least one of SEQ ID NOs: 601-607. In some embodiments of any of the aspects, theAtty. Dkt. No. 043214-000114WOPTadeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 95% identical to at least one of SEQ ID NOs: 601-607. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 98% identical to at least one of SEQ ID NOs: 601-607.

[0107] In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with SEQ ID NO: 601. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 80% identical to SEQ ID NO: 601. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 85% identical to SEQ ID NO: 601. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 90% identical to SEQ ID NO: 601. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 95% identical to SEQ ID NO: 601. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 98% identical to SEQ ID NO: 601.

[0108] In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with SEQ ID NO: 602. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 80% identical to SEQ ID NO:Atty. Dkt. No. 043214-000114WOPT602. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 85% identical to SEQ ID NO: 602. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 90% identical to SEQ ID NO: 602. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 95% identical to SEQ ID NO: 602. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 98% identical to SEQ ID NO: 602.

[0109] In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with SEQ ID NO: 603. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 80% identical to SEQ ID NO: 603. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 85% identical to SEQ ID NO: 603. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 90% identical to SEQ ID NO: 603. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 95% identical to SEQ ID NO: 603. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 98% identical to SEQ ID NO: 603.Atty. Dkt. No. 043214-000114WOPT

[0110] In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with SEQ ID NO: 604. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 80% identical to SEQ ID NO: 604. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 85% identical to SEQ ID NO: 604. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 90% identical to SEQ ID NO: 604. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 95% identical to SEQ ID NO: 604. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 98% identical to SEQ ID NO: 604.

[0111] In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with SEQ ID NO: 605. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 80% identical to SEQ ID NO: 605. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 85% identical to SEQ ID NO: 605. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 90% identical to SEQ ID NO: 605. In some embodiments of any of the aspects, the adeno-Atty. Dkt. No. 043214-000114WOPTassociated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 95% identical to SEQ ID NO: 605. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 98% identical to SEQ ID NO: 605.

[0112] In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with SEQ ID NO: 606. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 80% identical to SEQ ID NO: 606. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 85% identical to SEQ ID NO: 606. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 90% identical to SEQ ID NO: 606. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 95% identical to SEQ ID NO: 606. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 98% identical to SEQ ID NO: 606.

[0113] In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with SEQ ID NO: 607. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 80% identical to SEQ ID NO: 607. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprisesAtty. Dkt. No. 043214-000114WOPTone or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 85% identical to SEQ ID NO: 607. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 90% identical to SEQ ID NO: 607. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 95% identical to SEQ ID NO: 607. In some embodiments of any of the aspects, the adeno-associated virus (AAV) vector comprises one or more nucleic acids encoding a polypeptide having at least 80% sequence identity to CasRx (SEQ ID NO: 206) and at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a sequence that is at least 98% identical to SEQ ID NO: 607.

[0114] In some embodiments of any of the aspects, the CasRx endonuclease comprises at least one nuclear localization sequence. In some embodiments of any of the aspects, the CasRx endonuclease comprises two nuclear localization sequences. In some embodiments of any of the aspects, the CasRx endonuclease comprises at least two nuclear localization sequences. In some embodiments of any of the aspects, the CasRx endonuclease comprises one affinity tag. In some embodiments of any of the aspects, the CasRx endonuclease comprises at least one affinity tag.

[0115] In some embodiments of any of the aspects, the CasRx endonuclease comprises at least one SV40 nuclear localization sequence. In some embodiments of any of the aspects, the CasRx endonuclease comprises two SV40 nuclear localization sequences. In some embodiments of any of the aspects, the CasRx endonuclease comprises at least two SV40 nuclear localization sequences. In some embodiments of any of the aspects, the CasRx endonuclease comprises one HA tag. In some embodiments of any of the aspects, the CasRx endonuclease comprises at least one HA tag.

[0116] In some embodiments of any of the aspects, the at least one nuclear localization sequence comprises SV40. In some embodiments of any of the aspects, the at least one nuclear localization sequence consists of SV40. In some embodiments of any of the aspects, the at least one nuclear localization sequence consists essentially of SV40.

[0117] In some embodiments of any of the aspects, the affinity tag comprises an HA tag. In some embodiments of any of the aspects, the affinity tag consists of an HA tag. In some embodiments of any of the aspects, the affinity tag consists essentially of an HA tag.

[0118] In some embodiments of any of the aspects, the at least one affinity tag comprises an HA tag. In some embodiments of any of the aspects, the at least one affinity tag consists of an HA tag.Atty. Dkt. No. 043214-000114WOPTIn some embodiments of any of the aspects, the at least one affinity tag consists essentially of an HA tag.

[0119] In some embodiments of any of the aspects, the CasRx endonuclease comprises two SV40 nuclear localization sequences and one HA tag. In some embodiments of any of the aspects, the CasRx endonuclease comprises at least one SV40 nuclear localization sequence and at least one HA tag. The sequences of SV40 nuclear localization signals and HA tags are known in the art.

[0120] As used herein, a nucleation localization sequence (NLS) refers to an amino acid sequence that tags a protein for import into the cell nucleus. The SV40 NLS is derived from simian virus 40 (SV40) T antigen. In some embodiments, SV40 NLS is installed as genetic fusion to direct the intracellular Cas9 proteins to the nucleus of cells. In some embodiments of any of the aspects, SV40 NLS has the sequence PKKKRKV (SEQ ID NO: 207).

[0121] As used herein “HA tag” refers to a protein tag derived from the human influenza hemagglutinin (HA) protein. In some embodiments of any of the aspects, HA tag has the sequence YPYDVPDYA (SEQ ID NO: 208).

[0122] In some embodiments of any of the aspects, the one or more nucleic acids encode a plurality of CRISPR-associated guide RNA sequences in series. In some embodiments of any of the aspects, the one or more nucleic acids encode two CRISPR-associated guide RNA sequences in series. In some embodiments of any of the aspects, the one or more nucleic acids encode three CRISPR-associated guide RNA sequences in series. In some embodiments of any of the aspects, the one or more nucleic acids encode four CRISPR-associated guide RNA sequences in series. In some embodiments of any of the aspects, the one or more nucleic acids encode four or more CRISPR-associated guide RNA sequences in series.

[0123] In some embodiments of any of the aspects, the nucleic acid encoding a Cas endonuclease is operably linked to a promoter. In some embodiments of any of the aspects, the nucleic acid encoding at least one CRISPR-associated guide RNA sequence is operably linked to a promoter. In some embodiments of any of the aspects, the nucleic acid encoding a Cas endonuclease and the nucleic acid encoding at least one CRISPR-associated guide RNA sequence are operably linked to the same promoter. In some embodiments of any of the aspects, the nucleic acid encoding a Cas endonuclease is operably linked to a first promoter and the nucleic acid encoding at least one CRISPR-associated guide RNA sequence is operably linked to a second promoter.

[0124] “Operably linked” refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, control elements operably linked to a coding sequence are capable of effecting the expression of the coding sequence. The control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can beAtty. Dkt. No. 043214-000114WOPTpresent between a promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.

[0125] As used herein, a “promoter” refers to a specific region of DNA, located upstream of a gene, that initiates transcription. Promoters are classified as constitutive, tissue-specific, stage / temporal-specific, or inducible based on their ability to control gene expression. T

[0126] The EFS promoter (SEQ ID NO: 201), also referred to as the EF-1 Alpha Short promoter, is a cellular-derived enhancer / promoter with decreased cross-activation of nearby promoters. The EFS promoter is described in more detail in, for example, Kao, R. et al., Blood (2014) 124 (21): 3497, the contents of which are hereby incorporated in its entirety.

[0127] The U6 promoter (SEQ ID NO: 204) is a type 3 Pol III promoter. U6 comprises a ~21 bp proximal sequence element, and a ~8 bp TATA box located upstream of the transcription start site (+1) which are reported to be conserved among species. In some embodiments, U6 promoters can drive small hairpin RNA (shRNA) expression in vector-based RNA interference. U6 promoter is described in more detail in, for example, Nie, L. et al., Genomics Proteomics Bioinformatics 2010 Sep; 8(3): 170-179, the contents of which are hereby incorporated in its entirety.

[0128] In some embodiments of any of the aspects, the promoter is an EFS promoter. In some embodiments of any of the aspects, the promoter comprises an EFS promoter. In some embodiments of any of the aspects, the promoter consists of an EFS promoter. In some embodiments of any of the aspects, the promoter consists essentially of an EFS promoter.

[0129] In some embodiments of any of the aspects, the promoter is a U6 promoter. In some embodiments of any of the aspects, the promoter comprises a U6 promoter. In some embodiments of any of the aspects, the promoter consists of a U6 promoter. In some embodiments of any of the aspects, the promoter consists essentially of a U6 promoter.

[0130] In some aspects of any of the embodiments, disclosed herein is an adeno-associated virus (AAV) vector comprising a nucleic acid encoding a soluble receptor and an antibody reagent.

[0131] A soluble receptor is a receptor lacking a transmembrane region. Examples of types of soluble receptors include, but are not limited to, cytokines and growth factors. In some embodiments, soluble receptors can affect cytokine and growth factor signaling at a distance from their site of origin. In some embodiments of any of the aspects, a soluble receptor can be a synthetic or engineered polypeptide comprising only an extracellular domain of a naturally-occurring receptor which is membrane-bound in its wildtype form.

[0132] In some embodiments of any of the aspects, the soluble receptor is a soluble VEGF receptor. In some embodiments of any of the aspects, the soluble receptor is a soluble VEGF receptor comprising 7 extracellular domains (e.g., a polypeptide encoded by SEQ ID NO: 501). In some embodiments of any of the aspects, the soluble VEGF receptor comprises one or more extracellular domains of human VEGF receptor 1 (e.g., a polypeptide encoded by SEQ ID NO: 502) and humanAtty. Dkt. No. 043214-000114WOPTVEGF receptor 2 (e.g., a polypeptide encoded by SEQ ID NO: 503). In some embodiments of any of the aspects, the soluble VEGF receptor consists of one or more extracellular domains of human VEGF receptor 1 (e.g., a polypeptide encoded by SEQ ID NO: 502) and human VEGF receptor 2 (e.g., a polypeptide encoded by SEQ ID NO: 503). In some embodiments of any of the aspects, the soluble VEGF receptor consists essentially of one or more extracellular domains of human VEGF receptor 1 (e.g., a polypeptide encoded by SEQ ID NO: 502) and human VEGF receptor 2 (e.g., a polypeptide encoded by SEQ ID NO: 503).

[0133] As used herein, “Vascular Endothelial Growth Factor receptor” or “VEGF receptor” refers to a protein comprising seven extracellular immunoglobulin-like domains, a single transmembrane region, and an intracellular domain. As used herein, a “soluble VEGF receptor” comprises seven extracellular immunoglobulin-like domains.

[0134] In some embodiments of any of the aspects, the soluble VEGF receptor is encoded by a sequence having at least 80% sequence identity to SEQ ID NO: 501. In some embodiments of any of the aspects, the soluble VEGF receptor is encoded by a sequence having at least 85% sequence identity to SEQ ID NO: 501. In some embodiments of any of the aspects, the soluble VEGF receptor is encoded by a sequence having at least 90% sequence identity to SEQ ID NO: 501. In some embodiments of any of the aspects, the soluble VEGF receptor is encoded by a sequence having at least 95% sequence identity to SEQ ID NO: 501. In some embodiments of any of the aspects, the soluble VEGF receptor is encoded by a sequence having at least 98% sequence identity to SEQ ID NO: 501.

[0135] In some embodiments of any of the aspects, the soluble VEGF receptor is encoded by a sequence having at least 80% sequence identity to SEQ ID NO: 502. In some embodiments of any of the aspects, the soluble VEGF receptor is encoded by a sequence having at least 85% sequence identity to SEQ ID NO: 502. In some embodiments of any of the aspects, the soluble VEGF receptor is encoded by a sequence having at least 90% sequence identity to SEQ ID NO: 502. In some embodiments of any of the aspects, the soluble VEGF receptor is encoded by a sequence having at least 95% sequence identity to SEQ ID NO: 502. In some embodiments of any of the aspects, the soluble VEGF receptor is encoded by a sequence having at least 98% sequence identity to SEQ ID NO: 502.

[0136] In some embodiments of any of the aspects, the soluble VEGF receptor is encoded by a sequence having at least 80% sequence identity to SEQ ID NO: the polypeptide encoded by 503. In some embodiments of any of the aspects, the soluble VEGF receptor is encoded by a sequence having at least 85% sequence identity to the polypeptide encoded by SEQ ID NO: 503. In some embodiments of any of the aspects, the soluble VEGF receptor is encoded by a sequence having at least 90% sequence identity to the polypeptide encoded by SEQ ID NO: 503. In some embodiments of any of the aspects, the soluble VEGF receptor is encoded by a sequence having at least 95% sequenceAty. Dkt. No. 043214-000114WOPTidentity to the polypeptide encoded by SEQ ID NO: 503. In some embodiments of any of the aspects, the soluble VEGF receptor is encoded by a sequence having at least 98% sequence identity to the polypeptide encoded by SEQ ID NO: 503.

[0137] As used herein, the term “antibody reagent" refers to a polypeptide that includes at least one immunoglobulin variable domain or immunoglobulin variable domain sequence. In some embodiments, an antibody reagent specifically binds a given antigen. An antibody reagent can comprise an antibody or a polypeptide comprising an antigen-binding domain of an antibody. In some embodiments of any of the aspects, an antibody reagent can comprise a monoclonal antibody or a polypeptide comprising an antigen-binding domain of a monoclonal antibody. For example, an antibody can include a heavy (H) chain variable region (abbreviated herein as VH), and a light (L) chain variable region (abbreviated herein as VL). In another example, an antibody includes two heavy (H) chain variable regions and two light (L) chain variable regions. The term "antibody reagent" encompasses antigen-binding fragments of antibodies (e.g., single chain antibodies, Fab and sFab fragments, F(ab')2, Fd fragments, Fv fragments, scFv, and domain antibodies (dAb) fragments as well as complete antibodies. Antibody reagents that are therapeutic and / or specific for any particular target antigen are readily selected by one of skill in the art from known antibody reagents, e.g. from FDA-approved therapeutic antibody reagents and / or commercially available antibody reagents which are listed in catalogs according to their target specificity.

[0138] The term “antigen-binding portion” of an antibody refers to one or more portions of an antibody as described herein, said one or more portions still having the binding affinities as defined above herein. Portions of a complete antibody have been shown to be able to carry out the antigenbinding function of an antibody. In accordance with the term “antigen-binding portion” of an antibody, examples of binding portions include (i) an Fab portion, i.e., a monovalent portion composed of the VL, VH, CL and CHI domains; (ii) an F(ab’)2 portion, i.e., a bivalent portion comprising two Fab portions linked to one another in the hinge region via a disulfide bridge; (iii) an Fd portion composed of the VH and CHI domains; (iv) an Fv portion composed of the FL and VH domains of a single arm of an antibody; and (v) a dAb portion consisting of a VH domain or of VH, CHI, CH2, DH3, or VH, CH2, CH3 (dAbs, or single domain antibodies, comprising only VL domains have also been shown to specifically bind to target eptiopes).

[0139] Although the two domains of the Fv portion, namely VL and VH, are encoded by separate genes, they may further be linked to one another using a synthetic linker, e.g., a poly-G4S amino acid sequence (‘G4S’) (SEQ ID NO: 500), and recombinant methods, making it possible to prepare them as a single protein chain in which the VL and VH regions combine in order to form monovalent molecules (known as single chain Fv (ScFv)).

[0140] The term “antigen-binding portion” of an antibody is also intended to comprise such single chain antibodies. Other forms of single chain antibodies such as “diabodies” can also beAtty. Dkt. No. 043214-000114WOPTincluded. Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker which is too short for the two domains being able to combine on the same chain, thereby forcing said domains to pair with complementary domains of a different chain and to form two antigen-binding sites. An immunoglobulin constant domain refers to a heavy or light chain constant domain.

[0141] As used herein, the term “antibody” refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The term also refers to antibodies comprised of two immunoglobulin heavy chains and two immunoglobulin light chains as well as a variety of forms including full length antibodies and antigen-binding portions thereof; including, for example, an immunoglobulin molecule, a monoclonal antibody, a chimeric antibody, a CDR-grafted antibody, a humanized antibody, a Fab, a Fab', a F(ab')2, a Fv, a disulfide linked Fv, a scFv, a single domain antibody (dAb), a diabody, a multispecific antibody, a dual specific antibody, an anti-idiotypic antibody, a bispecific antibody, a functionally active epitope-binding portion thereof, and / or bifunctional hybrid antibodies. Each heavy chain is composed of a variable region of said heavy chain (abbreviated here as HCVR or VH) and a constant region of said heavy chain. The heavy chain constant region consists of three domains CHI, CH2 and CH3. Each light chain is composed of a variable region of said light chain (abbreviated here as LCVR or VL) and a constant region of said light chain. The light chain constant region consists of a CL domain. The VH and VL regions may be further divided into hypervariable regions referred to as complementarity-determining regions (CDRs) and interspersed with conserved regions referred to as framework regions (FR). Each VH and VL region thus consists of three CDRs and four FRs which are arranged from the N terminus to the C terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. This structure is well known to those skilled in the art. In some embodiments of any of the aspects, the VH region comprises the polypeptide encoded by SEQ ID NO: 506. In some embodiments of any of the aspects, the VH region consists of the polypeptide encoded by SEQ ID NO: 506. In some embodiments of any of the aspects, the VH region consists essentially of the polypeptide encoded by SEQ ID NO: 506. In some embodiments of any of the aspects, the VL region comprises the polypeptide encoded by SEQ ID NO: 507. In some embodiments of any of the aspects, the VL region consists of the polypeptide encoded by SEQ ID NO: 507. In some embodiments of any of the aspects, the VL region consists essentially of the polypeptide encoded by SEQ ID NO: 507. In some embodiments of any of the aspects, the VH region is encoded by SEQ ID NO: 506. In some embodiments of any of the aspects, the VL region is encoded by SEQ ID NO: 507.

[0142] Antibodies and / or antibody reagents can include an immunoglobulin molecule, a monoclonal antibody, a chimeric antibody, a CDR-grafted antibody, a humanized antibody, a fully human antibody, a Fab, a Fab', a F(ab')2, a Fv, a disulfide linked Fv, a scFv, a single domain antibody,Atty. Dkt. No. 043214-000114WOPTa diabody, a multispecific antibody, a dual specific antibody, an anti-idiotypic antibody, a bispecific antibody, and a functionally active epitope-binding portion thereof.

[0143] As used herein, the term “nanobody” or single domain antibody (sdAb) refers to an antibody comprising the small single variable domain (VHH) of antibodies obtained from camelids and dromedaries. Antibody proteins obtained from members of the camel and dromedary (Camelus baclrianus and Calelus dromaderius) family including new world members such as llama species Lama paccos, Lama glama and Lama vicugna) have been characterized with respect to size, structural complexity and antigenicity for human subjects. Certain IgG antibodies from this family of mammals as found in nature lack light chains, and are thus structurally distinct from the typical four chain quaternary structure having two heavy and two light chains, for antibodies from other animals. See PCT / EP93 / 02214 (WO 94 / 04678 published 3 Mar. 1994; which is incorporated by reference herein in its entirety).

[0144] A region of the camelid antibody which is the small single variable domain identified as VHH can be obtained by genetic engineering to yield a small protein having high affinity for a target, resulting in a low molecular weight antibody-derived protein known as a “camelid nanobody”. See U. S. Pat. No. 5,759,808 issued Jun. 2, 1998; see also Stijlemans, B. et al., 2004 J Biol Chem 279: 1256-1261; Dumoulin, M. et al., 2003 Nature 424: 783-788; Pleschberger, M. et al. 2003 Bioconjugate Chem 14: 440-448; Cortez-Retamozo, V. et al. 2002 Int J Cancer 89: 456-62; and Lauwereys, M. et al. 1998 EMBO J. 17: 3512-3520; each of which is incorporated by reference herein in its entirety. Engineered libraries of camelid antibodies and antibody fragments are commercially available, for example, from Ab lynx, Ghent, Belgium. As with other antibodies of non-human origin, an amino acid sequence of a camelid antibody can be altered recombinantly to obtain a sequence that more closely resembles a human sequence, i.e., the nanobody can be “humanized”. Thus the natural low antigenicity of camelid antibodies to humans can be further reduced.

[0145] The camelid nanobody has a molecular weight approximately one-tenth that of a human IgG molecule and the protein has a physical diameter of only a few nanometers. One consequence of the small size is the ability of camelid nanobodies to bind to antigenic sites that are functionally invisible to laiger antibody proteins, i.e., camelid nanobodies are useful as reagents detect antigens that are otherwise cryptic using classical immunological techniques, and as possible therapeutic agents. Thus yet another consequence of small size is that a camelid nanobody can inhibit as a result of binding to a specific site in a groove or narrow cleft of a target protein, and hence can serve in a capacity that more closely resembles the function of a classical low molecular weight drug than that of a classical antibody. The low molecular weight and compact size further result in camelid nanobodies being extremely thermostable, stable to extreme pH and to proteolytic digestion, and poorly antigenic. See U. S. patent application 20040161738 published Aug. 19, 2004; which isAtty. Dkt. No. 043214-000114WOPTincorporated by reference herein in its entirety. These features combined with the low antigenicity to humans indicate great therapeutic potential.

[0146] In some embodiments of any of the aspects, the antibody reagent is a scFv. In some embodiments of any of the aspects, the antibody reagent comprises a scFv. In some embodiments of any of the aspects, the antibody reagent consists of a scFv. In some embodiments of any of the aspects, the antibody reagent consists essentially of a scFv. In some embodiments of any of the aspects, the scFv is anti- TGF 1 (e.g., the polypeptide encoded by SEQ ID NO: 508). In some embodiments of any of the aspects, the scFv comprises anti- TGF 1 (e.g., the polypeptide encoded by SEQ ID NO: 508). In some embodiments of any of the aspects, the scFv consists of anti- TGF 1 (e.g., the polypeptide encoded by SEQ ID NO: 508). In some embodiments of any of the aspects, the scFv consists essentially of anti- TGF 1 (e.g., the polypeptide encoded by SEQ ID NO: 508). In some embodiments of any of the aspects, the scFv comprises the six CDRs encoded by SEQ ID NO: 508.

[0147] In some embodiments of any of the aspects, the antibody reagent binds specifically to Transforming growth factor-beta 1 (TGF 1). As used herein, “TGFpi” refers to a protein comprising an N-terminal signal polypeptide region, a latency-associated polypeptide (LAP) region, and a C-terminal polypeptide region. In some embodiments, the N-terminal signal polypeptide region comprises from about 20 to about 30 amino acids. In some embodiments, the N-terminal signal polypeptide region plays a role in secretion of TGFpi from a cell. In some embodiments of any of the aspects, the C-terminal region comprises from about 112 to about 114 amino acids. In some embodiments of any of the aspects, TGFpi forms a dimer with another TGFpi protein. In some embodiments of any of the aspects, TGFpi is encoded by a nucleotide comprising SEQ ID NO: 509.

[0148] In some aspects of any of the embodiments, disclosed herein is a composition for intranasal delivery, the composition comprising the AAV of any one of the embodiments described herein. In some embodiments of any of the aspects, the composition further comprises a pharmaceutically acceptable excipient.

[0149] “Intranasal delivery” refers to administration of a composition through the nose. In some embodiments, intranasal delivery is used to deliver drugs to the systemic circulation via absorption into the capillary blood vessels underlying the nasal mucosa.

[0150] As used herein, the term “pharmaceutical composition” refers to the active agent in combination with a pharmaceutically acceptable carrier or excipient e.g. a carrier or excipient commonly used in the pharmaceutical industry. The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. In some embodiments of any of the aspects, a pharmaceutically acceptable carrier can be a carrier other than water. In some embodimentsAtty. Dkt. No. 043214-000114WOPTof any of the aspects, a pharmaceutically acceptable carrier or excipient can be a cream, emulsion, gel, liposome, nanoparticle, and / or ointment. In some embodiments of any of the aspects, a pharmaceutically acceptable carrier or excipient can be an artificial or engineered carrier, e.g., a carrier that the active ingredient would not be found to occur in in nature.

[0151] As used herein, the term “nanoparticle” refers to particles that are on the order of about 1 to 1,000 nanometers in diameter or width. The term “nanoparticle” includes nanospheres; nanorods; nanoshells; and nanoprisms; these nanoparticles may be part of a nanonetwork. The term “nanoparticles” also encompasses liposomes and lipid particles having the size of a nanoparticle. Exemplary nanoparticles include lipid nanoparticles or ferritin nanoparticles. Lipid nanoparticles can comprise multiple componenents, including, e.g., ionizable lipids (such as MC3, DLin-MC3-DMA, ALC-0315, or SM-102), pegylated lipids (such as PEG2000-C-DMG, PEG2000-DMG, ALC-0159), phospholipids (such as DSPC), and cholesterol.

[0152] Exemplary liposomes can comprise, e.g., DSPC, DPPC, DSPG, Cholesterol, hydrogenated soy phosphatidylcholine, soy phosphatidyl choline, methoxypolyethylene glycol (mPEG-DSPE) phosphatidyl choline (PC), phosphatidyl glycerol (PG), distearoylphosphatidylcholine, and combinations thereof.

[0153] The formulations can be mixed with auxiliary agents which do not deleteriously react with the active agent (e.g., the composition comprising an AAV). Such additives can include wetting agents, emulsifying and suspending agents, salt for influencing osmotic pressure, buffers and / or coloring substances preserving agents, sweetening agents or flavoring agents. The compositions can also be sterilized if desired.

[0154] If a liquid carrier is used, the preparation can be in the form of a liquid such as an aqueous liquid suspension or solution. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution.

[0155] The composition may be provided as a powder suitable for reconstitution with an appropriate solution. Examples of these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates. The composition can optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these. A unit dosage form can be in individual containers or in multi-dose containers.

[0156] Compositions described herein may include, for example, micelles or liposomes, or some other encapsulated form, or can be administered in an extended release form to provide a prolonged storage and / or delivery effect, e.g., using biodegradable polymers, e.g., polylactidepolyglycolide. Examples of other biodegradable polymers include poly(orthoesters) andpoly(anhydrides).Atty. Dkt. No. 043214-000114WOPT

[0157] Compositions may comprise a permeation enhancer to modify membrane permeability. Examples of permeation enhancers include, but are not limited to, surfactants, e.g., lauroylcamitine (LC), bile salts, lipids, cyclodextrins, polymers, or tight junction modifiers.

[0158] In some embodiments of any of the aspects, the composition further comprises a mucoadhesive agent, a thermosensitive agent, a viscosity enhancing agent, or a combination thereof. For example, the composition further comprises a mucoadhesive agent, a thermosensitive agent, a viscosity enhancing agent, both a mucoadhesive agent and a thermosensitive agent, both a mucoadhesive agent and a viscosity enhancing agent, both a thermosensitive agent and a viscosity enhancing agent, or each of a mucoadhesive agent, a thermosensitive agent, and a viscosity enhancing agent.

[0159] As used herein, the term “mucoadhesive agent” refers to an agent included in compositions for intranasal delivery which may reduce clearance, prolong the residence time of the formulation at the delivery site, and / or increase transport along direct pathways. Examples of mucoadhesive agents include, but are not limited to, sodium hyaluronate, chitosan, acrylic acid derivatives, lectin, and low methylated pectin, surface-engineered nanoparticles, efflux transporter inhibitors, and vasoconstrictors.

[0160] As used herein, thermosensitive agents are compounds, typically polymers or liposomes, that undergo physical state changes in response to variations in temperature. Exemplary thermosensitive agents include, but are not limited to, poly(N-isopoprylacrilamide) (PNIPAAm), poly (N, N'-diethyl acrylamide), poly (dimethylamino ethyl methacrylate and poly (N-(L)-(l-hydroxymethyl) propyl methacrylamide), copolymers blocks of poly(ethylene glycol) / poly(lactide-coglicolide) (PEG / PLGA), polyoxyethylenepolyoxypropylene (PEO / PPO), triple blocks of copolymers polyoxyethylene-polyoxypropylene-polyoxyethylene (PEO-PPOPEO) and polyethylene glycol)-poly(lactic acid)-poly(ethylene glycol) (PEG-PLA-PEG)

[0161] As used herein, a viscosity enhancing agent is a compound that increases the viscosity of a composition. Exemplary viscosity enhancing agents include, but are not limited to, hydroxypropyl cellulose, hydroxyethyl cellulose, polysaccharides, carbomer, polyvinyl alcohol, colloidal silicon dioxide, lipophilic silicon dioxide, cetylalcohol, stearic acid, glycerylbehenate, wax, beeswax, petrolatum, lipophilic gum, triglycerides, lanolin, and inulin.

[0162] In some embodiments of any of the aspects, the composition further comprises a sweetener, a polyol, a fragrance, or a combination thereof. For example, the composition further comprises a sweetener, a polyol, a fragrance, both a sweetener and a polyol, both a sweetener and a fragrance, both a polyol and a fragrance, or each of a sweetener, a polyol, and a fragrance.

[0163] In some embodiments of any of the aspects, the composition further comprises a sweetener. Exemplary sweeteners include, but are not limited to, Stevia extract Steviol Glycosides, xylitol, sucrose, fructose, fructooligosaccharides, glucose, glucose syrup, invert sugar, maltodextrins,4908-5102-0199.5Atty. Dkt. No. 043214-000114WOPTMagnasweet, eryritol, sorbitol, maltitol, lactitol, mannitol, isomalt, sucralose, aspartame, acesulfame K, neohesperidine, dihydrochalcone, thaumatin, saccharin and saccharin salts.

[0164] In some embodiments of any of the aspects, the composition further comprises a polyol. As used herein, a polyol is a compound comprising more than one hydroxyl group. Exemplary polyols include, but are not limited to, propylene glycol, butylene glycol, butynediol, pentylene glycol, hexylene glycol, octylene glycol, neopentyl glycol, 2-methyl-l, 3-propanediol, diethylene glycol, triethylene glycol, tetraethylene glycol, dipropylene glycol, dibutylene glycol, glycerol, butane-1, 2, 3-triol, butane-1, 2, 4-triol andhexane-1, 2, 6-triol.

[0165] In some embodiments of any of the aspects, the composition further comprises a fragrance. Exemplary fragrances include, but are not limited to 2,4-dimethyl-3-cyclohexene-l-carbaldehyde; isocyclocitral; menthone; isomenthone; methyl 2,2-dimethyl-6-methylene-l-cyclohexanecarboxylate; nerone; terpineol; dihydroterpineol; terpenyl acetate; dihydroterpenyl acetate; dipentene; eucalyptol; hexylate; rose oxide; (S)-l,8-p-menthadiene-7-ol; l-p-menthene-4-ol; (lRS,3RS,4SR)-3-p-mentanyl acetate; (lR,2S,4R)-4,6,6-trimethyl-bicyclo[3,l,l]heptan-2-ol; tetrahydro-4-methyl-2-phenyl-2H-pyran; cyclohexyl acetate; cyclanol acetate; Fructalate (1,4-cyclohexane diethyldicarboxylate); (3ARS,6SR,7ASR)-perhydro-3,6-dimethyl-benzo[B]furan-2-one; (6R)-perhydro-3,6-dimethyl-benzo[B]furan-2-one); 2,4,6-trimethyl-4-phenyl- 1,3-dioxane; 2,4,6-trimethyl-3-cyclohexene-l-carbaldehyde; (E)-3-methyl-5-(2,2,3-trimethyl-3-cyclopenten-l-yl)-4-penten-2-ol; ( 1 'R, E)-2-ethyl-4-(2',2',3 '-trimethyl-3 '-cyclopenten- 1 '-yl)-2-buten- 1 -ol; ( l'R, E)-3,3 -dimethyl-5-(2',2',3,-trimethyl-3,-cyclopenten-r-yl)-4-penten-2-ol; fleuramone; methyl-(lR)-cis-3-oxo-2-pentyl-l -cyclopentane acetate; Velotone 2,2,5-Trimethyl-5-pentyl-l-cyclopentanone; 3,3-dimethyl-5-(2,2,3-trimethyl-3-cyclopenten-l-yl)-4-penten-2-ol; 3-methyl-5-(2,2,3-trimethyl-3-cyclopenten-l-yl)-2-pentanol; damascenes; l-(5,5-dimethyl-l-cyclohexen-l-yl)-4-penten-l-one; nectalactone ((1'R)-2-[2-(4'-methyl-3'-cyclohexen-r-yl)propyl]cyclopentanone); alpha-ionone; beta-ionone; damascenone; a mixture of l-(5,5-dimethyl-l-cyclohexen-l-yl)-4-penten-l-one and l-(3,3-dimethyl-1 -cyclohexen- 1 -yl)-4-penten- 1 -one; 1 -(2,6,6-trimethyl-l -cyclohexen- 1 -yl)-2-buten- 1 -one; (1 S, 1 'R)-[l-(3',3'-Dimethyl-r-cyclohexyl)ethoxycarbonyl]methylpropanoate; 2-tert-butyl-l -cyclohexyl acetate; 1 -(2,2,3,6-tetramethyl-cyclohexyl)-3-hexanol; trans- 1 -(2,2,6-trimethyl- 1 -cyclohexyl)-3-hexanol; (E)-3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-l-yl)-3-buten-2-one; terpenyl isobutyrate; 4-(1,1 -dimethylethyl)- 1 -cyclohexyl acetate; 8-methoxy-l -p-menthene; (1 S, 1 'R)-2-[l -(3',3'-dimethyl-l'-cyclohexyl) ethoxy] -2-methylpropyl propanoate; para tert-butylcyclohexanone; menthenethiol; 1-methyl-4-(4-methyl-3-pentenyl)-3-cyclohexene-l-carbaldehyde; allyl cyclohexylpropionate; cyclohexyl salicylate; Methyl cedryl ketone; Verdylate; vetyverol; vetyverone; 1 -(octahydro-2, 3,8,8-tetramethyl-2-naphtalenyl)-l -ethanone; (5RS,9RS,10SR)-2,6,9,10-tetramethyl-l-oxaspiro[4.5]deca-3,6-diene and the (5RS,9SR,10RS) isomer; 6-ethyl-2,10,10-trimethyl-l-oxaspiro[4.5]deca-3,6-diene; l,2,3,5,6,7-hexahydro-l,l,2,3,3-pentamethyl-4-indenone; a mixture of 3-(3,3-dimethyl-5-indanyl)propanal and 3-(l,l-dimethyl-5-indanyl)propanal; 3',4-dimethyl-tricyclo[6.2.1.0(2,7)]undec-Atty. Dkt. No. 043214-000114WOPT4-ene-9-spiro-2'-oxirane; 9 / 10-ethyldiene-3-oxatricyclo[6.2.1,0(2,7)]undecane; perhydro-5,5,8A-trimethyl-2-naphthalenyl acetate; octalynol; (dodecahydro-3a,6,6,9a-tetramethyl-naphtho[2,l-b]furan); tricyclo[5.2.1.0(2,6)]dec-3-en-8-yl acetate andtricyclo[5.2.1.0(2,6)]dec-4-en-8-yl acetate as well as tricyclo[5.2.1.0(2,6)]dec-3-en-8-yl propanoate and tricyclo[5.2.1.0(2,6)]dec-4-en-8-yl propanoate; camphor; borneol; isobomyl acetate; 8-isopropyl-6-methyl-bicyclo[2.2.2]oct-5-ene-2-carbaldehyde; camphopinene; cedramber (8-methoxy-2,6,6,8-tetramethyl-tricyclo[5.3.1.0(1, 5)]undecane); cedrene; cedrenol; cedrol; mixture of 9-ethylidene-3-oxatricyclo[6.2.1,0(2,7)]undecan-4-one and 10-ethylidene-3-oxatricyclo[6.2.1,0(2,7)]undecan-4-one; 3-methoxy-7,7-dimethyl-10-methylene-bicyclo[4.3.1]decane; trimethyl-13-oxabicyclo-[10.1.0]-trideca-4,8-diene; Ambrettolide LG ((E)-9-hexadecen- 16-olide); pentadecenolide; muscenone (3-methyl-(4 / 5)-cyclopentadecenone); muscone; cyclopentadecanone; (l-ethoxyethoxy)cyclododecane; Astrotone; and rosinol.

[0166] In some embodiments of any of the aspects, the composition is a suspension. In some embodiments of any of the aspects, the composition is an aerosol. In some embodiments of any of the aspects, the composition is a liquid. In some embodiments of any of the aspects, the composition is a powder. In some embodiments of any of the aspects, the composition is a gel.

[0167] A composition described herein can take any of a wide variety of forms, and include, for example, solutions, suspensions, aerosols, liquids, creams, sprays, gels, and the like. For instance, creams, as is well known in the arts of pharmaceutical composition, are viscous liquids or semisolid emulsions, either oil-in-water or water-in-oil. Cream bases are water-washable, and contain an oil phase, an emulsifier, and an aqueous phase. The oil phase, also called the “internal” phase, is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol. The aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. The emulsifier in a cream composition is generally a nonionic, anionic, cationic or amphoteric surfactant.

[0168] In some embodiments of any of the aspects, the composition is a solution. Solutions are homogeneous mixtures prepared by dissolving one or more chemical substances (solutes) in a liquid such that the molecules of the dissolved substance are dispersed among those of the solvent. The solution may contain other pharmaceutically acceptable chemicals to buffer, stabilize or preserve the solute. Common examples of solvents used in preparing solutions are ethanol, water, propylene glycol or any other pharmaceutically acceptable and vehicles.

[0169] In some embodiments of any of the aspects, a composition disclosed herein comprises a pH adjusting agent. In some embodiments of any of the aspects, the pH adjusting agent is selected from the group consisting of ascorbic acid, sodium ascorbate, tartaric acid, sodium tartrate, potassium tartrate, calcium tartrate, lithium tartrate, citric acid, sodium citrate, potassium citrate, calcium citrate, lithium citrate, phosphoric acid, sodium dihydrogenphosphate, sodium monohydrogenphosphate,Atty. Dkt. No. 043214-000114WOPTlithium phosphate, potassium phosphate, calcium phosphate, sodium carbonate, sodium hydrogencarbonate, lactic acid, sodium lactate, potassium lactate, calcium lactate, acetic acid, sodium acetate, potassium acetate, calcium acetate, propionic acid, sulphuric acid, sodium sulphate, potassium sulphate, boric acid, sodium borate, maleic acid, lithium maleate, sodium maleate, potassium maleate, calcium maleate, succinic acid, lithium succinate, sodium succinate, potassium succinate, calcium succinate, fumaric acid, glutamic acid, formic acid, malic acid, hydrochloric acid, nitric acid, sodium hydroxide, potassium hydroxide, triethanolamine, diisopropanolamine, ammonia solution, monoethanole amine, diethanoleamine, triethanoleamine meglumine, sodium citrate, sodium bicarbonate, potassium bicarbonate, and any combination thereof. In some instances, a pH adjusting agent disclosed herein is acetic acid; adipic acid; ammonium aluminum sulphate; ammonium bicarbonate; ammonium carbonate; ammonium citrate, dibasic; ammonium citrate, monobasic; ammonium hydroxide; ammonium phosphate, dibasic; ammonium phosphate, monobasic; calcium acetate; calcium acid pyrophosphate; calcium carbonate; calcium chloride; calcium citrate; calcium fumarate; calcium gluconate; calcium hydroxide; calcium lactate; calcium oxide; calcium phosphate, dibasic; calcium phosphate, monobasic; calcium phosphate, tribasic; calcium sulphate; carbon dioxide; citric acid; cream of tartar; fumaric acid; gluconic acid; glucono-delta-lactone; hydrochloric acid; lactic acid; magnesium carbonate; magnesium citrate; magnesium fumarate; magnesium hydroxide; magnesium oxide; magnesium phosphate; magnesium sulphate; malic acid; manganese sulphate; metatartaric acid; phosphoric acid; potassium acid tartrate; potassium aluminum sulphate; potassium bicarbonate; potassium carbonate; potassium chloride; potassium citrate; potassium fumarate; potassium hydroxide; potassium lactate; potassium phosphate, dibasic; potassium phosphate, tribasic; potassium sulphate; potassium tartrate; potassium tripolyphosphate; sodium acetate; sodium acid pyrophosphate; sodium acid tartrate; sodium aluminum phosphate; sodium aluminum sulphate; sodium bicarbonate; sodium bisulphate; sodium carbonate; sodium citrate; sodium fumarate; sodium gluconate; sodium hexametaphosphate; sodium hydroxide; sodium lactate; sodium phosphate, dibasic; sodium phosphate, monobasic; sodium phosphate, tribasic; sodium potassium hexametaphosphate; sodium potassium tartrate; sodium potassium tripolyphosphate; sodium pyrophosphate, tetrabasic; sodium tripolyphosphate; sulphuric acid; sulphurous acid; tartaric acid; or any combination thereof.

[0170] Gels are semisolid, suspension-type systems. Single-phase gels contain organic macromolecules distributed substantially uniformly throughout the carrier liquid, which is typically aqueous, but also, preferably, contain an alcohol, and, optionally, an oil. Preferred “organic macromolecules,” i.e., gelling agents, may be chemically crosslinked polymers such as crosslinked acrylic acid polymers, for instance, the “carbomer” family of polymers, e.g., carboxypolyalkylenes. Also preferred in certain embodiments may be hydrophilic polymers such as polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers and polyvinylalcohol; cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropylAtty. Dkt. No. 043214-000114WOPTmethylcellulose phthalate, and methyl cellulose; gums such as tragacanth and xanthan gum; sodium alginate; and gelatin. In order to prepare a uniform gel, dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing or stirring, or combinations thereof.

[0171] As used herein, the term “aerosol” refers to suspension in the air. In particular, aerosol refers to the particlization or atomization of a composition described herein and its suspension in the air. In some embodiments of any of the aspects, the composition further comprises a dispersant. As used herein, the term “dispersant” refers to an agent that assists aerosolization of the compositions described herein or absorption of the compositions described herein in mucosal tissue, or both.

[0172] Suitable dispersing agents are well known in the art, and include but are not limited to surfactants. Such surfactants are generally used in the art to reduce surface induce aggregation of the compositions described herein caused by atomization of the solution forming the liquid aerosol and may be used in the methods and devices of the present disclosure. Examples of such surfactants include, but are not limited to, polyoxyethylene fatty acid esters and alcohols, and polyoxyethylene sorbitan fatty acid esters.

[0173] In some embodiments, the aerosolization of a liquid or a dry powder formulation for inhalation into the lung will require a propellent. The propellent may be any propellant generally used in the art, and include, but are not limited to, chloroflourocarbons, hydrofluorocarbons, hydochlorofluorocarbons, or hydrocarbons, including, but not limited to, trifluoromethane, dichlorodiflouromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetraflouroethane, or combinations thereof.

[0174] In some aspects of any of the embodiments, disclosed herein is method comprising contacting a cell with an adeno-associated virus (AAV) or composition of any one of the embodiments disclosed herein. In some embodiments of any of the aspects, the cell is a respiratory cell. In some embodiments of any of the aspects, the cell is a ciliated cell, a brush cell, an airway basal cell, a small granule cell, goblet cell, an a-tubulin-positive ciliated cell, a club cell, a trachea cell, or a ATI cell. In some embodiments of any of the aspects, the cell is in a subject. In some embodiments of any of the aspects, the cell is in a mammalian subject. In some embodiments of any of the aspects, the cell is in a human subject.

[0175] As used herein, “contacting" refers to any suitable means for delivering, or exposing, an agent to at least one cell. Exemplary delivery methods include, but are not limited to, direct delivery to cell culture medium, perfusion, injection, or other delivery method well known to one skilled in the art.

[0176] In some embodiments of any of the aspects, the AAV is administered by intranasal delivery. In some embodiments of any of the aspects, the AAV is administered by a dropper. In someAtty. Dkt. No. 043214-000114WOPTembodiments of any of the aspects, the AAV is administered as a spray. In some embodiments of any of the aspects, the AAV is administered by a nebulizer.

[0177] As used herein, the term "administering," refers to the placement of a compound as disclosed herein into a subject by a method or route which results in at least partial delivery of the agent at a desired site. Pharmaceutical compositions comprising the compounds disclosed herein can be administered by any appropriate route which results in an effective treatment in the subject. In some embodiments, administration comprises physical human activity, e.g., an injection, act of ingestion, an act of application, and / or manipulation of a delivery device or machine. In some embodiments, the administration is intranasal. Such activity can be performed, e.g., by a medical professional and / or the subject being treated. The compositions described herein can be formulated to provide quick, sustained, controlled, or delayed release, or any combination thereof, of the active agent (e.g., the AAV) after administration to the individual by employing procedures well known in the art.

[0178] In some aspects of any of the embodiments, disclosed herein is a device for intranasal administration of a composition comprising an AAV or composition of any one of the embodiments disclosed herein to a subject. In some embodiments of any of the aspects, the device is a dropper. In some embodiments of any of the aspects, device is a spray. In some embodiments of any of the aspects, the device is a nebulizer. In some embodiments of any of the aspects, the device is a needleless syringe. In some embodiments of any of the aspects, the device is a bi-directional nasal device.

[0179] Nasal delivery devices, such as sprays, nose droppers or needle-less syringes, may be employed to target the composition to different regions of the nasal cavity. OptiMist™ is a breath actuated device that targets liquid or powder nasal formulations to the nasal cavity, including the olfactory region, without deposition in the lungs or esophagus. The ViaNase™ device can also be used to target a nasal spray to the olfactory and respiratory epithelia of the nasal cavity.

[0180] In some embodiments of any of the aspects, the subject has a respiratory disease or infection. In some embodiments of any of the aspects, the disease is idiopathic pulmonary fibrosis (IPF). In some embodiments of any of the aspects, the infection is a viral infection. In some embodiments of any of the aspects, the viral infection is caused by SARS-CoV-2.

[0181] In some aspects of any of the embodiments, disclosed herein is method of treating respiratory disease or infection in a subject in need thereof, the method comprising: administering an AAV or compositions of any one of the embodiments disclosed herein to the subject. In some embodiments of any of the aspects, the disease is idiopathic pulmonary fibrosis (IPF). In some embodiments of any of the aspects, the infection is a viral infection. In some embodiments of any of the aspects, viral infection is caused by SARS-CoV-2.

[0182] Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease that affects the tissue surrounding the alveoli in the lungs, hindering oxygen absorption. Symptoms include, butAtty. Dkt. No. 043214-000114WOPTare not limited to, shortness of breath, cough, fatigue, weakness, loss of appetite, weight loss, and clubbed fingers.

[0183] As used herein, the terms "treat,” "treatment," "treating,” or “amelioration” refer to therapeutic treatments, wherein the object is to reverse, alleviate, ameliorate, inhibit, slow down or stop the progression or severity of a condition associated with a disease or disorder, e.g. SARS-CoV-2 infection or IPF. The term “treating" includes reducing or alleviating at least one adverse effect or symptom of a condition, disease or disorder associated with a SARS-CoV-2 infection or IPF.Treatment is generally “effective" if one or more symptoms or clinical markers are reduced.Alternatively, treatment is “effective" if the progression of a disease is reduced or halted. That is, “treatment" includes not just the improvement of symptoms or markers, but also a cessation of, or at least slowing of, progress or worsening of symptoms compared to what would be expected in the absence of treatment. Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of disease, stabilized (z.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, remission (whether partial or total), and / or decreased mortality, whether detectable or undetectable. The term "treatment" of a disease also includes providing relief from the symptoms or side-effects of the disease (including palliative treatment).

[0184] In some embodiments, effectiveness of treatment is measured by CT imaging, x-ray imaging, 6-minute walk tests, pulse oximetry, arterial blood gases, fractional exhaled nitric oxide, chest ultrasonography, cardiopulmonary exercise testing, spirometry (e.g., forced expiratory volume in 1 second, forced vital capacity), and quality of life questionnaires. In some embodiments, effectiveness of treatment is measured by viral load reduction, time to viral clearance, time to recovery, disease progression / severity, and reduction of symptoms.

[0185] In some embodiments of any of the aspects, described herein is a prophylactic method of treatment. As used herein “prophylactic” refers to the timing and intent of a treatment relative to a disease or symptom, that is, the treatment is administered prior to clinical detection or diagnosis of that particular disease or symptom in order to protect the patient from the disease or symptom. Prophylactic treatment can encompass a reduction in the severity or speed of onset of the disease or symptom, or contribute to faster recovery from the disease or symptom. Accordingly, the methods described herein can be prophylactic relative to IPF or SARS-CoV-2. In some embodiments of any of the aspects, prophylactic treatment is not prevention of all symptoms or signs of a disease.

[0186] The dose of AAV virions required to achieve a particular therapeutic effect, e.g., the units of dose in genome copies / per kilogram of body weight (GC / kg), will vary based on several factors including, but not limited to: the route of AAV administration, the level of gene or RNA expression required to achieve a therapeutic effect, the specific disease or disorder being treated, and the stability of the gene or RNA product. One of skill in the art can readily determineAtty. Dkt. No. 043214-000114WOPTan AAV dose range to treat a patient having a particular disease or disorder based on the aforementioned factors, as well as other factors.

[0187] An effective amount of an AAV is an amount sufficient to target infect an animal, target a desired tissue. In some embodiments, an effective amount of an AAV is an amount sufficient to produce a stable somatic transgenic animal model. The effective amount will depend primarily on factors such as the species, age, weight, health of the subject, and the tissue to be targeted, and may thus vary among animal and tissue. For example, an effective amount of the AAV is generally in the range of from about 1 ml to about 100 ml of solution containing from about 109to 1016genome copies. In some cases, a dosage between about 1011to 1013recombinant AAV genome copies is appropriate.

[0188] In some embodiments, a dose of AAV is administered to a subject no more than once per calendar day (e.g., a 24-hour period). In some embodiments, an AAV dose is administered to a subject no more than once per 2, 3, 4, 5, 6, or 7 calendar days. In some embodiments, an AAV dose is administered to a subject no more than once per calendar week (e.g., 7 calendar days). In some embodiments, an AAV dose is administered to a subject no more than bi-weekly (e.g., once in a two calendar week period). In some embodiments, an AAV dose is administered to a subject no more than once per calendar month (e.g., once in 30 calendar days). In some embodiments, an AAV dose is administered to a subject no more than once per six calendar months. In some embodiments, a dose of AAV is administered to a subject no more than once per calendar year (e.g., 365 days or 366 days in a leap year).

[0189] In some embodiments, AAV compositions are formulated to reduce aggregation of AAV particles in the composition, particularly where high AAV concentrations are present (e.g., -1013 GC / ml or more). Appropriate methods for reducing aggregation of may be used, including, for example, addition of surfactants, pH adjustment, salt concentration adjustment, etc. (See, e.g., Wright FR, et al., Molecular Therapy (2005) 12, 171-178, the contents of which are incorporated herein by reference.)

[0190] In some aspects of any of the embodiments, disclosed herein is a kit comprising the device of any of the embodiments disclosed herein and instructions for use.

[0191] In some embodiments of any of the aspects, a kit comprising a unit dosage of composition suitable for intranasal administration and an intranasal delivery device or dispenser is provided. In some embodiments of any of the aspects, kits include a carrier, package, or container that is compartmentalized to receive one or more blister packs, bottles, tubes, capsules, and the like. In some embodiments of any of the aspects, a pharmaceutical formulation is presented in a pack or dispenser device which contains one or more unit dosage forms containing a composition provided herein. In some embodiments of any of the aspects, a pack contains metal or plastic foil, such as aAtty. Dkt. No. 043214-000114WOPTblister pack. In some instances, a pack contains capsules, cartridges, vials, or tubes. In some embodiments of any of the aspects, a pack or dispenser device is accompanied by instructions for administration. In some embodiments of any of the aspects, a dispenser is disposable or single use, while in some embodiments, a dispenser is reusable. In certain embodiments, a pharmaceutical formulation is preloaded into a device.

[0192] As used herein, a "subject" means a human or animal. Usually the animal is a vertebrate such as a primate, rodent, domestic animal or game animal. Primates include chimpanzees, cynomolgus monkeys, spider monkeys, and macaques, e.g., Rhesus. Rodents include mice, rats, woodchucks, ferrets, rabbits and hamsters. Domestic and game animals include cows, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cat, canine species, e.g., dog, fox, wolf, avian species, e.g., chicken, emu, ostrich, and fish, e.g., trout, catfish and salmon. In some embodiments, the subject is a mammal, e.g., a primate, e.g., a human. The terms, “individual,” “patient” and “subject” are used interchangeably herein.

[0193] Preferably, the subject is a mammal. The mammal can be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but is not limited to these examples. Mammals other than humans can be advantageously used as subjects that represent animal models of IPF and / or SARS-CoV-2. A subject can be male or female.

[0194] A subject can be one who has been previously diagnosed with or identified as suffering from or having a condition in need of treatment (e.g. IPF or SARS-CoV-2) or one or more complications related to such a condition, and optionally, have already undergone treatment for IPF or SARS-CoV-2 or the one or more complications related to IPF or SARS-CoV-2. Alternatively, a subject can also be one who has not been previously diagnosed as having IPF or SARS-CoV-2 or one or more complications related to IPF or SARS-CoV-2. For example, a subject can be one who exhibits one or more risk factors for IPF or SARS-CoV-2 or one or more complications related to IPF or SARS-CoV-2 or a subject who does not exhibit risk factors. A “subject in need” of treatment for a particular condition can be a subject having that condition, diagnosed as having that condition, or at risk of developing that condition.

[0195] As used herein, the terms “protein" and “polypeptide" are used interchangeably herein to designate a series of amino acid residues, connected to each other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues. The terms "protein", and "polypeptide" refer to a polymer of amino acids, including modified amino acids (e.g., phosphorylated, glycated, glycosylated, etc.) and amino acid analogs, regardless of its size or function. " Protein" and “polypeptide” are often used in reference to relatively large polypeptides, whereas the term "peptide" is often used in reference to small polypeptides, but usage of these terms in the art overlaps. The terms "protein" and "polypeptide" are used interchangeably herein when referring to a gene product and fragments thereof. Thus, exemplary polypeptides or proteins include gene products, naturallyAtty. Dkt. No. 043214-000114WOPToccurring proteins, homologs, orthologs, paralogs, fragments and other equivalents, variants, fragments, and analogs of the foregoing. The terms also refer to fragments or variants of the polypeptide that maintain at least 50% of the activity or effect, e.g. endonuclease activity, of the full length polypeptide, e.g., amino acids 1-967 of SEQ ID NO: 206, e.g. as measured by, for example, gene expression analysis.. Conservative substitution variants that maintain the activity of SEQ ID NO: 206 will include a conservative substitution as defined herein. The identification of amino acids most likely to be tolerant of conservative substitution while maintaining at least 50% of the activity of SEQ ID NO: 206 is guided by, for example, sequence alignment with Cas9 endonucleases. Amino acids that are identical between Cas endonuclease homologs are less likely to tolerate change, while those showing conservative differences are obviously much more likely to tolerate conservative change in the context of an artificial variant. Similarly, positions with non-conservative differences are less likely to be critical to function and more likely to tolerate conservative substitution in an artificial variant. Variants, fragments, and / or fusion proteins can be tested for activity, for example, by administering the variant to an appropriate animal model as described herein. Further discussion of the structure of CasRx can be found, e.g. in Chuang, Y. et al., Front Cell Dev Biol. 2021 Jun 11;9:667879 which is incorporated by reference herein in its entirety.

[0196] In some embodiments of any of the aspects, a polypeptide has at least 80% sequence identity to the entire length of SEQ ID NO: 206. In some embodiments of any of the aspects, a polypeptide has at least 85% sequence identity to the entire length of SEQ ID NO: 206. In some embodiments of any of the aspects, a polypeptide has at least 90% sequence identity to the entire length of SEQ ID NO: 206. In some embodiments of any of the aspects, a polypeptide has at least 95% sequence identity to the entire length of SEQ ID NO: 206. In some embodiments of any of the aspects, a polypeptide has at least 98% sequence identity to the entire length of SEQ ID NO: 206. In some embodiments of any of the aspects, a polypeptide has at least 99% sequence identity to the entire length of SEQ ID NO: 206. In some embodiments of any of the aspects, a polypeptide has 100% sequence identity to the entire length of SEQ ID NO: 206.

[0197] In some embodiments of any of the aspects, a polypeptide comprises a domain having at least 80% sequence identity to the entire length of SEQ ID NO: 206. In some embodiments of any of the aspects, a polypeptide comprises a domain having at least 85% sequence identity to the entire length of SEQ ID NO: 206. In some embodiments of any of the aspects, a polypeptide comprises a domain having at least 90% sequence identity to the entire length of SEQ ID NO: 206. In some embodiments of any of the aspects, a polypeptide comprises a domain having at least 95% sequence identity to the entire length of SEQ ID NO: 206. In some embodiments of any of the aspects, a polypeptide comprises a domain having at least 98% sequence identity to the entire length of SEQ ID NO: 206. In some embodiments of any of the aspects, a polypeptide comprises a domain having at least 99% sequence identity to the entire length of SEQ ID NO: 206. In some embodiments of any ofAtty. Dkt. No. 043214-000114WOPTthe aspects, a polypeptide comprises a domain having 100% sequence identity to the entire length of SEQ ID NO: 206.

[0198] In some embodiments, a polypeptide, e.g., a Cas endonuclease polypeptide, can be a variant of a sequence described herein, e.g. a variant of a CasRx polypeptide comprising the amino acid sequence of SEQ ID NO: 206. In some embodiments, the variant is a conservative substitution variant. Variants can be obtained by mutations of native nucleotide sequences, for example. A “variant,” as referred to herein, is a polypeptide substantially homologous to a native or reference polypeptide, but which has an amino acid sequence different from that of the native or reference polypeptide because of one or a plurality of deletions, insertions or substitutions. Polypeptide-encoding DNA sequences encompass sequences that comprise one or more additions, deletions, or substitutions of nucleotides when compared to a native or reference DNA sequence, but that encode a variant protein or fragment thereof that retains the relevant biological activity relative to the reference protein, e.g., has endonuclease activity at least 50% as well as wildtype SpCas9.. As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters a single amino acid or a small percentage, (i.e. 5% or fewer, e.g. 4% or fewer, or 3% or fewer, or 1% or fewer) of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. It is contemplated that some changes can potentially improve the relevant activity, such that a variant, whether conservative or not, has more than 100% of the activity of wildtype SpCas9, e.g. 110%, 125%, 150%, 175%, 200%, 500%, 1000% or more.

[0199] One method of identifying amino acid residues which can be substituted is to align more than on Cas endonuclease. Alignment can provide guidance regarding not only residues likely to be necessary for function but also, conversely, those residues likely to tolerate change. Where, for example, an alignment shows two identical or similar amino acids at corresponding positions, it is more likely that that site is important functionally. Where, conversely, alignment shows residues in corresponding positions to differ significantly in size, charge, hydrophobicity, etc., it is more likely that that site can tolerate variation in a functional polypeptide. The variant amino acid or DNA sequence can be at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more, identical to a native or reference sequence, e.g. SEQ ID NO: 206 or a nucleic acid encoding one of those amino acid sequences. The degree of homology (percent identity) between a native and a mutant sequence can be determined, for example, by comparing the two sequences using freely available computer programs commonly employed for this purpose on the world wide web. The variant amino acid or DNA sequence can be at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more, similar to the sequence from which it is derived (referred to herein as an “original” sequence). The degree of similarity (percent similarity) between an original and a mutant sequence can be determined, forAtty. Dkt. No. 043214-000114WOPTexample, by using a similarity matrix. Similarity matrices are well known in the art and a number of tools for comparing two sequences using similarity matrices are freely available online, e.g. BLASTp or BLASTn (available on the world wide web at blast.ncbi.nlm.nih.gov), with default parameters set.

[0200] In the various embodiments described herein, it is further contemplated that variants (naturally occurring or otherwise), alleles, homologs, conservatively modified variants, and / or conservative substitution variants of any of the particular polypeptides described are encompassed. As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid and retains the desired activity of the polypeptide. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles consistent with the disclosure.

[0201] A given amino acid can be replaced by a residue having similar physiochemical characteristics, e.g., substituting one aliphatic residue for another (such as He, Vai, Leu, or Ala for one another), or substitution of one polar residue for another (such as between Lys and Arg; Glu and Asp; or Gin and Asn). Other such conservative substitutions, e.g., substitutions of entire regions having similar hydrophobicity characteristics, are well known. Polypeptides comprising conservative amino acid substitutions can be tested in any one of the assays described herein to confirm that a desired activity of a native or reference polypeptide is retained. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles consistent with the disclosure.

[0202] Amino acids can be grouped according to similarities in the properties of their side chains (in A. L. Lehninger, in Biochemistry, second ed., pp. 73-75, Worth Publishers, New York (1975)): (1) non-polar: Ala (A), Vai (V), Leu (L), He (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gin (Q); (3) acidic: Asp (D), Glu (E); (4) basic: Lys (K), Arg (R), His (H). Alternatively, naturally occurring residues can be divided into groups based on common side-chain properties: (1) hydrophobic: Norleucine, Met, Ala, Vai, Leu, He; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gin; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe. Nonconservative substitutions will entail exchanging a member of one of these classes for another class. Particular conservative substitutions include, for example; Ala into Gly or into Ser; Arg into Lys; Asn into Gin or into His; Asp into Glu; Cys into Ser; Gin into Asn; Glu into Asp; Gly into Ala or into Pro; His into Asn or into Gin; He into Leu or into Vai; Leu into He or into Vai; Lys into Arg, into Gin or into Glu; Met into Leu, into Tyr or into He; Phe into Met, into Leu or into Tyr; Ser into Thr; Thr intoAtty. Dkt. No. 043214-000114WOPTSer; Trp into Tyr; Tyr into Trp; and / or Phe into Vai, into He or into Leu. Typically conservative substitutions for one another also include: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).

[0203] In some embodiments, the polypeptide described herein (or a nucleic acid encoding such a polypeptide) can be a functional fragment of one of the amino acid sequences described herein. As used herein, a “functional fragment” is a fragment or segment of a peptide which retains at least 50% of the wildtype reference polypeptide’s activity according to the assays described below herein. A functional fragment can comprise conservative substitutions of the sequences disclosed herein.

[0204] In some embodiments, the polypeptide described herein can be a variant of a sequence described herein. In some embodiments, the variant is a conservatively modified variant. Conservative substitution variants can be obtained by mutations of native nucleotide sequences, for example. A “variant," as referred to herein, is a polypeptide substantially homologous to a native or reference polypeptide, but which has an amino acid sequence different from that of the native or reference polypeptide because of one or a plurality of deletions, insertions or substitutions. Variant polypeptide-encoding DNA sequences encompass sequences that comprise one or more additions, deletions, or substitutions of nucleotides when compared to a native or reference DNA sequence, but that encode a variant protein or fragment thereof that retains activity. A wide variety of PCR-based site-specific mutagenesis approaches are known in the art and can be applied by the ordinarily skilled artisan.

[0205] In some embodiments, a polypeptide can comprise one or more amino acid substitutions or modifications. In some embodiments, the substitutions and / or modifications can prevent or reduce proteolytic degradation and / or prolong half-life of the polypeptide in a subject. In some embodiments, a polypeptide can be modified by conjugating or fusing it to other polypeptide or polypeptide domains such as, by way of non-limiting example, transferrin (WO06096515A2), albumin (Yeh et al., 1992), growth hormone (US2003104578AA); cellulose (Levy and Shoseyov, 2002); and / or Fc fragments (Ashkenazi and Chamow, 1997). The references in the foregoing paragraph are incorporated by reference herein in their entireties.

[0206] In some embodiments, a polypeptide as described herein can comprise at least one peptide bond replacement. A polypeptide as described herein can comprise one type of peptide bond replacement or multiple types of peptide bond replacements, e.g. 2 types, 3 types, 4 types, 5 types, or more types of peptide bond replacements. Non-limiting examples of peptide bond replacements include urea, thiourea, carbamate, sulfonyl urea, trifluoroethylamine, ortho-(aminoalkyl)-phenylacetic acid, para-(aminoalkyl)-phenylacetic acid, meta-(aminoalkyl)-phenylacetic acid, thioamide, tetrazole, boronic ester, olefinic group, and derivatives thereof.Atty. Dkt. No. 043214-000114WOPT

[0207] In some embodiments, a polypeptide as described herein can comprise naturally occurring amino acids commonly found in polypeptides and / or proteins produced by living organisms, e.g. Ala (A), Vai (V), Leu (L), He (I), Pro (P), Phe (F), Trp (W), Met (M), Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gin (Q), Asp (D), Glu (E), Lys (K), Arg (R), and His (H). In some embodiments, a polypeptide as described herein can comprise alternative amino acids. Non-limiting examples of alternative amino acids include, D-amino acids; beta-amino acids; homocysteine, phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, gamma-carboxyglutamate; hippuric acid, octahydroindole-2-carboxylic acid, statine, l,2,3,4,-tetrahydroisoquinoline-3-carboxylic acid, penicillamine (3-mercapto-D-valine), ornithine, citruline, alpha-methyl-alanine, parabenzoylphenylalanine, para-amino phenylalanine, p-fluorophenylalanine, phenylglycine, propargylglycine, sarcosine, and tert-butylglycine), diaminobutyric acid, 7-hydroxy-tetrahydroisoquinoline carboxylic acid, naphthylalanine, biphenylalanine, cyclohexylalanine, aminoisobutyric acid, norvaline, norleucine, tert-leucine, tetrahydroisoquinoline carboxylic acid, pipecolic acid, phenylglycine, homophenylalanine, cyclohexylglycine, dehydroleucine, 2,2-diethylglycine, 1-amino-l-cyclopentanecarboxylic acid, 1-amino-l-cyclohexanecarboxylic acid, amino-benzoic acid, amino-naphthoic acid, gamma-aminobutyric acid, difluorophenylalanine, nipecotic acid, alpha-amino butyric acid, thienyl-alanine, t-butylglycine, trifluorovaline; hexafluoroleucine; fluorinated analogs; azide-modified amino acids; alkyne-modified amino acids; cyano-modified amino acids; and derivatives thereof.

[0208] In some embodiments, a polypeptide can be modified, e.g. by addition of a moiety to one or more of the amino acids that together comprise the peptide. In some embodiments, a polypeptide as described herein can comprise one or more moiety molecules, e.g. 1 or more moiety molecules per polypeptide, 2 or more moiety molecules per polypeptide, 5 or more moiety molecules per polypeptide, 10 or more moiety molecules per polypeptide or more moiety molecules per polypeptide. In some embodiments, a polypeptide as described herein can comprise one more types of modifications and / or moieties, e.g. 1 type of modification, 2 types of modifications, 3 types of modifications or more types of modifications. Non-limiting examples of modifications and / or moieties include PEGylation; glycosylation; HESylation; ELPylation; lipidation; acetylation; amidation; end-capping modifications; cyano groups; phosphorylation; albumin, and cyclization. In some embodiments, an end-capping modification can comprise acetylation at the N-terminus, N-terminal acylation, and N-terminal formylation. In some embodiments, an end-capping modification can comprise amidation at the C-terminus, introduction of C-terminal alcohol, aldehyde, ester, and thioester moieties. The half-life of a polypeptide can be increased by the addition of moieties, e.g. PEG, albumin, or other fusion partners (e.g. Fc fragment of an immunoglobin).

[0209] Any cysteine residue not involved in maintaining the proper conformation of the polypeptide also can be substituted, generally with serine, to improve the oxidative stability of theAtty. Dkt. No. 043214-000114WOPTmolecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) can be added to the polypeptide to improve its stability or facilitate oligomerization.

[0210] Alterations of the native amino acid sequence can be accomplished by any of a number of techniques known to one of skill in the art. Mutations can be introduced, for example, at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion. Alternatively, oligonucleotide-directed site-specific mutagenesis procedures can be employed to provide an altered nucleotide sequence having particular codons altered according to the substitution, deletion, or insertion required. Techniques for making such alterations are very well established. Alterations of the original amino acid sequence can be accomplished by any of a number of techniques known to one of skill in the art. Mutations can be introduced, for example, at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites permitting ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion.Alternatively, oligonucleotide-directed site-specific mutagenesis procedures can be employed to provide an altered nucleotide sequence having particular codons altered according to the substitution, deletion, or insertion required. Techniques for making such alterations include those disclosed by Khudyakov et al. “Artificial DNA: Methods and Applications” CRC Press, 2002; Braman “In Vitro Mutagenesis Protocols” Springer, 2004; and Rapley “The Nucleic Acid Protocols Handbook” Springer 2000; which are herein incorporated by reference in their entireties. In some embodiments, a polypeptide as described herein can be chemically synthesized and mutations can be incorporated as part of the chemical synthesis process.

[0211] As used herein, the term “nucleic acid” or “nucleic acid sequence” refers to any molecule, preferably a polymeric molecule, incorporating units of ribonucleic acid, deoxyribonucleic acid or an analog thereof. The nucleic acid can be either single-stranded or double-stranded. A singlestranded nucleic acid can be one nucleic acid strand of a denatured double- stranded DNA.Alternatively, it can be a single-stranded nucleic acid not derived from any double- stranded DNA. In one aspect, the nucleic acid can be DNA. In another aspect, the nucleic acid can be RNA. Suitable DNA can include, e.g., genomic DNA or cDNA. Suitable RNA can include, e.g., mRNA.

[0212] In some embodiments of any of the aspects, a nucleic acid has at least 80% sequence identity to the entire length of one of SEQ ID NOs: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid has at least 85% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid has at least 90% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid has at least 95%Atty. Dkt. No. 043214-000114WOPTsequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid has at least 98% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid has at least 99% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid has 100% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607.

[0213] In some embodiments of any of the aspects, a nucleic acid comprises a domain having at least 80% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid comprises a domain having at least 85% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid comprises a domain having at least 90% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid comprises a domain having at least 95% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid comprises a domain having at least 98% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid comprises a domain having at least 99% sequence identity to the one of entire length of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid comprises a domain having 100% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607.

[0214] In some embodiments of any of the aspects, a nucleic acid molecule has at least 80% sequence identity to the entire length of one of SEQ ID NOs: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid molecule has at least 85% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid molecule has at least 90% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid molecule has at least 95% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid molecule has at least 98% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid molecule has at least 99% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid molecule has 100% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607.

[0215] In some embodiments of any of the aspects, a nucleic acid molecule comprises a domain having at least 80% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid molecule comprises aAtty. Dkt. No. 043214-000114WOPTdomain having at least 85% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid molecule comprises a domain having at least 90% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid molecule comprises a domain having at least 95% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid molecule comprises a domain having at least 98% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid molecule comprises a domain having at least 99% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607. In some embodiments of any of the aspects, a nucleic acid molecule comprises a domain having 100% sequence identity to the entire length of one of SEQ ID NO: 1-59, 100, 201, or 601-607.

[0216] The term "expression" refers to the cellular processes involved in producing RNA and proteins and as appropriate, secreting proteins, including where applicable, but not limited to, for example, transcription, transcript processing, translation and protein folding, modification and processing. Expression can refer to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from a nucleic acid fragment or fragments of the invention and / or to the translation of mRNA into a polypeptide.

[0217] In some embodiments, the expression of a biomarker(s), target(s), or gene / polypeptide described herein is / are tissue-specific. In some embodiments, the expression of a biomarker(s), target(s), or gene / polypeptide described herein is / are global. In some embodiments, the expression of a biomarker(s), target(s), or gene / polypeptide described herein is systemic.

[0218] " Expression products" include RNA transcribed from a gene, and polypeptides obtained by translation of mRNA transcribed from a gene. The term "gene" means the nucleic acid sequence which is transcribed (DNA) to RNA in vitro or in vivo when operably linked to appropriate regulatory sequences. The gene may or may not include regions preceding and following the coding region, e.g. 5’ untranslated (5’UTR) or "leader" sequences and 3’ UTR or "trailer" sequences, as well as intervening sequences (introns) between individual coding segments (exons).

[0219] In some embodiments of any of the aspects, a polypeptide, nucleic acid, or cell as described herein can be engineered. As used herein, “engineered" refers to the aspect of having been manipulated by the hand of man. For example, a polypeptide is considered to be “engineered" when at least one aspect of the polypeptide, e.g., its sequence, has been manipulated by the hand of man to differ from the aspect as it exists in nature. As is common practice and is understood by those in the art, progeny of an engineered cell are typically still referred to as “engineered" even though the actual manipulation was performed on a prior entity.Atty. Dkt. No. 043214-000114WOPT

[0220] In some embodiments of any of the aspects, the nucleic acid or polypeptide described herein is exogenous. In some embodiments of any of the aspects, the nucleic acid or polypeptide described herein is ectopic. In some embodiments of any of the aspects, the nucleic acid or polypeptide described herein is not endogenous.

[0221] The term "exogenous" refers to a substance present in a cell other than its native source. The term "exogenous" when used herein can refer to a nucleic acid (e.g. a nucleic acid encoding a polypeptide) or a polypeptide that has been introduced by a process involving the hand of man into a biological system such as a cell or organism in which it is not normally found and one wishes to introduce the nucleic acid or polypeptide into such a cell or organism. Alternatively, “exogenous” can refer to a nucleic acid or a polypeptide that has been introduced by a process involving the hand of man into a biological system such as a cell or organism in which it is found in relatively low amounts and one wishes to increase the amount of the nucleic acid or polypeptide in the cell or organism, e.g., to create ectopic expression or levels. In contrast, the term "endogenous" refers to a substance that is native to the biological system or cell. As used herein, “ectopic” refers to a substance that is found in an unusual location and / or amount. An ectopic substance can be one that is normally found in a given cell, but at a much lower amount and / or at a different time. Ectopic also includes substance, such as a polypeptide or nucleic acid that is not naturally found or expressed in a given cell in its natural environment.

[0222] In some embodiments of any of the aspects, the disclosure described herein does not concern a process for cloning human beings, processes for modifying the germ line genetic identity of human beings, uses of human embryos for industrial or commercial purposes or processes for modifying the genetic identity of animals which are likely to cause them suffering without any substantial medical benefit to man or animal, and also animals resulting from such processes.

[0223] The description of embodiments of the disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. While specific embodiments of, and examples for, the disclosure are described herein for illustrative purposes, various equivalent modifications are possible within the scope of the disclosure, as those skilled in the relevant art will recognize. For example, while method steps or functions are presented in a given order, alternative embodiments may perform functions in a different order, or functions may be performed substantially concurrently. The teachings of the disclosure provided herein can be applied to other procedures or methods as appropriate. The various embodiments described herein can be combined to provide further embodiments. Aspects of the disclosure can be modified, if necessary, to employ the compositions, functions and concepts of the above references and application to provide yet further embodiments of the disclosure. These and other changes can be made to the disclosure in light of the detailed description. All such modifications are intended to be included within the scope of the appended claims.Atty. Dkt. No. 043214-000114WOPT

[0224] Specific elements of any of the foregoing embodiments can be combined or substituted for elements in other embodiments. Furthermore, while advantages associated with certain embodiments of the disclosure have been described in the context of these embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the disclosure.

[0225] Preferred embodiments of this application are described herein, including the best mode known to the inventors for carrying out the application. Variations on those preferred embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. It is contemplated that skilled artisans can employ such variations as appropriate, and the application can be practiced otherwise than specifically described herein. Accordingly, many embodiments of this application include all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the application unless otherwise indicated herein or otherwise clearly contradicted by context.

[0226] Unless stated otherwise, or implicit from context, the following terms and phrases include the meanings provided below. Unless explicitly stated otherwise, or apparent from context, the terms and phrases below do not exclude the meaning that the term or phrase has acquired in the art to which it pertains. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It should be understood that this invention is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such can vary. The definitions and terminology used herein are provided to aid in describing particular embodiments, and are not intended to limit the claimed invention, because the scope of the invention is limited only by the claims.

[0227] As used herein the term “comprising” or “comprises” is used in reference to compositions, methods, systems, articles of manufacture, apparatus, and respective component(s) thereof, that are useful to an embodiment, yet open to the inclusion of unspecified elements, whether useful or not. It will be understood by those within the art that, in general, terms used herein are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.). Although the open-ended term “comprising,” as a synonym of terms such as including, containing, or having, is used herein to describe and claim the invention, the present invention, or embodiments thereof, may alternatively be described using alternative terms such as “consisting of’ or “consisting essentially of.”

[0228] Other aspects and embodiments of the invention provide the aspects and embodiments described herein with the term "comprising" replaced by the term "consistingAtty. Dkt. No. 043214-000114WOPTof." Other aspects and embodiments of the invention provide the aspects and embodiments described herein with the term "comprising" replaced by the term "consisting essentially of."

[0229] Unless stated otherwise, the terms “a” and “an” and “the” and similar references used in the context of describing a particular embodiment of the application (especially in the context of claims) can be construed to cover both the singular and the plural. The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (for example, “such as”) provided with respect to certain embodiments herein is intended merely to better illuminate the application and does not pose a limitation on the scope of the application otherwise claimed.

[0230] The abbreviation, “e.g.” is derived from the Latin exempli gratia, and is used herein to indicate a non-limiting example. Thus, the abbreviation “e.g.” is synonymous with the term “for example.” No language in the specification should be construed as indicating any non-claimed element essential to the practice of the application.

[0231] “Optional" or “optionally” means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not.

[0232] In some embodiments of any one of the aspects described herein, the numbers expressing quantities of reagents, properties such as concentration, reaction conditions, and so forth, used to describe and claim certain embodiments of the invention are to be understood as being modified in some instances by the term “about.” The term “about” is used herein to provide literal support for the exact number that it precedes, as well as a number that is near to or approximately the number that the term precedes. In determining whether a number is near to or approximately a specifically recited number, the near or approximating unrecited number may be a number which, in the context in which it is presented, provides the substantial equivalent of the specifically recited number. Accordingly, in some embodiments of any one of the aspects described herein, the numerical parameters set forth in the written description and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment. In some embodiments of any one of the aspects described herein, the numerical parameters should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable. The numerical values presented in someAtty. Dkt. No. 043214-000114WOPTembodiments of the invention may contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.

[0233] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member can be referred to and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group can be included in, or deleted from, a group for reasons of convenience and / or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.

[0234] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0235] All references to NCBI database information such as Ref Seq’s and Gene ID’s herein, refer to the sequence information present in the database as of May 5, 2026.

[0236] The invention is further illustrated by the following examples which are intended to be purely exemplary of the invention, and which should not be construed as limiting the invention in any way. The following examples are illustrative only, and are not intended to limit, in any manner, any of the aspects described herein. The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the invention. To the extent that specific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the invention. One skilled in the art may develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the invention.

[0237] Some exemplary embodiments of the various aspects described herein can be defined as in any of the following numbered embodiments:

[0238] Embodiment 1: An adeno-associated virus (AAV) vector comprising:a) one or more nucleic acids encoding:i) a Cas endonuclease; andii) at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene selected from the group consisting of: 3C-like protease (3CL), Programmed ribosomal frameshifting (PRF),Atty. Dkt. No. 043214-000114WOPTRNA-dependent RNA polymerase (Rdrp), Spike (S), Envelope (E), Membrane (M), and Nucleocapsid (N).

[0239] Embodiment 2: An adeno-associated virus (AAV) vector comprising:a) one or more nucleic acids encoding:i) A polypeptide having at least 80% sequence identity to SEQ ID NO: 206; andii) at least one CRISPR-associated guide RNA sequence.

[0240] Embodiment 3: The AAV vector of any one of the preceding Embodiments, wherein the nucleic acid encodes a CasRx endonuclease.

[0241] Embodiment 4: The AAV vector of any one of the preceding Embodiments, wherein the CasRx endonuclease comprises two SV40 nuclear localization sequences.

[0242] Embodiment 5: The AAV vector of any one of the preceding Embodiments, wherein the CasRx endonuclease comprises one HA tag.

[0243] Embodiment 6: The AAV vector of any one of the preceding Embodiments, wherein the one or more nucleic acids encode four CRISPR-associated guide RNA sequences in series.

[0244] Embodiment 7: The AAV vector of any one of the preceding Embodiments, wherein the at least one CRISPR-associated guide RNA sequence targets the Rdrp gene in SARS-CoV-2.

[0245] Embodiment 8: The AAV vector of any one of the preceding Embodiments, wherein the nucleic acid encoding a Cas endonuclease is operably linked to a promoter.

[0246] Embodiment 9: The AAV vector of any one of the preceding Embodiments, wherein the nucleic acid encoding at least one CRISPR-associated guide RNA sequence is operably connected to a promoter.

[0247] Embodiment 10: The AAV vector of any one of the preceding Embodiments, wherein the nucleic acid encoding a Cas endonuclease and the nucleic acid encoding at least one CRISPR-associated guide RNA sequence are operably linked to the same promoter.

[0248] Embodiment 11: The AAV vector of any one of the preceding Embodiments, wherein the nucleic acid encoding a Cas endonuclease is operably linked to a first promoter and the nucleic acid encoding at least one CRISPR-associated guide RNA sequence is operably linked to a second promoter.

[0249] Embodiment 12: The AAV vector of any one of the preceding Embodiments, wherein the promoter is an EFS promoter.

[0250] Embodiment 13: The AAV vector of any one of the preceding Embodiments, wherein the promoter is a U6 promoter.

[0251] Embodiment 14: An adeno-associated virus (AAV) vector comprising a nucleic acid encoding:a) a soluble receptor; andAtty. Dkt. No. 043214-000114WOPTb) an antibody reagent.

[0252] Embodiment 15: The AAV vector of any one of the preceding Embodiments, wherein the soluble receptor is a soluble VEGF receptor.

[0253] Embodiment 16: The AAV vector of any one of the preceding Embodiments, wherein the soluble VEGF receptor comprises extracellular domains of human VEGF receptors 1 and 2.

[0254] Embodiment 17: The AAV vector of any one of the preceding Embodiments, wherein the antibody reagent is a scFv.

[0255] Embodiment 18: The AAV vector of any one of the preceding Embodiments, wherein the antibody reagent binds specifically to TGF 1.

[0256] Embodiment 19: An AAV comprising:a) the vector of any one of the preceding Embodiments; and b) at least one capsid polypeptide.

[0257] Embodiment 20: The AAV of any one of the preceding Embodiments, wherein the at least one capsid polypeptide comprises at least four contiguous amino acids from the sequence TVSALFK (SEQ ID NO: 301); TVSALK (SEQ ID NO: 302); KLASVT (SEQ ID NO: 303); or KFLASVT (SEQ ID NO: 304).

[0258] Embodiment 21: A composition for intranasal delivery, the composition comprising the AAV of any one of the preceding Embodiments.

[0259] Embodiment 22: The composition of any one of the preceding Embodiments, further comprising a pharmaceutically acceptable excipient.

[0260] Embodiment 23: The composition of any one of the preceding Embodiments, further comprising a mucoadhesive agent, a thermosensitive agent, a viscosity enhancing agent, or a combination thereof.

[0261] Embodiment 24: The composition of any one of the preceding Embodiments, further comprising a sweetener, a polyol, a fragrance, or a combination thereof.

[0262] Embodiment 25: The composition of any one of the preceding Embodiments, wherein the composition is a solution.

[0263] Embodiment 26: The composition of any one of the preceding Embodiments, wherein the composition is a suspension.

[0264] Embodiment 27: The composition of any one of the preceding Embodiments, wherein the composition is an aerosol.

[0265] Embodiment 28: The composition of any one of the preceding Embodiments, wherein the composition is a liquid.

[0266] Embodiment 29: The composition of any one of the preceding Embodiments, wherein the composition is a powder.Atty. Dkt. No. 043214-000114WOPT

[0267] Embodiment 30: The composition of any one of the preceding Embodiments, wherein the composition is a gel.

[0268] Embodiment 31: A method comprising: contacting a cell with an adeno-associated virus (AAV) or composition of any one of the preceding Embodiments.

[0269] Embodiment 32: The method of any one of the preceding Embodiments, wherein the cell is a respiratory cell.

[0270] Embodiment 33: The method of any one of the preceding Embodiments, wherein the cell is a ciliated cell, a brush cell, an airway basal cell, a small granule cell, goblet cell, an a-tubulin-positive ciliated cell, a club cell, a trachea cell, or a ATI cell.

[0271] Embodiment 34: The method of any one of the preceding Embodiments, wherein the cell is in a subject.

[0272] Embodiment 35: The method of any one of the preceding Embodiments, wherein the cell is in a mammalian subject.

[0273] Embodiment 36: The method of any one of the preceding Embodiments, wherein the cell is in a human subject.

[0274] Embodiment 37: The method of any one of the preceding Embodiments, wherein the subject has a respiratory disease or infection.

[0275] Embodiment 38: The method of any one of the preceding Embodiments, wherein the disease is idiopathic pulmonary fibrosis (IPF).

[0276] Embodiment 39: The method of any one of the preceding Embodiments, wherein the infection is a viral infection.

[0277] Embodiment 40: The method of any one of the preceding Embodiments, wherein the viral infection is caused by SARS-CoV-2.

[0278] Embodiment 41: A method of treating respiratory disease or infection in a subject in need thereof, the method comprising: administering an AAV or compositions of any one of the preceding Embodiments to the subject.

[0279] Embodiment 42: The method of any one of the preceding Embodiments, wherein the disease is idiopathic pulmonary fibrosis (IPF).

[0280] Embodiment 43: The method of any one of the preceding Embodiments, wherein the infection is a viral infection.

[0281] Embodiment 44: The method of any one of the preceding Embodiments, wherein the viral infection is caused by SARS-CoV-2.

[0282] Embodiment 45: The method of any one of the preceding Embodiments, wherein the AAV is administered by intranasal delivery.

[0283] Embodiment 46: The method of any one of the preceding Embodiments, wherein the AAV is administered by a dropper.Atty. Dkt. No. 043214-000114WOPT

[0284] Embodiment 47: The method of any one of the preceding Embodiments, wherein the AAV is administered as a spray.

[0285] Embodiment 48: The method of any one of the preceding Embodiments, wherein the AAV is administered by a nebulizer.

[0286] Embodiment 49: A device for intranasal administration of a composition comprising an AAV or composition of any one of the preceding Embodiments, to a subject.

[0287] Embodiment 50: The device of any one of the preceding Embodiments, wherein the device is a dropper.

[0288] Embodiment 51: The device of any one of the preceding Embodiments, the device is a spray.

[0289] Embodiment 52: The device of any one of the preceding Embodiments, wherein the device is a nebulizer.

[0290] Embodiment 53: A kit comprising the device of any one of the preceding Embodiments and instructions for use.

[0291] The technology described herein is further illustrated by the following examples which in no way should be construed as being further limiting.EXAMPLESExample 1: Cross-species tropism of AAV. CPP.16 in the respiratory tract and its gene therapies against pulmonary fibrosis and viral infection

[0292] Efficient gene delivery vectors are crucial for respiratory and lung disease therapies. Described herein is AAV. CPP.16, an engineered adeno-associated virus (AAV) variant derived from AAV9. In some embodiments of any of the aspects described herein, AAV. CPP.16 efficiently transduces airway and lung cells in mice and non-human primates via intranasal administration. In some embodiments of any of the aspects described herein, AAV. CPP.16 outperforms AAV6 and AAV9, two wild-type AAVs with demonstrated tropism for respiratory tissues and efficiently targets key respiratory cell types. In some embodiments of any of the aspects described herein, AAV. CPP.16 supports gene supplementation and editing therapies in two clinically relevant mouse models of respiratory and lung diseases. In some embodiments of any of the aspects described herein, a single intranasal dose of AAV. CPP.16 expressing a dual-taiget, VEGF / TGFpi -neutralizing protein protected lungs from idiopathic pulmonary fibrosis, while a similar application of AAV. CPP.16 carrying an “all-in-one” CRISPR-Casl3d system inhibited transcription of the SARS-CoV-2-derived RNA-dependent RNA polymerase (Rdrp) gene. These findings highlight AAV. CPP.16 as a promising vector for respiratory and lung gene therapy.Atty. Dkt. No. 043214-000114WOPT

[0293] Progress in respiratory gene therapy and gene editing is hampered by a lack of efficient delivery vectors. Adeno-associated virus (AAV) is a viral vector for in vivo gene delivery with accumulating clinical trial experiences.1Recently, the inventors reported an AAV9-derived capsid AAV. CPP.16 with species-conserved neurotropism after systemic administration.6The inventors have observed enhanced transduction of the lung by AAV. CPP.16 relative to its parent capsid AAV9. Herein, the use of AAV. CPP.16 as an intranasal gene transfer vector for gene therapy and gene editing for potential treatment of respiratory diseases and airborne viral infection is disclosed.

[0294] Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease that affects over 3 million people worldwide.7Characterized by scarring of the lungs and declining respiratory function, IPF significantly impairs quality of life and is often fatal, with a median survival rate of 3 to 5 years if left untreated.7In IPF, a combination of environmental and genetic factors converge on the lung epithelium, triggering a maladaptive response. This malfunctioning epithelium then produces mediators that drive the fibroblast-to-myofibroblast transition, ultimately resulting in fibrotic remodeling of the lungs. A major focus of IPF drug development has been identifying key “druggable” mediators of this process.7Currently, existing monotherapies only slow disease progression; more targeted and effective therapies are needed to halt, or even reverse IPF.

[0295] SARS-CoV-2, an RNA virus, continues to pose a significant threat to global healthcare. Vaccination is less effective or even invalid in vulnerable populations of immune-deficient patients.11Furthermore, constant mutation and evolution of viruses have led to the emerging of variants that could potentially break through the protective barrier established by active vaccination and / or passive viral exposure.12Continuous research on non-immune-based antiviral approaches may provide additional prevention and treatment options for SARS-CoV-2 infection.13

[0296] The inventors report herein a systematic characterization of AAV. CPP.16 as a gene therapy vector for intranasal treatment of respiratory and lung diseases. In comparison with wild-type AAV6 andAAV9, the inventors observed markedly enhanced tropism of AAV. CPP16 for major cell types that belong to the respiratory system in cell culture, mouse and non-human primate (NHP) models. Using AAV. CPP.16 as a vector, the inventors then engineered an intranasal gene therapy for IPF and found that partially sequestering two fibrotic mediators VEGF (vascular endothelial growth factor) and TGF 1 (transforming growth factor beta 1) provided marked anti-fibrotic protection for the lung in a mouse model of IPF. Furthermore, the inventors designed and tested an AAV. CPP.16-mediated, passive prophylaxis to SARS-CoV-2 infection using a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) system that inhibited the highly conserved RNA-dependent RNA polymerase (Rdrp) gene in SARS-CoV-2.

[0297] Tropism of AAV. CPP.16 for airway cells and mouse respiratory tract. The inventors first examined the transduction efficiency of AAV. CPP.16 in cultured airway cells and inAtty. Dkt. No. 043214-000114WOPTmice and compared it with AAV6 and AAV9. (FIG.1A). Single-stranded AAV vectors were packaged carrying a GFP reporter with a ubiquitous CAG promoter (AAV-CAG-GFP). RPMI 2650 cell, a human nasal epithelial cell line, was prepared and treated with AAV s for 4 days using a multiplicity of injection (MOI) of 1 x 105. It was found that the average fluorescence intensity of GFP expressed by AAVCPP.16 was 3.0-fold and 6.6-fold greater than AAV 6 and AAV9 respectively (P = 0.0023, P = 0.0006 respectively) (FIGs. IB and 1C). No significant difference of GFP signals between AAV6 and AAV9 was observed.

[0298] To test AAVCPP.16 in mice, intranasal administration of 1 x 1011vg AAV s-CAG-GFP per animal was performed using both nostrils in C57BL / 6J mice. 3 weeks later, nasal cavity, trachea and lung tissues were fixed and harvested for assessing AAV-mediated GFP expression, while other organs were collected for further biodistribution analysis. The fluorescence images revealed superior fluorescence intensity in the nasal cavity of mice treated with AAVCPP.16 (2.7-fold vs. AAV9 and 1,8-fold vs. AAV6, FIGs. ID and IE). Strong and broad GFP signal was observed in membranous structures in anatomical regions including the nasal septum, nasal turbinate and different regions of nasal meatuses, while only partial and weak expression of GFP was noticed in nostrils treated with AAV6 or AAV9 (FIG. ID). No GFP expression was observed in deep tissues in the nasal cavity. A similar examination revealed significantly enhanced transduction efficiency by AAVCPP.16 in inner linings of the trachea (FIGs. IF and 1G) and the lung (FIGs. 1H and II) as compared with AAV6 andAAV9. No statistical differences were observed when comparing AAV6 to AAV9 in the nasal cavity, trachea and lung tissues. In addition, intranasal injection of AAV6, AAV9, and AAVCPP.16 resulted in no to little transduction in the brain, retina, tongue, liver, spleen, intestine, stomach, kidney and muscle (FIG.7), suggesting relative selectivity of intranasally administered AAVs for targeting the respiratory tract. A small number of transduced cells were observed in the liver in mice treated with AAVCPP.16.

[0299] Next, the inventors examined the types of AAV-transduced airway cells using antibody markers (FIG.2A). In the nasal cavity, immunostaining against MUC5A and a-Tubulin19were used for labeling the two primary cell types, namely, the goblet- and ciliated cells respectively. The inventors found that AAVCPP.16-GFP of 1 x 1011vg transduced approximately 42.7% of MUC5A-positive goblet cell, as compared with much lower transduction percentages of 3.0% for AAV6 and 7.8% for AAV9 (FIGs.2B and 2E). AAVCPP.16-GFP also appears to transduce more a-Tubulin-positive ciliated cells per unit areas in the nasal cavity in comparison to AAV6-GFP and AAV9-GFP (FIG.8A), although the percentage transduction of ciliated cells could not be determined using a-Tubulin as a marker.

[0300] In the trachea, the inventors analyzed the two major component cells, club- and ciliated cells, using antibody markers CC1020and a-Tubulin respectively. AAVCPP.16-GFP transduced 71.0% of the club cells, exhibiting significantly higher transduction efficiencies asAtty. Dkt. No. 043214-000114WOPTcompared with AAV6 (29.6%) andAAV9 (20.2%) (FIGs.2C and 2F). More GFP-positive cells were also observed by co-labeling for a-Tubulin in AAV. CPP.16-treated trachea tissues (FIG.8B). No significant difference in transduction was observed in either club or ciliated cells between AAV6 and AAV9 treatment.

[0301] Lastly, to characterize AAV transduction in the lung, the inventors focused on measuring the AAV expression on alveolar type I (ATI) cells in lung parenchyma, which cover more than 95% of alveolar surface,21as well as ciliated cells in lung bronchi. The inventors applied an antibody against RAGE21, a membrane protein, to determine ATI cells. Intranasal administration of AAV. CPP.16 resulted in increased transduction of RAGE-positive ATI cells (13.6% for AAV. CPP.16 vs. 2.8% for AAV6 and 1.9% for AAV9) (FTGs.2D and 2G). For ciliated cells located in the inner wall of lung bronchi, more of them were also transduced by AAV. CPP.16 as compared with AAV6 and AAV9 (FIG.8C).

[0302] AAV. CPP.16 maintains superior tropism for the respiratory tract in NHPs. To test if the enhanced tissue tropism of AAV. CPP.16 in the respiratory tract could translate from mice to NHPs, the inventors compared AAV. CPP.16 to AAV9 in adult rhesus macaques (Macaco mulatto) via intranasal administration. The inventors produced three AAV s expressing with GFP or RFP using the CAG promoter (i.e., AAV9-RFP, AAV9-GFP, and AAV. CPP.16-GFP) and verified their infectivity in HEK293T cells in vitro (FIGs.9A and 9B). Three NHPs were prepared after pre-screening for neutralizing antibodies against AAV9 capsid (Antibody titer <1:10, FIG.9C). Serving as a control, AAV9-RFP was co-injected in one NHP (#1) with AAV9-GFP and in two NHPs (#2 and #3) with AAV. CPP.16-GFP (4 x 1012vg per AAV per animal). 4 weeks after AAV administration, all 3 NHPs were subjected for histological examination. No behavioral abnormality or weight loss was observed in any of the three animals. Comprehensive blood tests performed across the duration of the study revealed no major adverse effects associated with AAV administration (See Tables 1-3).

[0303] In NHP #1 treated with AAV9-GFP / AAV9-RFP co-administration, a small amount of RFP and GFP labeled cells were observed on sections sampled from the nasal cavity, trachea and lung (FIGs.3A, 3C, and 3E). Cells co-labeled with RFP and GFP were not detected. For quantification, ImageJ software was used to measure the RFP and GFP fluorescence intensities using DAPI nuclear staining signal as benchmark. The GFP / RFP ratio was calculated and used for comparing the transduction efficiencies of AAVs. As expected, AAV9-GFP and AAV9-RFP had similar transduction efficiencies for all examined tissues with the GFP / RFP ratios close to 1 as seen in NHP#1.

[0304] In NHPs #2 and #3 treated with AAV. CPP.16-GFP / AAV9-RFP co-administration, substantially stronger GFP fluorescence was measured in the respiratory tract in comparison with the RFP signal, suggesting a better transduction efficiency by AAV. CPP.16 relative to AAV9. Change folds of AAV. CPP.16 vs. AAV9 ranged from 3.9 to 7.6 in NHP#2 and from 2.5 to 10.5 in NHP#3 in examined respiratory parts (FIGs.3B, 3D, and 3F). As in the mouse study, the invention furtherAtty. Dkt. No. 043214-000114WOPTexamined the cell types transduced by the AAVs including MUC5A-positive goblet cells in the nasal cavity, CC 10-positive club cells in the trachea, and RAGE-positive alveolar type I cells in the lung. While AAV9 resulted in little transduction of these three cell types, AAV. CPP.16 was able to transduce 23% and 14% of goblet cells, 11% and 18% of club cells, 33% and 27% of alveolar type I cells, in NHP#2 and NHP#3 respectively (FIGs.9D-9F). These results suggest the enhanced tropism of AAV. CPP.16 over AAV9 can translate from mice to NHPs.

[0305] Additional histology analysis in all three NHPs revealed no detectable AAV expression in the heart, spleen or brain tissues (FIGs. 10-11). The inventors found AAV. CPP.16-GFP resulted in the transduction of some cells in the liver and possibly in the kidney in both NHP#2 and NHP#3 (FIG. 10).

[0306] An AAV. CPP.16-mediated gene supplementation therapy for IPF. The inventors’ findings of enhanced gene delivery efficiency of AAV. CPP.16 in both proximal and distal airways and the lung prompted us to further explore its application in gene therapy for respiratory and lung diseases. The inventors first focused on IPF, a severe lung disease in which more targeted and effective therapies are needed. Nintedanib and PFD are two pleiotropic anti-fibrotic molecules approved for IPF treatment8. While nintedanib22is a tyrosine kinase antagonist that inhibits activities of many growth factors including VEGF,23PFD24,25is a pyridine with a myriad of anti-inflammatory, antioxidant, and anti-fibrotic effects including downregulating the cellular effects of TGFpi.26Given the reported roles of VEGF27'29and TGF 130-32in IPF, we hypothesized that one-time administration of an AAV. CPP.16-mediated gene therapy downregulating both VEGF and TGF 1 pathways could provide lasting protection for the lung against IPF.

[0307] The inventors constructed an AAV. CPP.16 gene therapy that expressed a secreted, bifunctional fusion protein that comprised a VEGF decoy receptor and a single-chain variable fragment (scFv) against mouse TGF 1 (see design of AAV-Aflibercept-TGFP trap in FIG.4A). The VEGF decoy receptor was designed as in Aflibercept, a clinically approved anti- VEGF drug, that consists of the extracellular domains of the human VEGF receptors 1 and 2.33Aflibercept binds to both human and mouse VEGFs.34The scFv against mouse TGFpi was derived from the anti-TGFpi IgG antibody Clone 13 Al.35,36

[0308] To evaluate the efficacy of this AAV gene therapy (i.e., CPP16-IPF trap), we utilized a bleomycin (BLM)-induced IPF mouse model31(FIG.4B). Successful induction of IPF was confirmed by a >10% bodyweight loss on Day 4 after intratracheal (i.t.) instillation of BLM (1 mg / kg) (FIGs. 12A-12D). Randomly selected BLM-treated mice received either sham operation, or one-time intranasal inhaling (inhal.) of CPP.16- IPF trap (4 x 1011vg per mouse) on Day 4 using a vaporizing device, or intragastric (i.g.) instillation of PFD (250 mg / kg) every day for 25 days. All animals were sacrificed for analysis on Day 29.Atty. Dkt. No. 043214-000114WOPT

[0309] As shown in representative images with hematoxylin and eosin (HE) staining (FIG.4C), BLM treatment resulted in notable pathological hallmarks in the lung, including distorted alveolar structure, thickened alveolar walls and formation of fibrotic foci. The percentage of interstitial tissue area was significantly increased in BLM-treated lung sections, indicative of pulmonary fibrosis and alveolus volume reduction (FIG.4D). Both CPP.16-IPF trap and PFD treatments preserved the lung structure and significantly attenuated the alveolus volume reduction induced by BLM treatment (FIGs.4C and 4D). To further examine lung fibrosis, we performed Masson’s trichrome stain, picrosirius red stain, and immunohistochemical (IHC) staining of the fibrosis marker a-SMA (FIG.4E). Consistent with HE staining, pulmonary fibrosis level was significant increased after BLM treatment, as evidenced by increases in collagen fibers (blue in Masson stain and red in picrosirius red stain) and a-SMA (brown in IHC stain). Similar to PFD drug treatment, gene therapy CPP.16-IPF trap intervention markedly reduced BLM-induced pulmonary fibrosis (FIGs. 4E and 4F). These results suggest that a single administration of intranasal CPP.16-IPF trap gene therapy could provide a targeted treatment for IPF, potentially serving as an alternative to the repeated dosing required with the chemical drug PFD.

[0310] Dual-targeting of VEGF and TGF 01 by AAV. CPP.16-IPF trap. The inventors next verified that the CPP.16-IPF trap gene therapy had engaged with its VEGF and TGF01 targets in the treated IPF lung. The inventors observed expression of the viral payload in the lung tissue using two sets of primers that taiget the Aflibercept and TGF01 trap fragments (FIG.5A). ELISA essay further confirmed significant reduction of VEGFa and TGF01 proteins in gene therapy-treated lungs in comparison with non-treated IPF lungs (FIGs.5B and 5C). Interestingly, VEGFa and TGF01 protein levels were also reduced by PFD treatment. Additionally, we observed reduction in mRNA of fibrogenic genes (Acta2, Postn, Fri) and inflammatory cytokine genes (Tnfa, 116, Illb) in both gene therapy and PFD treated lungs, in accordance with the anti-fibrotic and anti-inflammatory effects of the two therapies (FIGs.5D and 5E). Moreover, extracellular matrix (ECM) associated proteins (COL1A1, fibronectin), fibroblast activation associated proteins (aSMA, periostin) and inflammatory cytokines (TNFa, IL-6, IL-1 ) were significantly downregulated in mouse lung tissues after CPP.16-IPF trap treatment (Figures 5F-5H). In summary, these findings confirm the dual inhibition of VEGF and TGF01 pathways by CPP.16-IPF trap gene therapy treatment.

[0311] AAV. CPP.16-mediated CRISPR gene therapy against SARS-CoV-2. In addition to gene supplementation therapy, the inventors also asked if AAV. CPP.16 could be used for gene editing in respiratory diseases. SARS-CoV-2 is a respiratory RNA virus that remains as a major threat to human health. Here, we designed an “all-in-one”, broad-spectrum CRISPR gene therapy against SARS-CoV-2 and explored the application of AAV. CPP.16 for its in vivo delivery.

[0312] For targeting viral RNA in SARS-CoV-2, the inventors chose to use CasRx, an RNA-guided CRISPR RNA endonuclease that belongs to the class 2 type VI-D CRISPR-Casl3d system.Atty. Dkt. No. 043214-000114WOPTDerived from Ruminococcus flavefaciens XPD3002 (RfxCasl3d, or CasRx),37CasRx is small (967 amino acids), specific and strong in its catalytic activity; it employs short, customizable CRISPR-associated guide RNAs (gRNAs) for target recognition and engagement. To design effective gRNA sequences, the inventors first performed genome mapping of sequenced SARS-CoV-2 strains and analyzed CasRx-targetable regions. The inventors analyzed 2815 SARS-CoV-2 genomes downloaded from the public database NCBI SARS-CoV-2 Resources and identified 7 conserved regions located within putative open reading frames, including regions 3C-like protease (3CL), Programmed ribosomal frameshifting (PRF), RNA-dependent RNA polymerase (Rdrp), Spike (S), Envelop (E), Membrane (M), and Nucleocapsid (N) (Figure S8A). The conservation scores of these 7 regions arranged from 0.973 to 0.999 out of 1 (FIG. 14B; Table 4), suggesting vital roles of these genes and thus potential value as targets. The inventors then performed 23-nucleotide (nt) candidate gRNAs prediction analysis for all 7 conserved genes based on published Casl3 gRNA design principles.38The inventors decided to focus on the Rdrp as the CasRx targeting gene because: 1, sufficient output of good gRNA candidates was obtained with 460 candidates located at the 4thquartile out of 2,614 sequences in total; 2, Rdrp is essential for the replication of the SARS-CoV-2 viral genome and transcription of its genes,39,40and its value as a therapeutic target has been demonstrated by several clinically proven small molecule antiviral drugs;413, Rdrp is believed to be under less evolution pressure, as compared with the Spike gene, so the risk of mutational escape would be lower.

[0313] The inventors performed off-target filtration on the 460 gRNAs with high predicted Rdrp-targeting scores, excluded 377 of them with off-targets containing 2 or fewer mismatches in the human and mouse transcriptomes, and retained 83 with little predicted off-targeting. Four conserved regions were previously described in the Rdrp protein including Niran, Interface, Finger, Finger / Palm and Thumb.39,41,45The inventors found 8 of the 83 remaining gRNAs target the Niran region, 7 target Interface, 44 target Finger, 13 target Finger / Palm, 11 target Thumb (FIG. 14C). We selected 4 gRNAs with relatively wide coverage for each conserved region of Rdrp and constructed a pooled 4x gRNA sequence that contains all 4 gRNAs in tandem. 5 pooled gRNA sequences were generated in total with each targeting one of the five conserved regions in Rdrp (FIG. 14D, Table 5).

[0314] Next, the inventors designed and constructed a dual-promoter, all-in-one AAV-CasRx-gRNA system that could express both CasRx and the 4x gRNAs in one vector (FIG.6A; Table 6). CasRx with two 7-amino acid SV40 nuclear localization signal (NLS) sequences and one 9-amino acid HA tag was expressed under the regulation of the small EFS promoter (212-bp or base pairs) and a 2x sNRPl(the soluble neuropilin- 1) polyadenylation sequence (34 bp).46The U6 promoter was used to drive the expression of the 4x gRNAs and the 30-bp Casl3d direct repeats (DRs) that are essential for gRNA expression.37The length of the DNA sequence between the two inverted terminal repeats (ITRs) was approximately 3.8k bp, which is well within the 4.7k bp packaging capacity for AAV. With five different 4x gRNA sequences targeting the Rdrp, we generated five AAV plasmid vectors including pAAV-CasRx-gRNA. Niran, pAAV-CasRx-gRNA. Interface, pAAV-CasRx-gRNA. Finger,Atty. Dkt. No. 043214-000114WOPTpAAV-CasRx-gRNA. Palm, and pAAV-CasRx-gRNA. Thumb. In addition, the inventors generated two control plasmids by replacing the 4x gRNA with a scramble sequence (pAAV-CasRx-scramble) and a previously published gRNA sequence targeting the Rdrp (pAAV-CasRx-gRNA. Abbott).40To test the Rdrp inhibition efficiency of our plasmid vectors, we co-transfected each of the pAAV-CasRx plasmid vectors into HEK-293T cells with a Rdrp reporter plasmid and measured Rdrp transcript abundance RNA 48 hours later by quantitative real-time PCR (FIG.6B). Compared with Rdrp transfection alone, co-transfection of the scramble plasmid resulted in no reduction of Rdrp transcription. Like the effect of the “Abbott” plasmid which deceased Rdrp by 46%, all our Rdrp-targeting plasmid vectors achieved Rdrp inhibition by a magnitude ranging from 44% to 58% (FIG.6C).

[0315] Next, the inventors tested AAV. CPP.16-mediated Rdrp inhibition as a prophylactic treatment strategy against SARS-CoV-2 in a pseudovirus model. Recombinant Ad5 viruses carrying the viral Rdrp gene (1.2xl08pfu / well) were used to artificially express the Rdrp gene in the human nasal epithelial cells RPMI-1650 (FIG.6D). Two most efficient AAV plasmid vectors (i.e., “Niran” and “Interface” with inhibition efficiencies of 54% and 58% respectively), along with the scramble, were selected and packaged into AAV s with the AAV. CPP.16 capsid. Indeed, treatment of AAV. CPP.16-CasRx-gRNA. Niran or AAV. CPP.16-CasRx-gRNA. Interface (5x10” vg / well) prevented Ad5-mediated Rdrp transcription by 50% and 60% respectively (FIG.6E). For further testing in mice, intranasal administration of AAV. CPP.16-CasRx-gRNA. Interface or AAV. CPP.16-CasRx-scramble (5xlOnvg / mice) was performed in adult C57BL / 6 mice, followed by a second intranasal administration of Ad5-Rdrp (4xl08pfu / mice) 7 days later (FIG.6F). Animals were sacrificed after another 3 weeks and tissues collected for RNA analysis. Ad5-Rdrp alone resulted in remarkable overexpression (50-300 fold) in mouse nostrils, tracheas and lungs 4 weeks after intranasal injection (FIG. 14E). Compared with the scramble AAV, AAV. CPP.16-CasRx-gRNA. Interface resulted in significantly reduced Rdrp transcription in all examined regions of the respiratory tract with near complete blockade of Rdrp transcription in the nostril (FIG.6G).

[0316] Developing gene therapies for respiratory diseases such as cystic fibrosis, IPF, and airborne viral infections has proven more challenging than initially anticipated. A major technical hurdle lies in the efficient delivery of therapeutic genes to disease-relevant cell types, particularly airway epithelial and lung parenchyma cells. To develop efficacious gene therapy for respiratory conditions, particularly through intranasal administration, the primary objective is to achieve efficient transduction in both proximal and distal airway cells. Indeed, AAV. CPP.16 outperforms AAV6 and AAV9 in transducing the cultured human nasal epithelial cells and mouse airway and lung cells. The observed superiority of AAV. CPP.16 over the control AAV9 is particularly notable in our NHP studies.

[0317] By retaining its genetic payload in an episomal form in the nucleus of the host cell, AAV vectors are capable of safely sustaining transgene expression for at least years. Thus, AAV-mediated gene therapy has the potential for providing long-lasting treatments for many chronicAtty. Dkt. No. 043214-000114WOPTdiseases including IPF. Like other chronic diseases, IPF is regarded as a consequence of both genetic and environmental risk factors, and such complex etiology and pathophysiology makes it more challenging to develop a gene therapy due to lack of valid targets. Our study demonstrates the therapeutic benefit of simultaneously targeting VEGF and TGF 1 for IPF. Our gene therapy provides an opportunity to further augment existing monotherapies for IPF.

[0318] The inventors provide both in vitro and in vivo efficacy evidence supporting the use of CRISPR-Casl3 against SARS-CoV-2 using a clinically relevant AAV vector AAV. CPP.16. The lead candidate therapy (i.e., AAV. CPP.16-CasRx-gRNA. Interface) reduces Ad5-mediated Rdrp transcription by more than 60% in human nasal epithelial cells and mouse respiratory tract tissues. Intranasal pre-treatment of such gene therapy in mice almost totally prevents Ad5 -mediated Rdrp transcription in the nostrils, a key anatomical site for initial SARS-CoV-2 infection and amplification.

[0319] The risk of “breakthrough” SARS-CoV-2 mutants exists and treatment options for immune-compromised patients are still limited. The high efficiency of AAV. CPP.16 in targeting respiratory tract tissues in primates, robust and broad spectrum of our CRISPR gRNA array, and versatility of the CRISPR system in general all support the currently described gene therapy as a supplementary strategy against current and emerging SARS-CoV-2 variants.

[0320] In summary, the inventors present AAV. CPP.16 as an intranasal gene delivery vector with high tropism for respiratory tract tissues in both mice and non-human primates. The inventors further describe two AAV. CPP.16-mediated gene therapies: one for idiopathic pulmonary fibrosis (IPF) by expressing a bifunctional fusion protein that inhibits VEGF and TGF 1, and one as passive prophylaxis to SARS-CoV-2 infection using a CRISPR-Casl3 system.Supplemental Information for Example 1

[0321] Cell culture: Human embryonic kidney (HEK293T) cells (CRL-3216) and Human nasal epithelial cell RPMI 2650 (CCL-30) were purchased from the American Type Culture Collection (ATCC). No additional authentication was performed for either cell line. Cell lines were not tested for mycoplasma contamination.

[0322] Animals: Mouse experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at Brigham and Women’s hospital, Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, and Soochow University. For AAV distribution study, both male and female adult mice aged over 8 weeks were used. Mouses strains C57BL / 6J were purchased from Jackson Laboratory. Non-human primate (NHP) study was performed by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited contract research organization Kunming Primate Research Center (Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China) with its IACUC approval. All NHP protocols were further reviewed and approved by Kunming Medical University. Adult rhesus macaques (Macaca mulatta) were pre-screened for health status before study enrollment and housed in individual cages on a 12-h light / dark scheduleAtty. Dkt. No. 043214-000114WOPTin well-ventilated rooms (temperatures: 18-29 °C, humidity: 40-70%). Standard care was provided to all NHPs in accordance with AAALAC and local research animal guidelines. All NHPs were screened against pre-existing neutralizing antibody of AAV9.

[0323] Cell Culture: All cell lines were incubated at 37 °C and at 5% CO2 using standard cell culture techniques. HEK293T cells were cultured in 10% fetal bovine serum (A5670701, Thermo Fisher Scientific) in DMEM (11995073, Gibco). RPMI 2650 cells were cultured in 10% FBS in EMEM (30-2003, ATCC).

[0324] AAV Production: Recombinant AAVs used for experiments other than in NHP were packaged in-house as previously reported.6Briefly, the HEK293T cells were co-transfected with three-plasmids, RC plasmid containing AAV rep and cap genes, pHelper plasmid (240071-12, Agilent Technologies) and pAAV for in a 1: 1: 1 molar ratio using polyethylenimine (PEI, 23966, Polysciences). The AAV production media were collected 72 h and 120 h post transfection and concentrated using a PEG-precipitation method with 8% PEG-8000 (wt / vol; V3011, Promega). The harvested cell pellets were re-suspended and lysed through sonication. Vectors were purified by iodixanol gradient (15%, 25%, 40% and 60%) with ultracentrifugation at 48,000 x g for 1 h at 18°C. rAAVs were then buffer-exchanged and concentrated using Millipore Amicon filter unit (UFC910008, 100K MWCO) with lx DPBS containing 0.001% Pluronic F-68 (Gibco). AAV titer was quantified by measuring DNase-resistant genome copies using “Free-ITR” qPCR method with specific primers detecting WPRE element in AAV vectors. All titers were calculated using PVUII (NEB) digested linearized AAV plasmid as a standard and normalized to a rAAV-2 reference standard (VR-1616, ATCC). AAV s used in NHP studies were produced and tittered by PackGene Biotech.

[0325] In vitro AAV transduction assay: For RPMI 1650 cells, 4 x 109vg of AAV-CAG-GFP was applied at MOI of 1 x 105in 24-well plates. For 293 cells, 1 x 1010vg of AAVs were applied at MOI of 5 x 104. 72 hours after AAV infection, cells were fixed with 4% PFA for 15 min and followed by DAPI staining for 30 min. Intensity of native fluorescence was measured using ImageJ and normalized to DAPI signal.

[0326] Intranasal administration in mice: Adult mice older than 8 weeks of age were anaesthetized with 2.5% isoflurane and placed in a prone position. A blunt needle attached to a 10 pL Hamilton syringe (Cat # Model 701N, Hamilton) was inserted into the back of one nostril. 20 pL of AAV vectors diluted in sterile saline were slowly infused while ensuring no airway blockade. A second infusion of 20 pL of AAV solution was performed in the other nostril to add up to 40 pL of AAV vectors per animal. Similar procedure was performed for intranasal administration of Ad5. For tissue harvest, transcardial perfusion was performed with phosphate-buffered saline (PBS) before tissues were collected for viral genome quantification, or with PBS and then followed tissue fixation using 4% paraformaldehyde (PFA) for histology use.Atty. Dkt. No. 043214-000114WOPT

[0327] Intranasal administration in NHPs: Adult rhesus macaques (Macaco mulatto) were sedated with ketamine (10 mg / kg). AAV vectors diluted in lx PBS were slowly injected into the nostril using a 1 mL pipette. The total injection volume per animal was 1 mL with 0.5 ml for per nostril. Blood samples were taken 1 day before AAV injection (day 0), 3 days and 21 days after AAV injection for metabolic panel test and complete blood count. Animals were monitored closely, checked at least twice a day for any signs of abnormality. No immunomodulatory drug was administered. 3 weeks after AAV injection, animals were anesthetized with phenobarbital sodium (30 mg / kg) and subjected to transcardial perfusion with PBS, followed by 4% PFA. Tissues were then harvested and processed for paraffin embedding and sectioning.

[0328] Neutralizing antibody titration: Neutralizing antibody titers in NHPs were determined using a cellular luciferase report assay. Venous blood samples were collected into serumseparating vacutainer tubes (BD). Serum supernatant was isolated by centrifuging at l,000x g for 10 mins and transferred to a clean tube. HEK293T cells were seeded at 2 x 104per each well in 96-well plates (Coming). 24 hours later, serial-diluted serum samples were prepared and mixed with AAV9 expressing luciferase (104vg / cell). The mixtures were then incubated at 37 °C for 1 hour prior to adding to the prepared HEK293T cells. 24 hours later, the cells were prepared for the Bright-Glo Luciferase Assay according to the manufacturer’s protocol (Promega). Luciferase activity was detected by using a luminescence microplate reader (Cytation 5, BioTek). Neutralizing antibody of selected NHPs was detected as 1:10 dilution at which 50% or less inhibition of the luciferase signal was measured.

[0329] Immunostaining: For mice, PFA-fixed tissues were dehydrated in 30% sucrose and embedded in OCT for frozen sectioning. Typically, 30 pm thick sections for tissues were cut for standard immunohistochemistry with antibody staining. Processing of NHP tissues was carried out by Servicebio Inc (Wuhan, China). Briefly, tissues were fixed in a 4% paraformaldehyde (PFA) solution for over 24 hours. Sections with a thickness of 20 pm were prepared, deparaffinized using xylene, and rehydrated through a series of ethanol gradients. Antigen retrieval was conducted by employing a citric acid (pH 6.0) antigen repair solution at a sub-boiling temperature. Following this, the sections were immersed in a 3% hydrogen peroxide solution to inhibit endogenous peroxidase activity, incubated in a 3% bovine serum albumin solution to prevent nonspecificbinding, and then treated with primary and corresponding secondary antibodies. For some multiple immunofluorescent co-labelling, tyramide signal amplification (TSA) protocol was used. First, sections were incubated with the anti-RFP antibody overnight and followed by incubation with an anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody (1:500, GB23303, Servicebio) for 50 mins at room temperature in dark condition. Then, slides were further treated with a CY3-TSA solution (G1223, Servicebio) for 10 mins in a dark condition. After that, both first primary and secondary antibodies were removed through the application of an EDTA antigen repair solution. To detect GFP signal on the same slides, a mouse anti-GFP antibody was applied, followed by application of an Alexa Fluor 488-conjugated goat-anti-mouse secondary antibodyAtty. Dkt. No. 043214-000114WOPT(1:400, GB25301, Servicebio). To visualize additional antigens including cell type markers, slides were further incubated with relevant primary antibodies and then with corresponding HRP-conjugated secondary antibodies, before being treated with a CY5-TSA solution. Nucleus counterstaining was performed using DAPI. Sections were imaged using a slide scanner (PANNORAMIC, 3D HISTECH). Primary antibodies included: chicken anti-GFP (1:1000, AB 13970, Abeam), mouse anti-EGFP (1:3000, GB12602, Servicebio); rabbit anti-RFP (1:1000, 600-401-379, Rockland), rabbit anti-a-Tubulin (1:400, 5335, Cell Signaling Technology), mouse anti-MUC5A (1:400, MA5-12178, Thermo Fisher Scientific), mouse anti-CClO (1:400, sc-390313, Santa Cruz Biotechnology), rabbit anti-SCGB1A1 (CC10) (1:200, A16997, Abclonal), mouse / rat anti-RAGE (1:400, MAB1179-SP, R& D systems), rabbit anti- AGER (RAGE) (1:200, 16346-1-AP, Proteintech). Fluorescence images were taken using confocal microscopy with integrated automatic image stitching function (Zeiss LSM710), processed and analyzed using ImageJ.

[0330] AAV-IPF trap construction: An AAV vector with CAG promoter was used to generate pAAV-Aflibercept-TGFP trap, i.e., AAV-IPF trap. The IL-2 signal peptide (IL-2SP) was attached to the bifunctional fusion protein. To generate VEGF decoy receptor, the extracellular domains of human VEGF receptors VEGFR1 (D2) and VEGFR2 (D3) were genetically fused via a flexible (Gly4Ser)3 linker (SEQ ID NO: 609). The resulting VEGF decoy receptor was fused to a scFv against mouse TGFpi. The TGFpi scFv was derived from the TGFpi IgG antibody Clone 13A1 by linking variable region heavy chain (13A1 VH) and light chain (13A1 VL) via a flexible (Gly4Ser)3 linker (SEQ ID NO: 609).

[0331] Bleomycin-induced IPF model: 6-8-week-old male C57BL / 6 mice of approximately 20 g received a 50 j l intratracheal instillation (i.t.) of 0.4 mg / ml bleomycin (MedChemExpress, HY-17565A) at the dose of 1 mg / kg (body wight) on Day 0. Success of IPF induction was defined as loss of over 10% body weight on Day 4. Treatments tested included an one-time 40 j l inhaled instillation (inhal.) of 1x1013 vg / ml AAV. CPP.16- IPF trap at the dose of 4 x 1011 vg per mouse on Day 4, and approximately 200 j l intragastric instillation (i.g.) of 25 mg / ml PFD (Aladdin, D2321339) at the dose of 250 mg / kg (body weight) daily from Day 4 to Day 29. All mice were euthanized on Day 29 with the lung and other samples collected for further analysis.

[0332] Lung histology: Mouse lungs were fixed overnight in 4% paraformaldehyde (PFA), embedded in paraffin, and sectioned for fibrosis analysis. Hematoxylin and Eosin (HE) staining (Servicebio, G1076), picrosirius red (Servicebio, G1078), Masson staining (Servicebio, G1006), immunohistochemical (IHC) staining for rabbit anti-cx-SMA (1:500, ab5694, Abeam) were performed according to manufacturers’ instructions. Fibrotic area of mouse lung was quantified by ImageJ.

[0333] Western blotting: Mouse lung tissues were homogenized by lx Cell Lysis Buffer (Cell Signaling Technology, 9803) supplemented with a protease inhibitor and phosphatase inhibitor cocktail (MedChemExpress, HY-K0021). Cell lysates were then centrifuged at 4 °C for 10 mins at 10,000 x g.Atty. Dkt. No. 043214-000114WOPTSupernatant was collected and mixed with 4x Protein Loading Buffer, followed by boiling for 10 mins at 100 °C. Protein samples were fractionated on 15% SDS-PAGE gel and transferred to PVDF membranes, which were blocked in a blocking buffer (5% BSA, 0.1% Tween 20 in PBS). Membranes were incubated at 4 °C overnight, with primary antibodies against rabbit anti-COLlAl (1:1000, ab270993, Abeam), rabbit anti-a-SMA (1:500, ab5694, Abeam), rabbit anti-Periostin (1:1000, abl52099, Abeam), rabbit anti-Fibronectin (1:400, ab2413, Abeam), rabbit anti-TNFa (1:1000, abl83218, Abeam), rabbit anti-IL6 (1:1000, ab290735, Abeam), rabbit anti-P-actin (1:1000, 3700, Cell Signaling Technology). The membranes were then incubated at room temperature for 2 hours with a secondary antibody including anti-mouse IgG (H+L) (DyLight 800 4X PEG Conjugate) (1:10000, 5257, Cell Signaling Technology) and anti-rabbit IgG (H+L) (DyLight 800 4X PEG Conjugate) (1:10000, 5151, Cell Signaling Technology). The band signals were visualized by the Odyssey Infrared Imagining System (LI-COR, Odyssey CLx) and were quantified for signal intensity by ImageJ.

[0334] ELISA: For BLM-induced IPF mouse study, mouse serums were collected after the animals were sacrificed. Colorimetric ELISA was performed according to the manufacturer’s instructions to detect mouse TGF 1 (ELK Biotechnology, ELK1186) and VEGFa (ELK Biotechnology, ELK1293).

[0335] SARS-CoV-2 genome sequences analysis: SARS-CoV-2 genome sequences were downloaded fromNCBI SARS-CoV-2 Resources. Full genomes were mapped to SARS-CoV-2 Wuhan-Hu-1 NCBI reference genome (NC 045512.2, Genbank ID: MN908947.3, 29903 bp linear RNA) by MAFFT. The conservation identity was calculated as the percentage of sequences matching the consensus. The identity was determined by employing Geneious Prime and subsequently visualized using R.

[0336] CasRx gRNA design: To design gRNAs for SARS-CoV-2, the 99% consensus sequences of PRF, Rdrp, 3CL protease, S, E, M, and N, were imported into a CasRx design software (available at gitlab) to predict potential guide sites and guide activities. 23-nucleotide (nt) sequences with perfect identity among the SARS-CoV-2 genomes were typically selected as candidates. Off-targets were scored against the human transcriptome (Hg38) and mouse transcriptome (M25) using Bowtie 1.2.3, to remove gRNAs that were mapped to the human and mouse transcriptome with less than 2 mismatches. 4 selected gRNAs were built into a gRNA pool for each taigeting. Scramble and positive control sequences were chosen based on a previous study40.

[0337] Rdrp reporter plasmid and Ad-Rdrp production: To express the Rdrp in HEK293T cells, the 2796 bp Rdrp genome sequence (NCBI nucleotide ID: NC_045512.2, 13441-16236) was synthesized and inserted into the pcDNA vector with a CMV promoter by GenScript. To express the Rdrp in RPMI 1650 cells and in mice, Rdrp was cloned into an Ad5-CMV vector (pADM-FH, Vigene Biosciences) and recombinant adenoviruses (Ad5-Rdrp) were packaged by Vigene Biosciences.Atty. Dkt. No. 043214-000114WOPT

[0338] Co-transfection in HEK-293T: 2 x 105 cells / well HEK-293T were plated in 24-well plates. On the following day, plasmid pAAV-EFS-CasRx-U6-4x gRNA, Rdrp reporter plasmid and PEI were mixed in a ratio of 2:0.3:6 in Opti-MEM. 48h after transfection, HEK293T cells were harvested for RNA isolation.

[0339] Co-transduction of AAV and Ad5 viruses in vitro: On day 0, 6 x 105 cells / well RPMI-1650 cells were plated in 24-well plates. On day 1, RPMI-1650 cells were infected with 1 x 1010 vg AAV-CasRx-gRNA. On day 2, Ad5-Rdrp was added with a MOI of 200 (1.2x 108 pfu). On day 3, RPMI-1650 cells were harvested for RNA isolation.

[0340] Quantitative real-time PCR: Quantitative real-time PCR (qRT-PCR) was performed to quantify RNA abundance. For each sample, total RNA was isolated by using Trizol (15596026, Thermo Fisher Scientific), followed by cDNA synthesis using the cDNA Synthesis Kit (6110A, Takara). All qRT-PCR primers were listed in Table S7. Quantitative real-time PCR was performed using the SYBR Green Mix (A25742, Applied Biosystems) in StepOne Plus system (Applied Biosystems) following manufacturers’ instructions. Ct values were used to quantify RNA abundance. The relative abundance of the Rdrp was normalized to a GAPDH internal control.

[0341] Quantification and statistical analysis: All statistical analyses were performed using GraphPad Prism software. For two-group comparisons, two-tailed unpaired Student’s t-test was applied. Multiple comparisons were analyzed by one-way ANOVA with Tukey’s post-test or two-way ANOVA with Sidak’s post-tests. Effect sizes are presented as mean ± 95% confidence intervals, p-values less than 0.05 were considered statistically significant.Example 2: CRISPR-Based AAV Gene Therapy against SARS-CoV-2

[0342] Progress in respiratory gene therapy and gene editing is hampered by a lack of efficient delivery vectors. Recently, the inventors reported an AAV9-derived capsid AAV. CPP.l 6 with species-conserved neurotropism after systemic administration.6During characterization of vector biodistribution, we also observed enhanced transduction of the lung by AAV. CPP.16 relative to its parent capsid AAV9. Thus, the inventors decided to further explore the use of AAV. CPP.16 as an intranasal gene transfer vector for gene therapy and gene editing for potential treatment of respiratory diseases and airborne viral infection.

[0343] Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease that affects over 3 million people worldwide.7Characterized by scarring of the lungs and declining respiratory function, IPF significantly impairs quality of life and is often fatal, with a median survival rate of 3 to 5 years if left untreated.7In IPF, a combination of environmental and genetic factors converge on the lung epithelium, triggering a maladaptive response. This malfunctioning epithelium then produces mediators that drive the fibroblast-to-myofibroblast transition, ultimately resulting in fibrotic remodeling of the lungs. Existing monotherapies only slow disease progression; more targeted and effective therapies are needed to halt, or even reverse IPF.Atty. Dkt. No. 043214-000114WOPT

[0344] SARS-CoV-2, an RNA virus, continues to pose a significant threat to global healthcare. Vaccination is less effective or even invalid in vulnerable populations of immune-deficient patients.11Furthermore, constant mutation and evolution of viruses have led to the emerging of variants that could potentially break through the protective barrier established by active vaccination and / or passive viral exposure.12

[0345] Disclosed herein is a Casl3d-based RNA knock-down construct against SARS-CoV-2 using AAV. CPP.16 as intranasal delivery vector. Efficient gene delivery vectors are crucial for respiratory and lung disease therapies. The inventors report that AAV. CPP.16, an engineered adeno-associated virus (AAV) variant derived from AAV9, efficiently transduces airway and lung cells in mice and non-human primates via intranasal administration. AAV. CPP.16 outperforms AAV6 and AAV9, two wild-type AAVs with demonstrated tropism for respiratory tissues and efficiently targets key respiratory cell types. It supports gene supplementation and editing therapies in two clinically relevant mouse models of respiratory and lung diseases. A single intranasal dose of AAV. CPP.16 expressing a dual-target, VEGF / TGFpi-neutralizing protein protected lungs from idiopathic pulmonary fibrosis, while a similar application of AAV. CPP.16 carrying an “all-in-one” CRISPR-Casl3d system inhibited transcription of the SARS-CoV-2-derived RNA-dependent RNA polymerase (Rdrp) gene. Our findings highlight AAV. CPP.16 as a promising vector for respiratory and lung gene therapy.

[0346] Some embodiments of the disclosure are described herein with reference to the accompanying figures that make apparent to a person having ordinary skill in the art how some embodiments of the disclosure may be practiced. The figures are for the purpose of illustrative discussion and no attempt is made to show structural details of an embodiment in more detail than is necessary for a fundamental understanding of the teachings of the disclosure. Where dimensions or ranges are given in the text or figures, these are merely exemplary and do not limit the scope or spirit of the disclosed invention.

[0347] The invention comprises, consists of, or consists essentially of the features disclosed herein and in the accompanying figures and examples, in any combination and / or order.

[0348] The inventors have demonstrated that AAV. CPP.16 outperforms other AAVs (AAV6 and AAV9) in transducing the respiratory system in both mice and non-human primates after intranasal administration.

[0349] The inventors have have performed bioinformatic analysis and generated candidate guide RNAs targeting SARS-CoV-2 Rdrp proteins across variants.

[0350] The inventors have have generated Casl3d-based all-in-one AAV vectors and confirmed their knock-down efficiency against SARS-CoV-2 Rdrp RNA in vitro.

[0351] The inventors have have preliminary data showing at least one of such AAV vectors knock-downs SARS- CoV-2 Rdrp RNA in the mouse respiratory system using pseudo-viruses.Atty. Dkt. No. 043214-000114WOPT

[0352] In this study, we systemically characterize AAV. CPP.16 as a gene therapy vector for intranasal treatment of respiratory and lung diseases. In comparison with wild-type AAV6 and AAV9, we observed markedly enhanced tropism of AAV. CPP16 for major cell types that belong to the respiratory system in cell culture, mouse and non-human primate (NHP) models. Using AAV. CPP.16 as a vector, we then engineered an intranasal gene therapy for IPF and found that partially sequestering two fibrotic mediators VEGF (vascular endothelial growth factor) and TGF 1 (transforming growth factor beta 1) provided marked anti-fibrotic protection for the lung in a mouse model of IPF. Furthermore, the inventors have designed and tested an AAV. CPP.16-mediated, passive prophylaxis to SARS-CoV-2 infection using a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) system that inhibited the highly conserved RNA-dependent RNA polymerase (Rdrp) gene in SARS-CoV-2.References

[0353] 1 Wang, D., Tai, P. W. L. & Gao, G. (2019). Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 18, 358-378.

[0354] 2 Gruntman, A. M., Mueller, C., Flotte, T. R. & Gao, G. (2012). Gene transfer in the lung using recombinant adeno-associated virus. Curr Protoc Microbiol. Chapter 14, Unitl4D 12.

[0355] 3 Limberis, M. P. & Wilson, J. M. (2006). Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci U SA. 103, 12993-12998.

[0356] 4 Limberis, M. P. et al. (2013). Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. Sci Transl Med. 5, 187ral72.

[0357] 5 Laursen, N. S. et al. (2018). Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science. 362, 598-602.

[0358] 6 Yao, Y. et al. (2022). Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood-brain barrier in rodents and primates. Nat Biomed Eng. 6, 1257-1271, https: / / doi.org / 10.1038 / s41551-022-00938-7.

[0359] 7 Martinez, F. J. et al. (2017). Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 3, 17074.

[0360] 8 Karimi-Shah, B. A. & Chowdhury, B. A. (2015). Forced vital capacity in idiopathic pulmonary fibrosis— FDA review of pirfenidone and nintedanib. N Engl J Med. 372, 1189-1191.

[0361] 9 Li, J. S. et al. (2023). Efficacy and safety of Kangxian Huanji Granule as adjunctive treatment in acute exacerbation of idiopathic pulmonary fibrosis: An exploratory randomized controlled trial. J Integr Med. 21, 543-549.

[0362] 10 Knoll, M. D. & Wonodi, C. (2021). Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 397, 72-74.Atty. Dkt. No. 043214-000114WOPT

[0363] 11 Zhu, F. C. et al. (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored CO VID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 396, 479-488.

[0364] 12 Wang, Q. et al. (2022). Alarming antibody evasion properties of rising SARS- CoV-2 BQ andXBB subvariants. Cell. 186, 279-286.

[0365] 13 Sims, J. J. et al. (2021). Intranasal gene therapy to prevent infection by SARS- CoV-2 variants. PLoS Pathog. 17, el009544.

[0366] 14 Halbert, C. L., Rutledge, E. A., Allen, J. M., Russell, D. W. & Miller, A. D. (2000). Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol. 74, 1524-1532.

[0367] 15 Kurosaki, F. et al. (2017). Optimization of adeno-associated virus vector-mediated gene transfer to the respiratory tract. Gene Ther. 24, 290-297.

[0368] 16 Kurosaki, F. et al. (2018). AAV6-Mediated IL-10 Expression in the Lung Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice. Hum Gene Ther. 29, 1242-1251.

[0369] 17 van Lieshout, L. P. et al. (2018). A Novel Triple-Mutant AAV 6 Capsid Induces Rapid and Potent Transgene Expression in the Muscle and Respiratory Tract of Mice. Mol Ther Methods Clin Dev. 9, 323-329.

[0370] 18 Wang, J. et al. (2022). Nestin promotes pulmonary fibrosis via facilitating recycling of TGF-beta receptor I. Eur Respir J. 59.

[0371] 19 Liu, J. et al. (2021). SARS-CoV-2 cell tropism and multiorgan infection. Cell Discov. 7, 17.

[0372] 20 Liang, S. Q. et al. (2022). AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airway. Mol Ther. 30, 238-243.

[0373] 21 Wang, Y. et al. (2018). Pulmonary alveolar type I cell population consists of two distinct subtypes that differ in cell fate. Proc Natl Acad Sci U SA. 115, 2407-2412.

[0374] 22 Richeldi, L. et al. (2014). Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 370, 2071-2082.

[0375] 23 Richeldi, L., Collard, H. R. & Jones, M. G. (2017). Idiopathic pulmonary fibrosis. Lancet. 389, 1941-1952.

[0376] 24 King, T. E., Jr. et al. (2014). A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 370, 2083-2092.

[0377] 25 Noble, P. W. et al. (2011). Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 377, 1760-1769.

[0378] 26 Lederer, D. J. & Martinez, F. J. (2018). Idiopathic Pulmonary Fibrosis. N Engl J Med. 378, 1811-1823.Atty. Dkt. No. 043214-000114WOPT

[0379] 27 Chaudhary, N. I. et al. (2007). Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. EurRespir J. 29, 976-985.

[0380] 28 Atamas, S. P. (2017). Vascular Endothelial Growth Factor in Idiopathic Pulmonary Fibrosis. An Imbalancing Act. Am J Respir Crit Care Med. 196, 409-411.

[0381] 29 Barratt, S. L. et al. (2017). Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis. Am J Respir Crit Care Med. 196, 479-493.

[0382] 30 Cohen, M. L. et al. (2024). A fibroblast-dependent TGF-betal / sFRP2 noncanonical Wnt signaling axis promotes epithelial metaplasia in idiopathic pulmonary fibrosis. J Clin Invest. 134.

[0383] 31 Lee, T. H. et al. (2020). Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGFbeta signaling through TGFBR1 stabilization. Nat Commun. 11, 4254.

[0384] 32 Celada, L. J. et al. (2018). PD-1 up-regulation on CD4(+) T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-betal production. Sci Transl Med. 10, eaar8356.

[0385] 33 Jhaveri, C. D. et al. (2022). Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. N Engl J Med. 387, 692-703.

[0386] 34 Ichiyama, Y. et al. (2022). Assessment of mouse VEGF neutralization by ranibizumab and aflibercept. PLoS One. 17, e0278951.

[0387] 35 Gupta, A. et al. (2021). Isoform specific anti-TGFbeta therapy enhances antitumor efficacy in mouse models of cancer. Commun Biol. 4, 1296.

[0388] 36 Uyttenhove, C. et al. (2011). Amine-reactive OVA multimers for autovaccination against cytokines and other mediators: perspectives illustrated for GCP-2 in L. major infection. J Leukoc Biol. 89, 1001-1007.

[0389] 37 Konermann, S. et al. (2018). Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors. Cell. 173, 665-676 e614.

[0390] 38 Wessels, H. H. et al. (2020). Massively parallel Casl3 screens reveal principles for guide RNA design. Nat Biotechnol. 38, 722-727.

[0391] 39 Hillen, H. S. et al. (2020). Structure of replicating SARS-CoV-2 polymerase. Nature. 584, 154-156.

[0392] 40 Abbott, T. R. et al. (2020). Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza. Cell. 181, 865-876 e812.

[0393] 41 Yin, W. et al. (2020). Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 368, 1499-1504.

[0394] 42 Cao, Z. et al. (2022). W116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. N Engl J Med. 388, 406-417.Atty. Dkt. No. 043214-000114WOPT

[0395] 43 Kaore, S. & Atal, S. (2022). Molnupiravir in COVID-19: A Scoping Review. Curr Drug Res Rev. 14, 203-214.

[0396] 44 Yu, B. & Chang, J. (2022). The first Chinese oral anti-COVID-19 drug Azvudine launched. Innovation (Camb). 3, 100321.

[0397] 45 Gao, Y. et al. (2020). Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 368, 779-782.

[0398] 46 McFarland, T. J. et al. (2006). Evaluation of a novel short polyadenylation signal as an alternative to the SV40 polyadenylation signal. Plasmid. 56, 62-67.

[0399] 47 Limberis, M. P., Vandenberghe, L. H., Zhang, L., Pickles, R. J. & Wilson, J. M. (2009). Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther. 17, 294-301.

[0400] 48 Mendell, J. R. et al. (2021). Current Clinical Applications of In Vivo Gene Therapy with AAV s. Mol Ther.29, 464-488.

[0401] 49 Duan, D. (2023). Lethal immunotoxicity in high-dose systemic AAV therapy. Mol Ther. 31, 3123-3126.

[0402] 50 Abudayyeh, O. O. et al. (2017). RNA targeting with CRISPR-Casl3. Nature.550, 280-284.

[0403] 51 Freije, C. A. et al. (2019). Programmable Inhibition and Detection of RNA Viruses Using Casl3. Mol Cell. 76, 826-837 e811.

[0404] 52 Kellner, M. J., Koob, J. G., Gootenberg, J. S., Abudayyeh, O. O. & Zhang, F. (2019). SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat Protoc. 14, 2986-3012.

[0405] 53 Nguyen, T. M., Zhang, Y. & Pandolfi, P. P. (2020). Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses. Cell Res. 30, 189-190.

[0406] 54 Lin, X. et al. (2021). A comprehensive analysis and resource to use CRISPR- Casl3 for broad-spectrum targeting of RNA viruses. Cell Rep Med. 2, 100245.

[0407] 55 Zeng, L. et al. (2022). Broad-spectrum CRISPR-mediated inhibition of SARS- CoV-2 variants and endemic coronaviruses in vitro. Nat Commun. 13, 2766.Atty. Dkt. No. 043214-000114WOPT1 NHP = non-human primate (Rhesus macaques, Macaca mulatta)2 IN = intranasal injection3 NAb = neutralizing antibody4 ALT= alanine aminotransferase (an indicator of liver damage)Table 2. Blood routine of all NHPs. Related to FIGs.3A-3F.Aty. Dkt. No. 043214-000114WOPTTable 3. Blood biochemistry of all NHPs. Related to FTGs.3A-3F.Aty. Dkt. No. 043214-000114WOPT Table 4. Virus RNA genome mapping. Related to FIGs. 6A-6G.Aty. Dkt. No. 043214-000114WOPTTable 6. DNA sequences for AAV-CasRx-Rdrp Interface vector. Related to FTGs.6A-6G. SEQ ID NO: 21: All-in-one AAV-CasRX-Rdrp Interface GRNA plasmid.4908-5102-0199.54908-5102-0199.54908-5102-0199.5Atty. Dkt. No. 043214-000114WOPT

[0408] All patents and other publications; including literature references, issued patents, published patent applications, and co-pending patent applications; cited throughout this application are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that might be used in connection with the technology described herein. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is basedAtty. Dkt. No. 043214-000114WOPTon the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.

Claims

Atty. Dkt. No. 043214-000114WOPTCLAIMSWhat is claimed is:

1. An adeno-associated virus (AAV) vector comprising:a) one or more nucleic acids encoding:i) a Cas endonuclease; andii) at least one CRISPR-associated guide RNA sequence that hybridizes specifically with a SARS-CoV-2 gene selected from the group consisting of: 3C-like protease (3CL), Programmed ribosomal frameshifting (PRF), RNA- dependent RNA polymerase (Rdrp), Spike (S), Envelope (E), Membrane (M), and Nucleocapsid (N).

2. An adeno-associated virus (AAV) vector comprising:a) one or more nucleic acids encoding:i) A polypeptide having at least 80% sequence identity to SEQ ID NO: 206; and ii) at least one CRISPR-associated guide RNA sequence.

3. The AAV vector of any one of the preceding claims, wherein the nucleic acid encodes a CasRx endonuclease.

4. The AAV vector of any one of the preceding claims, wherein the CasRx endonuclease comprises two SV40 nuclear localization sequences.

5. The AAV vector of any one of the preceding claims, wherein the CasRx endonuclease comprises one HA tag.

6. The AAV vector of any one of the preceding claims, wherein the one or more nucleic acids encode four CRISPR-associated guide RNA sequences in series.

7. The AAV vector of any one of the preceding claims, wherein the at least one CRISPR- associated guide RNA sequence targets the Rdrp gene in SARS-CoV-2.

8. The AAV vector of any one of the preceding claims, wherein the nucleic acid encoding a Cas endonuclease is operably linked to a promoter.

9. The AAV vector of any one of the preceding claims, wherein the nucleic acid encoding at least one CRISPR-associated guide RNA sequence is operably connected to a promoter.

10. The AAV vector of any one of the preceding claims, wherein the nucleic acid encoding a Cas endonuclease and the nucleic acid encoding at least one CRISPR-associated guide RNA sequence are operably linked to the same promoter.

11. The AAV vector of any one of the preceding claims, wherein the nucleic acid encoding a Cas endonuclease is operably linked to a first promoter and the nucleic acid encoding at least one CRISPR-associated guide RNA sequence is operably linked to a second promoter.Atty. Dkt. No. 043214-000114WOPT12. The AAV vector of any one of the preceding claims, wherein the promoter is an EFS promoter.

13. The AAV vector of any one of the preceding claims, wherein the promoter is a U6 promoter.

14. An adeno-associated virus (AAV) vector comprising a nucleic acid encoding:a) a soluble receptor; andb) an antibody reagent.

15. The AAV vector of any one of the preceding claims, wherein the soluble receptor is a soluble VEGF receptor.

16. The AAV vector of any one of the preceding claims, wherein the soluble VEGF receptor comprises extracellular domains of human VEGF receptors 1 and 2.

17. The AAV vector of any one of the preceding claims, wherein the antibody reagent is a scFv.

18. The AAV vector of any one of the preceding claims, wherein the antibody reagent binds specifically to TGF 1.

19. An AAV comprising:a) the vector of any one of the preceding claims; andb) at least one capsid polypeptide.

20. The AAV of any one of the preceding claims, wherein the at least one capsid polypeptide comprises at least four contiguous amino acids from the sequence TVSALFK (SEQ ID NO: 301); TVSALK (SEQ ID NO: 302); KLASVT (SEQ ID NO: 303); or KFLASVT (SEQ ID NO: 304).

21. A composition for intranasal delivery, the composition comprising the AAV of any one of the preceding claims.

22. The composition of any one of the preceding claims, further comprising a pharmaceutically acceptable excipient.

23. The composition of any one of the preceding claims, further comprising a mucoadhesive agent, a thermosensitive agent, a viscosity enhancing agent, or a combination thereof.

24. The composition of any one of the preceding claims, further comprising a sweetener, a polyol, a fragrance, or a combination thereof.

25. The composition of any one of the preceding claims, wherein the composition is a solution.

26. The composition of any one of the preceding claims, wherein the composition is a suspension.

27. The composition of any one of the preceding claims, wherein the composition is an aerosol.

28. The composition of any one of the preceding claims, wherein the composition is a liquid.Atty. Dkt. No. 043214-000114WOPT29. The composition of any one of the preceding claims, wherein the composition is a powder.

30. The composition of any one of the preceding claims, wherein the composition is a gel.

31. A method comprising:contacting a cell with an adeno-associated virus (AAV) or composition of any one of the preceding claims.

32. The method of any one of the preceding claims, wherein the cell is a respiratory cell.

33. The method of any one of the preceding claims, wherein the cell is a ciliated cell, a brush cell, an airway basal cell, a small granule cell, goblet cell, an a-tubulin-positive ciliated cell, a club cell, a trachea cell, or a ATI cell.

34. The method of any one of the preceding claims, wherein the cell is in a subject.

35. The method of any one of the preceding claims, wherein the cell is in a mammalian subject.

36. The method of any one of the preceding claims, wherein the cell is in a human subject.

37. The method of any one of the preceding claims, wherein the subject has a respiratory disease or infection.

38. The method of any one of the preceding claims, wherein the disease is idiopathic pulmonary fibrosis (IPF).

39. The method of any one of the preceding claims, wherein the infection is a viral infection.

40. The method of any one of the preceding claims, wherein the viral infection is caused by SARS-CoV-2.

41. A method of treating respiratory disease or infection in a subject in need thereof, the method comprising: administering an AAV or compositions of any one of the preceding claims to the subject.

42. The method of any one of the preceding claims, wherein the disease is idiopathic pulmonary fibrosis (IPF).

43. The method of any one of the preceding claims, wherein the infection is a viral infection.

44. The method of any one of the preceding claims, wherein the viral infection is caused by SARS-CoV-2.

45. The method of any one of the preceding claims, wherein the AAV is administered by intranasal delivery.

46. The method of any one of the preceding claims, wherein the AAV is administered by a dropper.

47. The method of any one of the preceding claims, wherein the AAV is administered as a spray.

48. The method of any one of the preceding claims, wherein the AAV is administered by a nebulizer.Atty. Dkt. No. 043214-000114WOPT49. A device for intranasal administration of a composition comprising an AAV or composition of any one of the preceding claims, to a subject.

50. The device of any one of the preceding claims, wherein the device is a dropper.

51. The device of any one of the preceding claims, the device is a spray.

52. The device of any one of the preceding claims, wherein the device is a nebulizer.

53. A kit comprising the device of any one of the preceding claims and instructions for use.